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Preface
This important book explores one of the most common pathologic abnormalities
of the female genital tract: fibroids. A fibroid is a benign tumor originating from
the smooth muscle of the uterus.
Written by authors and researchers in the field, this book examines uterine
fibroids over four sections. The first section covers the clinical presentation of
myoma. Some tumors are asymptomatic, whereas others may cause pelvic masses, 
abnormal vaginal bleeding, or pelvic pain. It also discusses sexual dysfunction as
well as reproductive symptoms like infertility and recurrent pregnancy loss.
The second section deals with the diagnosis, which can be accomplished by
conducting a clinical history and physical examination, including pelvic
examination. Diagnosis can be confirmed via pelvic ultrasound, computed 
tomography (CT) scan, or magnetic resonance imaging (MRI), all of which can
also be used to diagnose extra-uterine fibroids as well. This section includes a
chapter about submucous myoma and hysteroscopy and how the latter can treat
bleeding in uterine myxomatosis.
The third section deals with the management of uterine fibroids, including 
medical hormonal or non-hormonal treatment, herbal medicine, surgery (either
open or endoscopic), and uterine artery embolization. It also discusses women’s
perspectives about their bodies after hysterectomy.
Hassan Abduljabbar
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Fibroid, also called leiomyomas, is common tumor of the uterus. Usually, 
women of reproductive age are at risk of getting it. However, majority of these 
women develop fibroid (s) by the age of 50 years. This condition usually causes 
painful and unpleasant symptoms such as; heavy bleeding, prolonged periods, 
inter-menstrual bleeding, abdominal pain and cramps, anemia, pelvic pain and 
pain during sexual intercourse, among others. Abnormal bleeding, such as bleed-
ing that occurs with fibroids and heavy periods, often lasts more than 10 days per 
month. This fibroid symptom involves persistent bleeding between cycles, which 
can severely impact one’s quality of life. Abnormal bleeding, especially in fibroids, 
can be taken as missing three or more periods in a woman who had been having 
regular monthly period, or periods that last less than 21 days or more than 35 days 
apart from each other. Another indication of an abnormal period is bleeding 
through multiple pads and tampons in a short amount of time.
Keywords: per vaginal bleeding, abnormal bleeding, normal bleeding,  
menstrual bleeding, menstrual cycle
1. Introduction
In a normal adult human – female, menstrual cycle occurs to provide for release 
of oocyte, thus preparing the uterus for any possible pregnancy [1].
Thus, menstruation is a woman’s normal monthly per vaginal bleeding, usually 
called “monthly period.” When a woman menstruates, her body discards the monthly 
build-up of the lining of the uterus. The resultant blood, also called menstrual blood, 
and uterine tissues flow from the uterus through the cervix and then into the vagina 
and eventually out of the body [2]. In other words, menstruation is the cyclic and 
orderly sloughing off of the uterine lining which occurs in response to the interac-
tions of hormones produced by the hypothalamus, pituitary and ovaries [3].
Menstrual cycle is, thus, divided into three phases. These are follicular or prolif-
erative phase, ovulation and luteal or secretory phase. The number of days between 
the first day of menstrual bleeding of a woman’s cycle to the onset of menses of the 
next cycle is referred to as ‘the length of a menstrual cycle’. The average duration of 
a menstrual cycle is usually 28 days. However, some women may have shorter cycle 
of 21 days. Such women are referred to as ‘polymenorrheic women’. Some women 
also have longer cycle of 35 days or more. These are called oligomenorrheic women 
[3]. Thus, the complete cycle may last anywhere from 21 days to 35 days with an 
average duration of 28 days for most women.
Menstruation begins at puberty, usually between ranging 10 to 16 years of age 
of a normal girl child. It ends at menopause, corresponding to average age of 45 to 
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Ordinarily, the typical volume of blood lost during menstruation is approxi-
mately 30 milliliters (mL). Any amount of blood lost during menstruation which is 
greater than 80 mL is considered abnormal [4].
2. Physiology of normal uterine bleeding
There are four major circulating hormones involved in the menstrual cycle. 
These hormones are; follicle stimulating hormones (FSH), luteinizing hormones 
(LH), estradiol (estrogen) and progesterone. The concentrations of these hormones 
in blood vary and their levels provide characteristic changes during the menstrual 
cycle [5]. In particular, the body makes three main types of estrogen; estrone (E1), 
estradiol (E2) and estriol (E3). E1 is the only estrogen the body makes after meno-
pause. E2 is the most common type in women of childbearing age whereas E3 is the 
main estrogen during pregnancy [6].
The menstrual cycle is triggered by the gonadotropin-releasing hormone 
(GnRH) pulse generator in the hypothalamus. The GnRH pulse generator then 
releases gonadotropin-releasing hormone (GnRH) [7]. This GnRH in turn stimu-
lates the synthesis and release of the gonadotropins, luteinizing hormones (LH) 
and follicle stimulating hormones (FSH), from the anterior pituitary gland [5]. 
LH and FSH exert their effects in the ovaries. There are two types of cells respon-
sible for hormone production within the ovarian follicle; theca cells and granulosa 
cells. LH acts on theca cells to produce progesterone and androstenedione. The 
enzyme involved is cholesterol desmolase. Upon secretion of androstenedione, 
the hormone diffuses to granulosa cells. FSH then stimulates the granulosa cells 
to convert androstenedione to testosterone and eventually 17-beta-estradiol. The 
enzyme involved is aromatase. The levels of 17-beta-estradiol or progesterone 
increases accordingly, depending on the phase of the menstrual cycle. This 
increase triggers a negative feedback back to the anterior pituitary to lower the 
levels of FSH and LH which are being produced and subsequently, the levels of 
17-beta-estradiol and progesterone produced. The only exception occurs during 
ovulation, in which case, once a critical amount of 17-beta-estradiol is produced it 
provides positive feedback to the anterior pituitary instead of a negative feedback 
[5, 6]. This positive feedback results in increased amounts of FSH and LH, hence 
the LH surge bringing about ovulation [1].
The onset of the menstrual cycle, or menarche, usually at 10–16 years, begins 
at puberty and ceases at menopause, usually 45–55 years. The cycle has 3 phases: 
follicular or proliferative phase, ovulation and luteal or secretory phase [1, 5].
Follicular Phase: Usually, the first phase of the menstrual cycle is the follicular 
or proliferative phase. The phase is characterized by menstruation, resulting from 
shedding off of the initially thickened endometrial lining following failed fertiliza-
tion or implantation. It occurs from day zero to day 14 of the menstrual cycle (see 
Figures 1 and 2), based on the average duration of 28 days cycle. There is usually 
variability in the length of menstrual cycle and this is due to variations in the 
length of the follicular phase. The main hormone during this phase is estrogen, in 
particular 17-beta-estradiol [1, 5] from the ovary coupled with follicle stimulating 
hormone (FSH), released from anterior pituitary gland. Upon release from anterior 
pituitary, FSH and LH slowly rise in levels and cause the growth of follicles on the 
surface of the ovary. This process prepares the egg for ovulation. As the follicles 
grow, they begin releasing estrogens and a low level of progesterone. These ovar-




negative feedback process (See Figure 3). Thus, as the follicular phase progresses to 
the end, the increased amounts of 17-beta-estradiol will provide negative feedback 
to the anterior pituitary.
Due to the rise of FSH during the first days of the menstrual cycle or follicular 
phase, several ovarian follicles are stimulated. These ovarian follicles compete with 
each other for dominance. The follicle that reaches maturity is called a Graafian 
Figure 1. 
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follicle. During follicular phase, estrogen suppresses production of luteinizing 
hormone (LH) from the pituitary gland (Figures 4 and 5) [5].
Ovulation phase: Ovulation phase comes next. Ovulation occurs 14 days 
later after the first day of menstruation [1]. This means that with an average 
28-day cycle, ovulation occurs on day 14 (see Figure 1).
At the end of the proliferative phase, 17-beta-estradiol (E2) levels are high due to 
the follicle maturation. During the follicular phase, estrogen suppresses production 
of luteinizing hormone (LH) from the pituitary gland but in this phase it stimulates 
Figure 3. 
The follicular phase [5].
Figure 4. 




maturation a follicle and thickens the endometrial lining. At this time, only 17-beta-
estradiol (E2) provides positive feedback for FSH and LH production. A critical level 
of 17-beta-estradiol must be reached, at least 200 picograms per milliliter of plasma, 
to cause this positive feedback. The high levels of FSH and LH present during this 
time is called the LH surge [5]. The release of LH matures the ovum much further 
and weakens the wall of the follicle in the ovary, thus causing the fully developed 
follicle to release its secondary oocyte, in a process known as ovulation. After being 
released from the ovary, the ovum, also called egg, is swept into the fallopian tube.
The changes to the cervix which was initiated during the follicular phase is 
even further increased in ovulation phase allowing for increased, waterier cervical 
mucus in order to better accommodate the possible sperm. The levels of 17-beta-
estradiol fall at the end of ovulation [1, 5, 6].
Luteal or Secretory phase: The luteal phase follows ovulation. It is characterized 
by the development of corpus luteum, secretion of progesterone and the formation 
of thick mucus which blocks the cervix. Blocking of the cervix is in anticipation that 
implantation has occurred [5]. Luteal phase always occurs from day 14 to day 28 of 
the cycle (See Figure 1). Progesterone stimulated by LH is the dominant hormone 
during this phase to prepare the corpus luteum and the endometrium for possible 
implantation of the fertilized ovum. As the luteal phase comes to an end, progester-
one will provide negative feedback to the anterior pituitary to decrease FSH and LH 
levels and subsequently, the 17-beta-estradiol (E2) and progesterone levels [1, 5, 6].
Therefore, at the end of luteal phase, in the absence of implantation (preg-
nancy), when the level of progesterone drops, menses or menstruation occurs [1]. 
See Figure 2.
3. Clinical significance of physiology of normal uterine bleeding
A normal woman has an average of 450 menses throughout her lifetime. It is 
therefore, very important to fully understand the menstrual cycle and its physiology 
Figure 5. 
The luteal phase [5].
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as various complications may occur later in life for a woman [8]. The knowledge of 
this forms the cornerstone of making appropriate diagnosis and investigation [9].
Menstruation begins at puberty, usually between 10 to 16 years of age of a nor-
mal girl child. It ends at menopause, corresponding to average age of 45 to 55 years 
of a normal adult female [1].
Ordinarily, the typical volume of blood lost during menstruation is approxi-
mately 30 milliliters (mL). Any amount of blood lost during menstruation which is 
greater than 80 mL is considered abnormal [4].
The clinician needs to know all these in order to make appropriate diagnosis and 
investigation. Anything sort of this could result in gross errors.
4. Bleeding in fibroids
Fibroids are growths of muscle and fibrous tissue in or on the wall of the uterus.
They range in size from seedlings which are undetectable by human eye, to 
bulky masses that can disfigure or enlarge the uterus. One can have a single fibroid 
or multiple fibroids (See Figure 6) [10].
4.1 Normal versus abnormal bleeding
It is usually very difficult to tell between what is normal and what is abnormal 
when it comes to menstruation. This is because of the huge variation in women to 
the point that what is normal for one might be abnormal for another. Heavy men-
strual flow is highly subjective.
In addition to the above, there are many factors that influence length, heaviness, 
and frequency of a woman’s menstrual flow. Thus, paying close attention to one’s 
monthly period and observing the trend becomes paramount to detecting whether 
or not one has abnormal or normal menstrual flow. This observance might need to 
have been done over a significant period of time [11].
Vaginal bleeding is considered to be abnormal if it occurs between a woman’s 
menstrual cycles, in situations where flow is significantly heavier than normal for a 
particular individual or when it occurs after menopause.
4.1.1 Normal bleeding
Bleeding in normal period typically lasts between 3 and 8 days, usually with a 
heavier menstrual flow for the first two days. The flow gets increasingly lighter as 
Figure 6. 




the number of days progress. Women with normal periods may have limited spot-
ting, cramps that ache and bloating that goes away once the period is over.
4.1.2 Abnormal periods or fibroids bleeding
On another hand, abnormal bleeding, such as those bleedings occurring in 
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that can severely affect one’s quality of life [11].
Abnormal bleeding can be considered missing 3 or more periods in a row, or 
periods which occur less than 21 days or more than 35 days apart from each other. 
Another sign of an abnormal period is bleeding through multiple pads and tampons 
in a short amount of time [10, 11].
4.2 The cause of heavy bleeding in fibroids
The cause of heavy bleeding in fibroid is not well understood. Since fibroids 
are connected to your uterine lining, the fibroids can exert pressure against the 
uterine wall and cause the endometrial tissue to bleed more than normal [11]. 
See Figure 6.
During menstrual period, the uterine lining sheds off and the uterus has two 
basic mechanisms to stop itself from bleeding. The first mechanism is through the 
normal blood-clotting working throughout the body by forming plugs within the 
blood vessels. Secondly, since the uterus is a muscle, it also has the ability to con-
tract the bleeding vessels of the uterus, thus stopping the bleeding. The contractions 
are associated with menstrual cramps.
However, it is believed that fibroids interfere with adequate and proper con-
traction of the uterus. In this way, it does not stop menstrual bleeding adequately. 
Additionally, fibroids produce growth factors (proteins) that stimulate relaxation of 
the uterine blood vessels and thus causing more blood in the uterine cavity, which 
leads to heavier periods [11].
4.3 Treatment of abnormal bleeding and fibroids bleeding
The treatment of abnormal bleeding depend on; the cause, patient age, severity 
of bleeding and whether one wants to have children or not [12].
Otherwise, the common medical treatment options are;
1. Use of birth control pills
2. Hormone injections or a hormone-releasing IUD (intra-uterine device)
3. Surgery to control bleeding or to remove growths, such as fibroids, that are 
causing the bleeding. Surgical options available include endometrial ablation, 
endometrial polyp removal, myomectomy or even hysterectomy
The two medical treatments for heavy menstrual bleeding have been effective 
enough. First, levonorgestrel intra-uterine system was FDA approved for the treat-
ment of heavy menstrual bleeding in 2009. It is highly effective for decreasing men-
strual bleeding, treating anemia and improving the overall quality of life. Secondly, 
tranexamic acid, also FDA approved for heavy menstrual bleeding in 2009, reduces 
menstrual blood loss in 40% of women and improves quality of life. Moreover, in 
women with fibroids, tranexamic acid has been shown to decrease heavy menstrual 
bleeding and cause necrosis of the fibroids, especially larger fibroids [13].
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5. Conclusion
Research on bleeding in fibroids is still far from over. Much more is still wanting.
Uterine fibroids are common debilitating problems for many women. Almost 
60% of women with fibroids report that symptoms affect their quality of life and 
impede their physical activity. Again, 24% of them report that fibroid symptoms 
prevent them from reaching their full potential at work. Heavy menstrual bleeding, 
which is the most common symptom of uterine fibroids, affects approximately 
1.4 million women per year.
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Abstract
The ovulation is a complex physiological process which is very commonly 
affected in patients with PCOS. Understanding inflammatory process involved in 
ovulation is important with respect to its onset, diagnosis and treatment. There are 
multiple inflammatory factors are associated with ovulation however anovulation 
and contraception have not been therapeutically explored in context with inflam-
matory process. Therefore, this chapter is written to help readers to understand the 
basics of inflammation in ovulation and role of inflammatory mediators in ovula-
tion. This chapter also describes genetic and molecular aspects linked to ovulation.
Keywords: inflammation, ovulation, cytokine, prostaglandin, TNF-alpha, PPAR-γ
1. Introduction
Mammalian ovulation is a fundamental physiological process involves the 
rupturing of follicle and releasing of the dominant follicle from the ovary into the 
fallopian tube where it has the potential to get fertilized if it exposed to sperm. 
Oocyte is covered up of four different layers namely the granulosa cells, which form 
a protected layer within oocyte and the extra follicular microenvironment, then 
theca layers of theca-interna and theca-externa, tunica albuginea and the outermost 
one is epithelium [1, 2]. A thin transparent layer between oocyte and follicular 
membrane is made up of secretions by the oocyte, termed as zona pellucida [2].
The developing oocyte enclosed in a ovarian follicle which is float in a dynamic 
fluid i.e. Follicular fluid (FF), contain variety of signaling molecules such as poly-
saccharides, hormones, cytokines, chemokines, growth factors, reactive oxygen 
species (ROS), metabolites, antioxidant enzymes, etc. The follicular fluid formed in 
developing antral follicles, primarily to support the development and protection of 
oocytes. These molecules are also acts as communicators between somatic and germ 
cells [3].
The duration of ovulatory process in humans, pigs, rats and rabbits takes 
approximately 40, 22, 12 and 10 hours respectively to complete. Substantial tissue 
remodeling occurs during the ovulation, the follicle increases its own size, and 
the layers of theca cells fuse with the tunica albuginea, resulting into thinner and 
permitting rupturing of follicle to release the oocyte [4]. The mature oocyte when 
released by the rupturing of follicle its uptake facilitated by the fingure like opening 
projections of fallopian tube which is known as fimbriae, if fertilization occur here 
then the blastocyst further transfer it towards the uterus where the pregnancy takes 
place [5].
Inflammation is defensive mechanism of the cells that is crucial to health and 
it is delineated as a local immune response of living vascularized tissues to endog-
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then the blastocyst further transfer it towards the uterus where the pregnancy takes 
place [5].
Inflammation is defensive mechanism of the cells that is crucial to health and 
it is delineated as a local immune response of living vascularized tissues to endog-
enous and exogenous stimuli and its actions is to removal of injurious stimuli with 
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starting the healing process [6]. Inflammation is also initiated when the cells die 
from deficiency of nutrients or hypoxia, a condition that often is originated by the 
blood flow loss to the site. The chemical mediators of the inflammation generally 
originate from the blood plasma, platelets, white blood cells (monocytes, neutro-
phils, basophils, and macrophages), endothelial cells lining of the blood vessels, 
mast cells, and injured tissue cells. The chemical mediators responsible for the 
inflammation is histamine, that stimulates vasodilation and increases the vascular 
permeability, and lysosomal substances acting as vascular permeability enhancer 
which are secreted from neutrophils, and certain small proteins in the complement 
system, namely C3a and C5a. Various cytokines released by inflammatory cells 
also have vasoactive and chemotactic function. Many cells produce prostaglandins 
which linked to the fever and pain of inflammation; a group of fatty acids which 
involves in the augmentation of vascular permeability of the other substances, 
platelets aggregation; which is essential for coagulation [6].
The objective of this review is to understand and establish a relationship 
between how the inflammation as well as different mediators of inflammation 
that influence the ovulation process that is crucial for clinical management and 
prediction of gynecological complications for future study.
2. Inflammatory genetic mechanism
Inflammation is detected throughout many normal reproductive progressions, 
for the duration of ovulation, menstruation, implantation, as well as parturi-
tion. Ovulatory cycle is also considered as inflammatory process because the 
rupturing of dominant follicle undergoes the process of healing [7]. Throughout 
ovulation, the role of inflammation is very significant in terms of folliculogenesis 
and luteinization. In the course of the rupturing of follicle, there is significant 
surge of intra-follicular pressure which leads to weakening of follicle layer by the 
stimulation of gonadotropins resulted in inflammation [8]. The inflammation 
notably persuades in both ovulation and tissue remodeling phase which resulted 
in events of hyperemia, vasodilation, edema, collagenolysis, and proliferation of 
cells [1].
Wissing et al. isolated differentially expressed 1186 genes in human granulosa 
cells (GC) before and 36 h after the administration of hCG, besides 572 genes found 
to be up-regulated which represented angiogenesis, inflammation, extracellular 
matrix and growth factors and 614 genes down-regulated which denoted cell cycle 
and about 72 genes which has been earlier establish linked with ovarian cancer. 
H19/mir675, CD24, CLDN11, ANKRD22, and FBXO32 adds as new ovulation 
related genes and PTGS2, an inflammatory gene heavily up-regulated [5].
3. Inflammatory oxygen species and ovulation
The release of mature oocyte relies on the expansion of cumulus oocyte complex 
(COC), where the reactive oxygen species (ROS) function as critical modulator 
of inflammatory reaction. Residual growing follicles promoted to apoptosis by 
the ROS [8]. Simultaneously estrogen synthesis started with the influx of catalase 
and Glutathione (GSH) i.e. a non-enzymatic antioxidant species exists in oocytes 
and embryos, in growing residual follicles for the maintenance of normal ovarian 
function and counter the apoptotic process. The luteal phase begins with pro-
gesterone production for the maintenance of preliminary stage of pregnancy, if 




induction of cell proliferation, maturation, cellular-differentiation and ovulation 
the physiological level of ROS is very important [9]. Augmented ROS may outcomes 
to DNA damage, activation of signaling cascades, and epigenetic alterations [10]. 
Inflammation in the course of ovulation is also responsible for the oxidative stress, 
damaging of DNA and moreover in the neoplastic ovarian surface epithelium (OSE) 
cells transformation [11].
4. PCOS and inflammation
Elevated level of inflammation also involves in the pathogenicity of many 
reproductive disorder such as polycystic ovary syndrome (PCOS), characterized 
by biochemical hyperandrogenemia, chronic anovulation, and polycystic ovaries. 
About 5 to 15% of reproductive age woman are suffering with this disorder in the 
world. It is anticipated that the metabolic disorders associated with PCOS and the 
pathogenesis of PCOS due to systemic inflammation as well as dysfunctioning 
of mitochondria. About 33% adolescent PCOS girls are more prone to metabolic 
disorder are obese, which is 3 to 5 folds higher if compared with same age healthy 
girls and body mass index (BMI) [9]. Studies reported and found the significant 
increased level of monocytes, lymphocytes, CRP, interleukins IL-1, IL-6, IL-18, 
pro-inflammatory cytokines and TNF- α in addition to increased production of 
advanced oxidation protein, protein carbonylation and lipid peroxidation in PCOS 
patients compared with same reproductive aged healthy persons [9]. The PCOS 
patients suffered with chronic inflammation [12, 13]. Along with the deficiency 
of antioxidant i.e. Vitamin C, Vitamin E and Superoxide dismutases (SOD), this 
leads to cause inflammatory milieu and risk to develop the obesity, type-1 diabetes, 
insulin resistance, hyperandrogenism, and cardiovascular ailment [1, 14].
5. Anti-inflammatory agents and ovulation
The surge of luteinizing hormone (LH) stimulate the production of cyclic 
adenosine monophosphate (cAMP), steroidal hormones, histamine discharge and 
various mediators of inflammation e.g. prostaglandins, bradykinins, C-reactive 
protein (CRP), Proinflammatory cytokines, etc. [1]. Christina et al. study states that 
the successful folliculogenesis, oocyte maturation, and ovulation require a healthy 
inflammatory response.
There are many findings illustrate that the importance of untroubled inflam-
matory response for proper folliculogenesis and ovulation, if it altered, may 
contribute to oocyte quality concern and reproductive dysfunctions such as 
anovulation, infertility, menstrual irregularities, etc. [5, 8]. It is reported that low 
dose of Aspirin taken by the patients suffering with higher systemic inflammation 
were able to reestablish the pregnancy [4, 12].
6. Correlation between hormone and inflammation
The level of LH also positive correlation with release of prostaglandins and 
eicosanoids that are the source to trigger the fibroblasts, promotes the angiogenesis 
and hyperemia, collagenase activation, release of proteolytic enzymes, some of 
which degrade the follicular connective tissue resulting ovulation, and cause the 
inflammation. The gene hyaluronan (HA) synthase-2 (Has2) associated with COC 
matrix formation. Bradykinin play a key role in vasodilation which appears to be 10 
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dose of Aspirin taken by the patients suffering with higher systemic inflammation 
were able to reestablish the pregnancy [4, 12].
6. Correlation between hormone and inflammation
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eicosanoids that are the source to trigger the fibroblasts, promotes the angiogenesis 
and hyperemia, collagenase activation, release of proteolytic enzymes, some of 
which degrade the follicular connective tissue resulting ovulation, and cause the 
inflammation. The gene hyaluronan (HA) synthase-2 (Has2) associated with COC 
matrix formation. Bradykinin play a key role in vasodilation which appears to be 10 
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folds increased during ovulation. The serum C- reactive protein (CRP), a marker of 
inflammation also raised to stimulate the production of interlukin-6 from macro-
phages, tumor necrosis factor α (TNFα) and the competent system of inflammatory 
response further activated by the adipocytes [13].
7. Role of proinflammatory cytokines
The role of proinflammatory cytokines is also important throughout folliculo-
genesis and induction of ovulation [5]. Higher level of follicular TNF-α resulted in 
the poor quality of oocyte which compromised with the fertility, also the elevated 
level of interleukin (IL-6) associated with less chances of conceiving while the 
another interleukin (IL-1) found to be regulated by FSH and its higher follicular 
level has been resulted in the higher chance on embryo implantation [7, 15].
8. Nucleotide leukin rich polypeptide -3 inflammasomes
A recent finding added a new mechanism for ovulatory process regulation, 
suggested that the NLRP3 activation of nucleotide leukin rich polypeptide 3 
(NLRP3) inflammasomes started before the ovulation lasting completion of 
ovulation. They induces the follicular development by 52 hours’ treatment using 
Pregnant mare serum gonadotropin (PMSG). It was found that the expression 
of NLRP3 inflammasomes and adaptor protein apoptosis-associated speck-like 
protein (ASC) significantly increased, and it was appeared a dramatic surge in 
caspase-1 activity and production of IL-1β [16].
9. Gonadotropin in inflammation
Gonadotropin surge trigger the ovlation with the parllel stimulation of two 
gens of preovulatory follicles in granulosa cells, prostaglandin-endoperoxide 
synthase 2 (PTGS2) and progesterone receptor (PGR). Secretion of LH stimulates 
the induction of both PTGS2 and PGR in preovulatory granulosa cells. Expression 
of PTGS2 stimulates inflammation by releasing pro-inflammatory prostaglandins 
wheras anti-inflammatory action through the PGR by the supression of pro-
inflamatory genes or thru the stimulation of antiinflammatory genes. Higher level 
of PGE2 and PTGS2 are associated with the ovarian disorders such as ovarian 
carcinoma, ovarian hyperstimulation syndrome (OHSS) as well as polycystic ovar-
ian syndrome (PCOS) [11].
10. Inflammatory prostaglandins
Prostaglandins (PGs) are signaling molecules derived from dietary fats with 
clinically relevant roles in reproductive biology. PGE2, for instance, promotes 
ovulation downstream of the luteinizing hormone surge. Excess consumption of 
nonsteroidal anti-inflammatory drugs, which inhibit prostaglandin-endoperoxide 
synthase (cyclooxygenase or Cox), is associated with reversible female infertil-
ity, likely due to failed ovulation. On the other hand, proinflammatory cytokines 






A study (Bongrani et, al.) based on the adipokines roles in the pathophysiology 
of PCOS, they analyzed the adipokines profile in the normal-weight PCOS patients 
and obese women with PCOS and comparison of these with the women whose only 
have a Polycystic ovary morphology. Whereas they found the PCOS patient reported 
with lower adiponectin level in serum as well as FF, and also the lower expression in 
adipose tissue of AdipoR1 and AdipoR2. In granulosa cells AdipoR1 expression was 
positively correlated with the follicular numbers, oocytes count and embryos, on the 
other hand there was no significant difference in AdipoR2 reporters was found. No 
correlation was established among the FF adiponectin concentration and expres-
sion of its receptor, AdipoR1/AdipoR2 in GCs. Dysregulation of adiponectin may be 
likely mechanisms which could be responsible for impairment of insulin-sensitivity 
in PCOS patient, and it seems to be independent of insulin resistance severity and a 
potential role of adiponectin in folliculogenesis.
12. Omentin
The concentration of Omentin in FF was found to be positively correlated with 
BMI, higher in obese patients compared to the normal weight patients. They also 
point out that the omentin may possibly be controlled by means of inflammation, 
because the expression of omentin altered in inflammatory conditions [18].
13. Oxidative stress
ROS is necessary to maintain the normal female reproductive physiology, it is 
involved in the oocyte maturation, corpus luteum apoptosis as well as embryonic 
development process. The release of mature oocyte depends on the expansion of 
cumulus oocyte complex (COC), where the reactive oxygen species (ROS) function as 
critical modulator of inflammatory reaction. The exposure of ROS may lead to undergo 
transformative alterations of epithelial cells in the ovary and fallopian tubes [10].
14. Tumor necrosis factor-α
It has a significant role in the process of ovulation as well as to excrete out the 
damaged corpous luteum from the ovarian tissue. It works by the ligand gated 
receptors, TNFR-I and TNFR-II [10, 19]. It is also linked with the various pathological 
conditions when its level elevated. It is also reported that the infertile women with 
PCOS reported to have higher free fatty acids and blood serum level of TNF-α when 
compared with the healthy patients. Oxidative stressed cells also found to release 
higher levels of TNF-α than the normal ovarian epithelial cells which results in an 
autocrine surge of TNF-α mRNA as well as in the form of expression in other pro-
inflammatory cytokines, chemokines, and angiogenic factors [10, 20, 21].
15. Interleukins
Interleukin-15 is an important interleukin which is negatively associated with 
the oocyte maturation. It belongs to the cytokines family having four α-helix 
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bundle, i.e. pleiotropic glycoprotein. It was reported to be higher in women with an 
unsuccessful assisted reproductive techniques outcomes (median value 1.4 pg./ml) 
than of the women those succeeded the clinical pregnancy (median value 0.8 pg./ml) 
[22]. The IL-6 is a regulator of cumulus cell-oocyte complex (COC) expansion and 
responsible for the quality of murine oocyte during the in-vitro fertilization.
16. Matrix metalloproteinases
The another factor which has been found to be involved in follicular develop-
ment as well as in the ovulation process are Matrix metalloproteinases (MMPs). 
The matrix metalloproteinases activities regulated by the specific tissue 
inhibitors called metalloproteinases (TIMPs) and endogenous inhibitors. The 
balance of both these is very essential for their activity and to maintain the 
normal ovarian physiology. It is well noticed that the MMP-2 and MMP-9 level 
increased during and before the 3 hours of ovulation if compared to 20–22 hour 
before the ovulation. Augmented level of MMP-9 also postulated in the PCOS 
pathophysiology and is also linked with progression and etiological to many 
other ailments such as cystic fibrosis, asthma, ulcerative colitis, cardiovascular 
disorders, atherosclerosis, etc. [23, 24].
17. Peroxisome proliferator-activated receptor gamma
The Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) is established 
to have an ability to prevent the expression of various signaling molecules also 
regulates the levels of prostaglandins through regulation of cyclooxygenase-2 and 
differentiation of immune cells especially those which are a part of inflammation. 
Thereby controls ovarian function, fertilization, and ovulation. Its proinflammatory 
activity is linked to the formation of prostaglandin E by downregulation of COX-2 
mRNA of granulosa cells whereas it is upregulated twice in PCOS [25]. It is also 
being proven that the PPAR-γ controls genes responsible for expression of TNF-
alpha and Interleukins along with others. The study is supported by use of PPAR-γ 
agonist which affected the functioning of ovaries by involving signal transduction 
of insulin and IGF [20].
18. Chemokines
Earlier study reported the expression of chemokine receptor-2 (C-C motif) 
(CCR2) in the human ovarian cumulus-oocyte complexes, theca cells, preovulatory 
follicles and in feline ovarian follicle walls. This receptor is believed to be involved in 
folliculogenesis and determines the reproductive lifespan of female [25] (Figure 1).
19. Conclusions
Inflammation is believed to be involved in triggering the process of ovulation. 
There are several factors, genes, receptors, proinflammatory mediators playing 
important but diverse role in ovulation. The extent of their role and intensity 
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Inflammatory process in ovulation.
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Abstract
Leiomyomas are the most common gynecologic and uterine neoplasms. Uterine 
leiomyomas present in approximately 25% of women during reproductive age. 
Extrauterine leiomyomas (EULs) are rarer and usually arise in the genitourinary 
tract, however, may arise at nearly any anatomic location and possess a great 
diagnostic challenge. Moreover, the EULs may also present with unusual growth 
patterns such as disseminated peritoneal leiomyomatosis, intravenous leiomyoma-
tosis, benign metastasizing leiomyoma, parasitic leiomyoma, and retroperitoneal 
mass. However, the cell of origin from smooth muscle cells and histological benign 
characteristics is similar to their uterine counterpart. The presence of a synchronous 
uterine leiomyoma or history of previous hysterectomy is a considerable evidence 
for the diagnosis of these abnormally located and unusual growth pattern display-
ing EULs. Different imaging modalities like ultrasonography, computed tomogra-
phy, and magnetic resonance imaging are helpful in the diagnosis of EULs, however, 
sometimes a histopathological examination is required for the confirmation.
Keywords: Extrauterine, leiomyoma, disseminated peritoneal leiomyomatosis, 
benign metastasizing leiomyoma, parasitic leiomyoma, genitourinary tract
1. Introduction
Leiomyomas are benign smooth muscle tumours usually arise from the uterus 
[1]. Classical uterine leiomyoma manifest as firm, well circumscribed mass, and 
localized to the pelvic cavity [2]. Extrauterine leiomyomas (EULs) are very rare and 
their etiology is not clear [1]. They grow in unusual patterns and locations, thus 
possess greater diagnostic challenge. Different presentations of EUL are dissemi-
nated peritoneal leiomyomatosis (DPL), parasitic leiomyoma (PL), uterine-like 
mass lesions, adenomyoma and endomyometriosis [3]. Unusual sites involvement 
like vulval and rectovaginal leiomyomas are also found [4]. EULs arising in the 
gastrointestinal tract, genitourinary tract, as well as other rare locations including 
sinonasal cavities, orbits, and skin are also described in some case reports.
Uterine leiomyoma is a benign tumour which originates from smooth muscle 
cells. Leiomyomas can present in abnormal growth patterns and tend to occur 
in extrauterine location especially in cases with prior history of hysterectomy or 
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localized to the pelvic cavity [2]. Extrauterine leiomyomas (EULs) are very rare and 
their etiology is not clear [1]. They grow in unusual patterns and locations, thus 
possess greater diagnostic challenge. Different presentations of EUL are dissemi-
nated peritoneal leiomyomatosis (DPL), parasitic leiomyoma (PL), uterine-like 
mass lesions, adenomyoma and endomyometriosis [3]. Unusual sites involvement 
like vulval and rectovaginal leiomyomas are also found [4]. EULs arising in the 
gastrointestinal tract, genitourinary tract, as well as other rare locations including 
sinonasal cavities, orbits, and skin are also described in some case reports.
Uterine leiomyoma is a benign tumour which originates from smooth muscle 
cells. Leiomyomas can present in abnormal growth patterns and tend to occur 
in extrauterine location especially in cases with prior history of hysterectomy or 
surgery for uterine leiomyomas.
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2. Types of EULs
2.1 Disseminated peritoneal leiomyomatosis
Multifocal proliferation of multiple smooth nodules throughout the peritoneal 
surface histologically similar to uterine myomas is known as leiomyomatosis 
peritonealis disseminate (LPD) or disseminated peritoneal leiomyomatosis (DPL) 
[3, 5, 6]. The peritoneal cavity shows multiple nodules of smooth muscle (Figure 1) 
[6, 7]. DPL usually occurs in reproductive age group with an indolent course, and 
are mostly detected incidentally [6]. Uterine myoma morcellation is a known risk 
factor for the development of DPL with an incidence rate around 0.12 to 0.95% 
after morcellation [5, 6]. Morcellation may lead to spreading of cellular materials 
of the myoma fragments. These morcellated tissues get disseminated if they are not 
removed and may become infarcted, necrotic or even parasitic [3]. Other causes 
which can contribute in the pathogenesis of DPL includes; hormonal, genetic, and 
sub-peritoneal mesenchymal stem cells metaplasia.
Pelvic region is the commonest site especially in pouch of douglas, may also 
spread to entire abdomen to involve omentum and mesentery. DPL is very invasive 
and very difficult for complete surgical excision, which may invade into blad-
der, retroperitoneal space, liver and small bowel [5]. They present as numerous 
subcentimetric grey -white firm nodules, sometimes with solid cystic hemorrhagic 
changes [5]. DPL can presents with ascites and adenopathy, which can be confused 
with peritoneal carcinomatosis. Sometimes, DPL may evolve into leiomyosarcoma, 
though it is extremely rare and possess high mortality rate [5, 6]. Due to unusual 
multifocal presentation, peritoneal myomas mimic malignant peritoneal tumor, so 
aggressive treatment at first surgical line should be avoided [6].
Some cases of gastrointestinal tract (GIT) leiomyomas have been reported with 
intestinal obstruction or bleeding without past or present history of uterine fibroid. 
But GIT leiomyomas are different from LPD. GIT leiomyomas can develop from 
intestinal wall and may reach the lumen whereas LPD mostly reach peritoneal cav-
ity and omentum [5]. But disseminated GIT leiomyoma could be related to LPD, if 
there is no evidence of uterine myomas [5].
2.2 Benign metastasizing leiomyoma
Benign metastasizing leiomyoma (BML) is a rare condition that affects women with 
a history of uterine myomectomy, which is found to metastasize to extra-uterine sites. 
The disease is characterized by monoclonal proliferation of smooth muscle cells and 
haematogenous spread from uterine leiomyoma to distant locations, most commonly 
Figure 1. 
(A) Contrast-enhanced T1-weighted fat-suppressed fast spin echo magnetic resonance image shows multiple 
homogeneously enhancing peritoneal leiomyomas (arrows), (B) Intra-operative gross image showing multiple 




the lungs (Figure 2) [2, 8]. The other uncommon site of metastasis includes heart and 
spinal cord [2]. Metaplastic transformation of the coelomic epithelium may explain 
BML in almost any place where mesothelial mesenchyme exists [2]. BML commonly 
occur during peri-menopausal period. Surgical excision is the treatment of choice.
2.3 Intravenous leiomyomatosis
Intravenous leiomyomatosis (IVL) also included under smooth muscle tumours 
with unusual growth pattern like that of benign metastasizing leiomyoma (BML) 
and diffuse peritoneal leiomyomatosis (DPL) and difficult to distinguish from them 
[2]. IVL is very rare variant of benign leiomyomas. It presents as fragile and mal-
leable leiomyoma that extends through adjacent venous structures in a worm-like 
fashion (Figure 3) [2]. Rarey, IVL may infiltrate into the right heart chamber and 
the lungs [6]. Due to wide range of clinical manifestation, IVL is difficult to diag-
nose pre-operatively [2].
2.4 Parasitic leiomyoma
Parasitic leiomyoma is termed when leiomyoma especially subserous fibroid 
is pedunculated off the uterine serosa or when fragments of a fibroid detach, get 
implanted and grow within the peritoneal cavity or becomes adherent to other 
structures, especially the omentum (Figure 4) [3]. They obtain their blood supply 
from nearby organ and the uterine pedicle either or become avascular and disap-
pear completely. These are also known as ectopic leiomyoma [3]. Cucinella et al. 
suggested morcellated hysterectomies or myomectomies as an important cause for 
development of parasitic leiomyoma [9].
Figure 2. 
(A) Abdomino-pelvic computed tomography showing a large pelvic mass, and (B) thoracic computed 
tomography showing bilateral lung nodules, Gross specimens (C) pelvic mass excision and (D) video-assisted 
thoracoscopic guided surgical resection of bilateral basal lung nodule in an operated case of total abdominal 
hysterectomy with bilateral salpingo-oopherectomy.
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Extrauterine adenomyomas (EUA) are benign tumours composed of smooth 
muscles, endometrial glands and endometrial stroma (Figure 5) [10]. In the 
literature, four hypotheses have been proposed for the development of EUA which 
includes (1) Müllerian duct fusion defect - the failure of fusion of Müllerian 
ducts result in either duplication or atresia of the uterus which is suggested by the 
formation of uterine-like masses, (2) Subcoelomic mesenchyme transformation - 
Subcoelomic mesenchyme is a layer of tissue that lies underneath the mesothelial 
surface of the peritoneum. It also lies underneath the subserosal stroma of uterus, 
uterine ligaments, ovaries and fallopian tubes, (3) Müllerianosis - It is a heterotopic 
Müllerian rests incorporated into other organs during organogenesis which may 
proliferate in response to hormones and (4) Endomyometriosis - along with endo-
myometriosis, smooth muscle hyperplasia or metaplasia leads to EUA [11, 12].
3. Role of hormones
Leiomyomas are clonal neoplasm and express more number of estrogen and 
progesterone receptors in comparison to normal myometrium [1, 2]. Circulating 
estrogen, progesterone and other growth factors like epidermal growth factor and 
Figure 3. 
(A) Magnetic resonance image showing a ‘comma’ shaped thrombosis, extending from the intrahepatic portion 
of inferior vena cava (IVC) to the right atrium, (B) Echocardiography showing an intracardiac mass with 
dynamic movement past the tricuspid valve into the right ventricle, (C) Gross specimen of total abdominal 
hysterectomy with left salpingo-oophorectomy, and IVC and intracardiac mass.
Figure 4. 
(A) Magnetic resonance image showing two large lobulated peritoneal masses with similar signal and 
enhancement characteristics, (B) Gross specimen of peritoneal fibroid vascularized by omental vessels in a 




insulin like growth factors are involved in the growth of uterine leiomyomas [1]. 
Estrogen stimulates the growth of leiomyoma independent of its location whether 
uterine or extrauterine [1]. However, the role of progesterone remains uncertain in 
extrauterine leiomyoma and it’s serum levels are either normal or low. Withdrawal 
of progesterone and of sex steroid down regulates expression of estrogen receptors 
(ER) in both leiomyomas and myometrium. This indicates that progesterone and 
progestins have a dual role on leiomyomas. First, limitation of the tissue response 
due to blocking of ER replacement and leading to unopposed estrogenic growth 
effect either by direct stimulation or by increased expression of progesterone recep-
tors (PR). Second, progesterone may leads to an intrinsic growth-stimulation [1]. 
Progesterone causes increased mitotic division causing myoma growth and leads to 
the higher propensity for development of the somatic mutations in the myomas. It is 
suggested that PR is highly expressed in leiomyomas occurring in the reproductive 
period [1]. Such hormones influence rapid increase in size of leiomyoma in preg-
nancy which may lead to fetal wastage. However, there is lower expression of PR in 
EUL than in UL suggesting that different factors may contribute to the development 
of these tumours. Sen et al found a significant difference for labeling indices of 
PR between UL and EUL, however it was not significant for ER. Thus, therapeutic 
models targeting PRs may not be effective on EUL.
4. Diagnosis
Patient may present with menorrhagia, or diagnosed incidentally with the 
history of previous myoma or myomectomy [3]. Ultrasound is useful for diagnosis 
of uterine fibroid. Prior diagnosis of extra-uterine fibroids is often difficult owing 
to non-specific clinical and radiological findings. MRI is very helpful when ultra-
sound shows poor delineation, and in case of rapidly growing fibroid suspicious for 
Figure 5. 
Intra-operative laparoscopic images of (A) pararectal adenomyoma and (B) right ovarian adenomyoma, 
histopathology images of ovarian adenomyoma (C) low power and (D) high power delineating smooth muscle 
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4. Diagnosis
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history of previous myoma or myomectomy [3]. Ultrasound is useful for diagnosis 
of uterine fibroid. Prior diagnosis of extra-uterine fibroids is often difficult owing 
to non-specific clinical and radiological findings. MRI is very helpful when ultra-
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Figure 5. 
Intra-operative laparoscopic images of (A) pararectal adenomyoma and (B) right ovarian adenomyoma, 
histopathology images of ovarian adenomyoma (C) low power and (D) high power delineating smooth muscle 
bundles with embedded endometrial glands in a patient underwent laparoscopic myomectomy 5 years earlier.
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malignant transformation. MRI is also very useful for the diagnosis of DPL as well 
as to determine its extent of spread for surgical planning (Figure 1A) [3]. In case of 
IVL, apart from trans-vaginal ultrasound, and other modalities such as pelvic MRI, 
trans-thoracic echocardiography, abdomen or chest computed tomography (CT), 
and positron emission tomography (PET) are beneficial [2]. But there is limitation 
of MRI in locating retroperitoneal leiomyoma in which exact anatomical location 
can be often ascertained only intraoperatively [3]. Few cases may turn into leiomyo-
sarcoma. Peritoneal cytology should be done in case of ascites [3].
Despite the extrauterine manifestation of leiomyoma, benign leiomyomas can be 
distinguished from leiomyosarcoma histologically. Sarcoma is marked by high grade 
cellular atypia, mitotic index of greater than 10, and presence of coagulative tumor 
cell necrosis [2]. IVL, usually found within uterine venous channels and micro-
scopically shows benign appearing smooth muscle cells with low mitotic activity 
which stain for actin and desmin [2].
Recent investigations showed that IVL and BML share the same cytogenetic origin, 
demonstrated by comparative genomic hybridization, clonal number, and copy vari-
ance [2]. Leiomyoma and leiomyosarcoma both shows smooth muscle differentiation, 
however biologically they are different in relation to clinical, cytogenetic, and molecu-
lar features [13]. MED12, the mediator complex subunit 12 gene, is a recently described 
oncogene found in both primary and metastatic leiomyosarcoma. It is detected in as 
many as 70% of sporadic uterine leiomyoma [13]. Oncogenic roles of MED 12 gene is 
also detected in smooth muscle tumours arising in extrauterine locations, however, fur-
ther validating studies required for confirming its exact role in their pathogenesis [13].
5. Treatment
Complete surgical excision is considered the mainstay and definitive treatment 
for EULs [14]. LPD mimics carcinomatosis, so total abdominal hysterectomy along 
with bilateral oophorectomy is often the preferred surgical treatment [5]. However, 
spontaneous regression has been also described in few case reports in the literature 
[5]. Surgical treatment affects reproductive ability in pre-menopausal women, 
so it should always be planned considering the family planning of the patient. In 
such situation diagnosis by intra-operative frozen section is very helpful [5]. Young 
patient in child bearing age group, especially who shows positivity for ER or PR 
markers in EUL, should be subject to ovary-sparing procedures and might be ben-
efited from adjuvant therapy using GnRH agonist [2]. In histological proven DPL 
cases, debulking is very effective for relieving symptoms, provided the appropriate 
evaluation of general health conditions of the patient [5]. In unresectable cases of 
EULs, a medical treatment with aromatase inhibitors, chemotherapeutic agents 
or a gonadotropin agonist can be considered [2, 6]. During morcellation, falling 
pieces of myoma fragments should be avoided and proper attention should be given 
during removal via the port site. Post morcellation, reverse trendelenburg position 
should be attempted and thorough inspection with copious peritoneal lavage is 
recommended to aid the removal of remnant myoma pieces [3]. The Food and Drug 
Administration guidelines discourage the uses of laparoscopic power morcellation 
during hysterectomy or myomectomy for the treatment of uterine fibroids [3].
6. Follow-up
A routine follow-up is advised in all the patients of uterine fibroid undergo-
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essential in all the operated cases of EUL, particularly, DPL. In EULs, recurrence, 
if any, usually occur within 6 months after surgical resection. Since, these tumours 
are hormone sensitive, they usually show regression after reduction in estrogen 
exposure like after attainment of menopause. Repeat surgeries for recurrent EULs 
usually entail greater surgical difficulty and risks including visceral injuries [3].
7. Complications
DPL may leads to peritonitis and bowel obstruction which can result into sepsis 
and gangrene. Also, recurrence is not unusual in DPL cases due extensive involve-
ment of peritoneal cavity. Sometimes, malignant transformation may occur in long 
standing cases.
8. Conclusions
EULs possess a great diagnostic challenge due to abnormal locations as well as 
their unusual growth patterns and more commonly associated with the complications 
in comparison to uterine leiomyomas. Though, histologically they show similarities 
with their uterine counter parts, however their pathogenesis is different and yet not 
well understood. These EULs, are hormone sensitive and may regress automatically 
after the recession of hormonal sources, however, this phenomenon is not universal 
in all cases. Due to their higher propensity for recurrence and rare malignant trans-
formation a close follow-up is required. A peritoneal cytology and/or frozen section 
examination is recommended before major surgical procedures in EULs.
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cellular atypia, mitotic index of greater than 10, and presence of coagulative tumor 
cell necrosis [2]. IVL, usually found within uterine venous channels and micro-
scopically shows benign appearing smooth muscle cells with low mitotic activity 
which stain for actin and desmin [2].
Recent investigations showed that IVL and BML share the same cytogenetic origin, 
demonstrated by comparative genomic hybridization, clonal number, and copy vari-
ance [2]. Leiomyoma and leiomyosarcoma both shows smooth muscle differentiation, 
however biologically they are different in relation to clinical, cytogenetic, and molecu-
lar features [13]. MED12, the mediator complex subunit 12 gene, is a recently described 
oncogene found in both primary and metastatic leiomyosarcoma. It is detected in as 
many as 70% of sporadic uterine leiomyoma [13]. Oncogenic roles of MED 12 gene is 
also detected in smooth muscle tumours arising in extrauterine locations, however, fur-
ther validating studies required for confirming its exact role in their pathogenesis [13].
5. Treatment
Complete surgical excision is considered the mainstay and definitive treatment 
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with bilateral oophorectomy is often the preferred surgical treatment [5]. However, 
spontaneous regression has been also described in few case reports in the literature 
[5]. Surgical treatment affects reproductive ability in pre-menopausal women, 
so it should always be planned considering the family planning of the patient. In 
such situation diagnosis by intra-operative frozen section is very helpful [5]. Young 
patient in child bearing age group, especially who shows positivity for ER or PR 
markers in EUL, should be subject to ovary-sparing procedures and might be ben-
efited from adjuvant therapy using GnRH agonist [2]. In histological proven DPL 
cases, debulking is very effective for relieving symptoms, provided the appropriate 
evaluation of general health conditions of the patient [5]. In unresectable cases of 
EULs, a medical treatment with aromatase inhibitors, chemotherapeutic agents 
or a gonadotropin agonist can be considered [2, 6]. During morcellation, falling 
pieces of myoma fragments should be avoided and proper attention should be given 
during removal via the port site. Post morcellation, reverse trendelenburg position 
should be attempted and thorough inspection with copious peritoneal lavage is 
recommended to aid the removal of remnant myoma pieces [3]. The Food and Drug 
Administration guidelines discourage the uses of laparoscopic power morcellation 
during hysterectomy or myomectomy for the treatment of uterine fibroids [3].
6. Follow-up
A routine follow-up is advised in all the patients of uterine fibroid undergo-
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essential in all the operated cases of EUL, particularly, DPL. In EULs, recurrence, 
if any, usually occur within 6 months after surgical resection. Since, these tumours 
are hormone sensitive, they usually show regression after reduction in estrogen 
exposure like after attainment of menopause. Repeat surgeries for recurrent EULs 
usually entail greater surgical difficulty and risks including visceral injuries [3].
7. Complications
DPL may leads to peritonitis and bowel obstruction which can result into sepsis 
and gangrene. Also, recurrence is not unusual in DPL cases due extensive involve-
ment of peritoneal cavity. Sometimes, malignant transformation may occur in long 
standing cases.
8. Conclusions
EULs possess a great diagnostic challenge due to abnormal locations as well as 
their unusual growth patterns and more commonly associated with the complications 
in comparison to uterine leiomyomas. Though, histologically they show similarities 
with their uterine counter parts, however their pathogenesis is different and yet not 
well understood. These EULs, are hormone sensitive and may regress automatically 
after the recession of hormonal sources, however, this phenomenon is not universal 
in all cases. Due to their higher propensity for recurrence and rare malignant trans-
formation a close follow-up is required. A peritoneal cytology and/or frozen section 
examination is recommended before major surgical procedures in EULs.
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Submucosal fibroids account for 10% of total fibroids. They significantly impact 
quality of life causing abnormal uterine bleeding (AUB), reduction in fertility 
rates/infertility, obstetrics complications and abdominal pain. They are a major 
public health concern because of economic cost their monitoring and treatment 
requires. Hysteroscopic myomectomy is the first line minimally invasive and 
conservative surgical treatment. Treating a fibroid correctly implies knowing its 
physiopathology: What is a submucosal fibroids and what is its origin, what is 
the Pseudocapsule?. Proper diagnosis and standardized classification such as the 
Wamsteker classification are required. What are the limits to perform a hystero-
scopic myomectomy? What devices are currently used? What are the requirements 
for conducting myomectomy procedures in the outpatient setting?. Different forms 
of surgical approach. Complications and consequences of a myomectomy. What 
will we do in the future with the management of small submucosal fibroids in 
asymptomatic patients with future genetic desires and can we resect type 3 fibroids 
by hysteroscopy avoiding a higher risk surgery by abdominal route?
Keywords: submucosal fibroid, pseudocapsule, hysteroscopic approach,  
outpatient myomectomy, economic impact
1. Introduction
Uterine fibroids are the most common benign pelvic tumors of the female geni-
tal tract. Their incidence is approximately 25–30% and may be higher depending on 
race, family history and genetics. Although most fibroid tumors are asymptomatic, 
they are a significant health issue due to the economic cost incurred by healthcare 
systems to monitor and treat them. The impact on the quality of life of women with 
this condition can be considerable.
Direct medical care expenses include surgery, treatment expenses for outpatient 
care and monitoring expenses. The indirect expenses include costs derived from 
inability to work and deterioration in the ability to perform usual tasks. Moreover, 
they include the expenses for obstetrical complications related to their presence or 
treatment. Obstetrical morbidity costs amount to $7.76 billion in the annual costs of 
myoma in the US. They cost more each year in the US than breast, ovarian and colon 
cancer [1–3].
When talking about fibroids and hysteroscopy, we are talking about submucosal 
fibroids, since they are the types of fibroids in the FIGO classification that can be 
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Submucosal fibroids account for 10% of total fibroids. They significantly impact 
quality of life causing abnormal uterine bleeding (AUB), reduction in fertility 
rates/infertility, obstetrics complications and abdominal pain. They are a major 
public health concern because of economic cost their monitoring and treatment 
requires. Hysteroscopic myomectomy is the first line minimally invasive and 
conservative surgical treatment. Treating a fibroid correctly implies knowing its 
physiopathology: What is a submucosal fibroids and what is its origin, what is 
the Pseudocapsule?. Proper diagnosis and standardized classification such as the 
Wamsteker classification are required. What are the limits to perform a hystero-
scopic myomectomy? What devices are currently used? What are the requirements 
for conducting myomectomy procedures in the outpatient setting?. Different forms 
of surgical approach. Complications and consequences of a myomectomy. What 
will we do in the future with the management of small submucosal fibroids in 
asymptomatic patients with future genetic desires and can we resect type 3 fibroids 
by hysteroscopy avoiding a higher risk surgery by abdominal route?
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1. Introduction
Uterine fibroids are the most common benign pelvic tumors of the female geni-
tal tract. Their incidence is approximately 25–30% and may be higher depending on 
race, family history and genetics. Although most fibroid tumors are asymptomatic, 
they are a significant health issue due to the economic cost incurred by healthcare 
systems to monitor and treat them. The impact on the quality of life of women with 
this condition can be considerable.
Direct medical care expenses include surgery, treatment expenses for outpatient 
care and monitoring expenses. The indirect expenses include costs derived from 
inability to work and deterioration in the ability to perform usual tasks. Moreover, 
they include the expenses for obstetrical complications related to their presence or 
treatment. Obstetrical morbidity costs amount to $7.76 billion in the annual costs of 
myoma in the US. They cost more each year in the US than breast, ovarian and colon 
cancer [1–3].
When talking about fibroids and hysteroscopy, we are talking about submucosal 
fibroids, since they are the types of fibroids in the FIGO classification that can be 
approached in this way (FIGO Leiomyoma classification system) (Figure 1).
Fibroids
34
Submucosal fibroids amount to 5.5–10% of all uterine fibroids. They are fre-
quently associated with abnormal uterine bleeding and infertility: women with 
submucous myomas are less likely to conceive, have significantly higher miscar-
riage rates and lower rates of successful deliveries, regardless of the conceptive 
method. There is scientific proof to support this fact. They have an impact on the 
functioning of the uterus and they cause changes in the normal anatomy of the 
uterus, alterations in blood supply, increased contractility, local hormonal changes 
and an action on the genetic expression of the endometrium (the endometrial RNA 
levels of HOXA11, LIF and BTEB1 decrease significantly in unfertile patients with 
uterine fibromas compared to healthy fertile control subjects at the moment of 
implantation). Removal of the myoma increases the fertility potential and the IVF 
results, increasing pregnancy rates from 17% to up to 80% according to the series. 
Therefore, it is reasonable to recommend surgical treatment in women who want to 
get pregnant and women that present abnormal uterine bleeding (AUB) [4–6].
Hysteroscopic myomectomy can be considered as the first-line minimally-inva-
sive surgical treatment for submucosal myomas. This technique allows submucosal 
fibroids to be removed and the uterus to be preserved with minimal complications 
and rapid recovery times [7–10].
The execution of surgical hysteroscopy on an outpatient setting has turned into 
the gold standard of the medical practice.
There are many benefits to performing hysteroscopy in an outpatient setting, 
provided it is done safely and effectively, compared to hysteroscopy in the operat-
ing room: it does not require hospital admission, preoperative testing, or general 
or local anesthesia; it decreases post-surgical recovery times and overall procedure 
costs and it improves procedure satisfaction level for both healthcare providers and 
patients [11–15].
2. Submucosal myoma. Physiopathology
Submucosal fibroids are those fibroids that grow into the uterine cavity 
(Figure 2).
2.1 Origin submucosal fibroid
In order to treat a fibroid correctly, we must know its origin and the concept of 
pseudocapsule.
Figure 1. 
FIGO Leiomyomas subclassification system.
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Fibroids are benign tumors that develop from a myometrial cell. It is not 
known why a myometrial cell starts multiplying uncontrollably, but we do know 
that their growth is estrogen-dependent. Fibroids have the mechanical capacity to 
push the healthy myometrium around them; the mechanical properties of fibroids 
are a key factor in their growth. Due to the compression exerted on surrounding 
structures, the fibroid induces gradual formation of a protective structure known 
as pseudocapsule that separates the fibroids from healthy uterine tissue. They 
grow inside the myometrium towards the least-resistance zone and, in the case of 
submucous myomas, they grow into the endometrial cavity. Submucosal myomas 
G0, G1 and G2 are classified as different transition phases of the same myoma 
[16] (Figure 3).
2.2 Pseudocapsule
Pseudocapsules are entities whose existence has been proven both histologically 
and through Doppler echography (this structure is seen as a ring of fire on an echo-
gram). It has a different genetic expression profile than a normal myometrium and 
the surrounding myoma. This pseudocapsule is an independent entity, expressed 
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blood vessels and neurofibers and it is rich in neuropeptides and neurotransmit-
ters. These substances are believed to have an important role in wound healing and 
nerve repair, and they may be important for sexual and reproductive functions after 
resection of the myoma.
The fibroid is anchored through the pseudocapsule through connective bridges 
and small vessels creating a clear abscission plane between the fibroid and the 
pseudocapsule.
Contrary to popular belief, and except for pedunculated fibroids, other fibroids 
do not have a vascular pedicle that feeds them. The neurovascular network of the 
pseudocapsule is responsible for their irrigation (Figure 4) [17, 18].
3. Hysteroscopy: diagnosis and treatment
Hysteroscopy is currently the gold standard used to diagnose and determine the 
feasibility of resection of submucosal fibroids. It allows direct visualization of the 
uterine cavity and the identification of other intracavitary lesions. However, it only 
provides a subjective assessment of the size of the fibroid and indirect information 
about the degree of extension of the fibroid into the endometrial cavity.
3.1 Historical perspective
During the last two decades, thanks to advances in instruments and refine-
ment of techniques, hysteroscopic myomectomy has acquired the status of ‘surgi-
cal technique’ and, today, represents the minimally invasive standard surgical 
procedure for the treatment of fibroids totally or mostly located in the uterine 
cavity.
William Norment performed the first hysteroscopic myomectomy in 1957 using 
the cutting handle. In 1976, Neuwirth and Amin reported a transcervical approach 
to excision of fibroids using a combination of techniques such as electrocautery 
and egg forceps. Neuwirth subsequently introduced a new technique for the 
resection of submucosal fibroids using the urologic resectoscope in 1978. Glycine 
(1.5% solution) was used for the first time by Haning et al. as a means of disten-
tion. Hallez created a specially designed dual-flow resectoscope for the uterus that 
allows full myomectomies even in cases of embedded fibroids. The gynecological 
resectoscope is currently the instrument of choice for the treatment of submucosal 
fibroids but mechanical morcellators are gaining popularity due to their mechanical 
Figure 4. 
Pseudocapsule and abscission plane.
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characteristics for the performance of myomectomy and their lower rates of com-
plications and synechiae after myoma surgery [19–23].
3.2 Other diagnostic procedures
There are other less invasive diagnostic procedures such as sonohysterography 
(SHG) that can provide better objective knowledge of the fibroid and with less cost 
and low complication rate.
Two-dimensional ultrasound with installation of sterile physiological saline in 
the endometrial cavity called sonohysterography is an established technique that 
allows the visualization of intracavitary lesions such as submucosal myomas with 
a higher precision than conventional two-dimensional ultrasound and comparable 
to that of diagnosis hysteroscopy. In addition, SHG allows an accurate assessment 
of the number of fibroids, measurement of fibroid size, and the thickness of the 
overlying myometrium, which is called the myometrial free margin.
The myometrial free margin is a limiting factor for safe myoma resection during 
hysteroscopic myomectomy, but we can fix this problem by taking advantage of 
the contractile capacity of the myometrium with different pressure changes of the 
distension medium [24].
3.3 Classification: fibroid types 0, 1, and 2
In 1993, in the face of the surgical complexity posed by some deeply penetrating 
submucosal myomas, Wamsteker et al. proposed a classification system for submu-
cosal fibroids to predict the difficulty of the surgical procedure, depending on the 
penetration degree of the fibroid in the myometrium. With this classification, gyne-
cologists can estimate the likelihood of completing the hysteroscopic removal of the 
submucosal fibroid in a single procedure. The Wamsteker classification was adopted 
by the European Gynecological Endoscopy Society (ESGE) and the leiomyoma 
classification system of the International Federation of Gynecology and Obstetrics 
(FIGO) includes the Wamsteker classification for submucosal fibroids, depending 
on the penetration degree of the fibroid in the myometrium, the fibroid will form 
an angle with the uterine cavity: Type 0 = fibroids attached to the cavity by a narrow 
pedicle, Type 1 = fibroids with an angle of less than 90° with the adjacent uterine 
wall, Type 2 = fibroids forming an angle of 90° or more with the adjacent uterine 
wall (Figure 5).
Figure 5. 
Wamsteker and ESGE classification depending depth myometrial penetration.
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pedicle, Type 1 = fibroids with an angle of less than 90° with the adjacent uterine 
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Should we treat all submucosal fibroids in the same way?
The approach to G0 fibroids with pedicles and without an intramural component 
should be different from G1-G2 fibroids that have an intramural component. We 
need to standardize the therapeutic approach to fibroids and follow pre-established 
guidelines [19, 25, 26].
4.1 Approach to fibroid type 0
It is recommended to cut the vascular pedicle and then the extract the fibroid 
with forceps, morcellation, vaporization, etc. These options depend on the size of 
the fibroid. Some authors recommend leaving the fibroma fragments inside the 
uterine cavity, which will be expelled naturally after several menstrual cycles.. 
There are other authors who advise against it due to bleeding and colicky pain until 
expulsion. A preliminary biopsy will always be necessary, if left ̈ in situ ̈ until its 
expulsion.
4.2 Approach to fibroid types 1 and 2
The general principle for a correct myomectomy is the enucleation of the 
fibroid; for that purpose, we must find the correct plane and that is the pseudo-
capsule plane. Enucleation of the fibroid through the pseudocapsule allows for 
preservation of the neurovascular network of the myoma, rich in neuropeptides 
and neurotransmitters, which are important for a correct healing of the affected 
myometrium. When cutting at the correct plane of the pseudocapsule, we find lax 
bridges of connecting tissue and multiple capillaries or small vessels. Dissecting 
this plane is easy due to its laxity, and it progressively detaches from the fibroid 
while its irrigation becomes compromised by cutting off the surrounding irrigation. 
Dissection of the correct layer decreases bleeding during surgery.. Another benefit 
of retaining its plane is the preservation of the integrity of the underlying myo-
metrium, thus preventing scars. Scars on the myometrium affect fertility after the 
procedure and contribute to the formation of post-surgical adhesions.
There are different techniques to approach the pseudocapsule, but in all of them 
we have to weaken the endometrial surface that covers the fibroid and that contains 
it within the intramural plane, we must weaken it to allow the fibroid to protrude 
into the uterine cavity, helped by the pressure changes of the median distensor 
and physiological myometrial contraction. The technique to address fibroids will 
depend on the intracavitary component:
On the one hand, if the fibroid has a small intracavitary component, we can 
choose one of the following techniques: all of them involve making an incision in 
the endometrial lining of the fibroid and promote the protrusion of the fibroid 
inside the uterine cavity. We can remove the fibroid in one or two step.
Bettochi technique (OPPIuM). this incision is made on the line of the reflection 
of the fibroid with uterine wall.
Myomectomy in toto. In this technique the incision is elliptical.
On the other hand, if the fibroid has a large intracavitary component, first we 
resect this component, then to perform the enucleation of the pseudocapsule and 
lastly remove the rest of fibroid, using the following techniques:
Mazzon technique. Also known as the “Cold loop” technique, developed by 
Mazzon in 1995, it uses monopolar or bipolar electrodes by slicing the intracavitary 
component and the Cold loop. It is a mechanical instrument to perform the enucle-
ation of the pseudocapsule.
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This technique is characterized by a sequence of three different opera-
tional steps:
First, the intracavitary portion of the fibroid is cut by repeated and progressive 
steps of a semicircular monopolar cut. This action stops at the plane of the endome-
trial surface so that the passage between the fibroid and the adjacent myometrium 
are clearly identified (pseudocapsule). Second, cold enucleation of the intramural 
portion of the fibroid is performed by pulling and lever maneuvers with non-elec-
trical “cold” loops. Once the intracavitary portion is resected, the usual cutting loop 
is replaced on the same resectoscope using a suitable cold loop blunt dissection. By 
gentle traction on the fibroid, the pseudocapsule is clearly identified and the cold 
loops are then inserted into this avascular space. These loops are progressively used 
in a mechanical form that hooks and lacerates the connective bridges that join the 
fibroid to normal tissue.
Lastly, the removal of the enucleated intramural portion is completed by 
progressive cutting, being completely dislocated and therefore safely treatable 
as a lesion with a total intracavitary development which can thus be completely 
and safely excised by standard progressive excision using an angled cutting 
loop [27].
Hydromassage Technique. It changes the distention pressures of the uterine 
cavity, which achieves the same effect as the mechanical instruments such as Cold 
loop and Tissue Removal device (TRD).
Hydromorcellation Technique: Maneuvers combined with the TRD and the 
irrigation system (continuous infusion pump) are performed to distend the intra-
uterine cavity, making changes in intrauterine pressure with rises and falls of flows 
that will favor myometrial contractions.
The objective of this combined technique is to weaken the endometrial surface 
that lines the fibroid and thus allow the fibroid to protrude into the cavity. To 
weaken the endometrial surface that covers the fibroid, we will use the TRD and to 
promote the protrusion of the fibroid into the uterine cavity with the contractions 
of the myometrium, we will perform “hydromassage maneuvers” with changes in 
the flow of intrauterine distension.
We will approach the TRD to the surface that covers the fibroma, either in 
its upper pole or in the cleavage plane of the fibroid with the uterine cavity and 
once this surface has been weakened, we will perform maneuvers to change the 
intrauterine distension, lowering and raising the pressures of flow, even stop-
ping the procedure for 1 or 2 minutes, in cases of fibroids with a large intramural 
component.
With these innovative maneuvers to change intrauterine pressure, we promote 
contractions of the myometrium and allow the myoma to protrude into the cavity, 
visualizing the plane of the pseudocapsule and its bridges and proceeding to mor-
cellate the intracavitary portion that protrudes from the intramural portion of the 
myoma [28].
4.3 On-site hysteroscopy
There are many centers where hysteroscopy, even diagnostic hysteroscopy, is 
commonly performed with general anesthesia in the operating room. In reality, 
while it is a challenge to perform hysteroscopy in an outpatient setting, it is even 
harder to convince gynecologists around the world, who are still performing this 
procedure as a surgical procedure that women deserve the option of a less invasive 
approach. While the skillset needed for outpatient hysteroscopy can be demanding, 
global progress in this procedure is patchy. Recommendations for the execution of 
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cavity, which achieves the same effect as the mechanical instruments such as Cold 
loop and Tissue Removal device (TRD).
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irrigation system (continuous infusion pump) are performed to distend the intra-
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that will favor myometrial contractions.
The objective of this combined technique is to weaken the endometrial surface 
that lines the fibroid and thus allow the fibroid to protrude into the cavity. To 
weaken the endometrial surface that covers the fibroid, we will use the TRD and to 
promote the protrusion of the fibroid into the uterine cavity with the contractions 
of the myometrium, we will perform “hydromassage maneuvers” with changes in 
the flow of intrauterine distension.
We will approach the TRD to the surface that covers the fibroma, either in 
its upper pole or in the cleavage plane of the fibroid with the uterine cavity and 
once this surface has been weakened, we will perform maneuvers to change the 
intrauterine distension, lowering and raising the pressures of flow, even stop-
ping the procedure for 1 or 2 minutes, in cases of fibroids with a large intramural 
component.
With these innovative maneuvers to change intrauterine pressure, we promote 
contractions of the myometrium and allow the myoma to protrude into the cavity, 
visualizing the plane of the pseudocapsule and its bridges and proceeding to mor-
cellate the intracavitary portion that protrudes from the intramural portion of the 
myoma [28].
4.3 On-site hysteroscopy
There are many centers where hysteroscopy, even diagnostic hysteroscopy, is 
commonly performed with general anesthesia in the operating room. In reality, 
while it is a challenge to perform hysteroscopy in an outpatient setting, it is even 
harder to convince gynecologists around the world, who are still performing this 
procedure as a surgical procedure that women deserve the option of a less invasive 
approach. While the skillset needed for outpatient hysteroscopy can be demanding, 
global progress in this procedure is patchy. Recommendations for the execution of 
an outpatient hysteroscopy [29–31].
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1. The incorporation of “outpatient hysteroscopy” into clinical practice has 
shown economic benefits (Grade II evidence, Grade A recommendation).
2. Gynecologists should be able to perform outpatient hysteroscopy for the diag-
nosis and treatment of women with abnormal uterine bleeding, infertility and 
intrauterine abnormalities.
3. Outpatient hysteroscopy should be performed in a room of adequate size and 
fully equipped, there must always be an assistant/companion in the room for 
patient safety and privacy (Grade II evidence, Grade B recommendation).
4. The hysteroscopist must have the skills and experience to perform a hysteros-
copy (Grade VI, Grade A recommendation).
5. Written informed consent must be obtained before initiating the procedure.
Moving hysteroscopic procedures outside the operating room and bringing them 
into the outpatient setting facilitates the logistics around hysteroscopy: they are more 
cost-effective, they will improve the productivity of doctors and allow for easier 
surgical scheduling, they will improve patient satisfaction and make recovery times 
shorter. In the United States in 2017, the payment for hysteroscopic polypectomy was 
reduced by $30 when performed in an operating room, while the payment increased 
by $972 when performed as an outpatient procedure. Performing the hysteroscopy as 
a surgical procedure will incur additional costs for anesthesia fees and hospital fees. 
There is a significant benefit in increasing the number of outpatient procedures.
Patients appreciate the convenience of the “see and treat” approach to a gyne-
cological problem and often prefer to avoid the inconvenience of going through 
surgery and the additional risks of undergoing anesthesia. They are associated 
with greater patient satisfaction and faster recovery compared to hysteroscopy in a 
hospital [12, 32].
The treatment sequence will depend on the workflow of each department and 
the surgical material available. It can be done in one step –“see and treat” – or in two 
or more steps, depending on the complexity of the pathology to be treated.
Therefore, it will be possible to conduct a hysteroscopy in an operating room or 
on an outpatient setting.
4.4 Surgical devices
Technological advances in surgical devices over the last 2 decades have brought 
hysteroscopy to maturity in the 21st century, allowing for many outpatient 
procedures.
Reliable equipment is an essential prerequisite for safe surgery.
The advent of modern small diameter (less than 5.5 mm) hysteroscopes, along 
with 5–7 Fr miniature mechanical ancillary instruments (scissors, forceps, bipolar 
electrodes, e.g. Versapoint™ [Gynecare, Ethicon Inc., Menlo Park, CA, USA). U.S]; 
tissue retrieval systems: TRUCLEAR ™ [Smith & Nephew Inc., Andover, MA, UH. 
USA], MyoSure® [Hologic, Marlborough, MA, USA] have led to a paradigm shift 
in surgical interventions leading to procedures that were performed under general 
anesthesia being conducted in an outpatient setting with local anesthesia only and 
if necessary [14, 33].
In 2005, Campo et al. evaluated the effects of instrument diameter, patient 
parity and surgeon experience of pain during office hysteroscopy and the suc-
cess rate of the procedure. They found that all outcomes (pain, visualization and 
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success rate) were largely influenced by patient parity and the diameter of the 
hysteroscope. Compared to less experienced surgeons, those with more experi-
ence caused less procedure pain. In contrast to the use of a hysteroscope with an 
outer diameter of 5 mm, outpatient hysteroscopy with a mini-hysteroscope (outer 
diameter of 3.5 mm) was preferable. The operating hysteroscope contains a work-
ing element which introduces electrosurgical and mechanical instruments for the 
myomectomy surgery [34].
Working with minimal intrauterine distension pressures, sufficient for adequate 
visualization, will reduce patient discomfort and serious complications such as 
fluid overload. Isotonic solutions (normal saline) are recommended as distension 
medium. It is essential that all hysteroscopic surgery offices have a control system 
for the balance fluids during the procedure and a protocol for the management of 
excessive fluid deficit [35–38].
In order to perform outpatient myomectomy, these devices must work quickly 
but the surgeon should also be comfortable with the device that they are using.
It exists new surgical devices with small diameters that can be used for myomas in 
an outpatient setting, without general or local anesthesia and using different types of 
energy such as the Versapoint system with bipolar energy, mechanical TRDs or laser.
4.4.1 Versapoint
Versapoint® with bipolar energy system. Currently, there are 5 bipolar elec-
trodes available on the market, three of these electrodes can be used with small-
diameter hysteroscopes and they have different terminals for specific tasks. The 
three different terminals are: the spring (for vaporization), the twizzle (for cutting) 
and the ball (for coagulation), and the other two electrodes can only be used with a 
classic resectoscope. They cannot be used in an outpatient setting.
4.4.2 Laser
This device achieves different effects depending on the wavelength: cutting, 
coagulation, vaporization. The laser most commonly used in hysteroscopy was the 
Neodymium laser and currently BIOLITEC with Selective Light Vaporization.
4.4.3 Mini-resectoscopy
The Gubbini Mini-resectoscope which has a small diameter for outpatient 
procedures uses terminals with bipolar energy and different tips (ball, loop, blade) 
to perform the same function as traditional resectoscopes.
4.4.4 Hysteroscopic TRDs
The Hysteroscopic TRD is a hysteroscopic mechanical system used to remove 
polyps and submucosal myomas. It has a terminal with a side window and a 
mechanical cutting blade, which rotates and oscillates at the same time. It is based 
on a rotary tubular cutting system with mechanical energy based on suction instead 
of the high-frequency electric power historically used in resectoscopy.
There are two brands in the market for performing outpatient myomectomy 
with different diameters and speeds.
The Truclear 5.0 system was the first mechanical TRD for intrauterine 
pathologies approved by the FDA (Food and Drug Administration) in 2005. It has 
a small diameter of 5 mm, ideal for outpatient procedures without anesthesia, with 
a speed of 750 rpm.
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ence caused less procedure pain. In contrast to the use of a hysteroscope with an 
outer diameter of 5 mm, outpatient hysteroscopy with a mini-hysteroscope (outer 
diameter of 3.5 mm) was preferable. The operating hysteroscope contains a work-
ing element which introduces electrosurgical and mechanical instruments for the 
myomectomy surgery [34].
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fluid overload. Isotonic solutions (normal saline) are recommended as distension 
medium. It is essential that all hysteroscopic surgery offices have a control system 
for the balance fluids during the procedure and a protocol for the management of 
excessive fluid deficit [35–38].
In order to perform outpatient myomectomy, these devices must work quickly 
but the surgeon should also be comfortable with the device that they are using.
It exists new surgical devices with small diameters that can be used for myomas in 
an outpatient setting, without general or local anesthesia and using different types of 
energy such as the Versapoint system with bipolar energy, mechanical TRDs or laser.
4.4.1 Versapoint
Versapoint® with bipolar energy system. Currently, there are 5 bipolar elec-
trodes available on the market, three of these electrodes can be used with small-
diameter hysteroscopes and they have different terminals for specific tasks. The 
three different terminals are: the spring (for vaporization), the twizzle (for cutting) 
and the ball (for coagulation), and the other two electrodes can only be used with a 
classic resectoscope. They cannot be used in an outpatient setting.
4.4.2 Laser
This device achieves different effects depending on the wavelength: cutting, 
coagulation, vaporization. The laser most commonly used in hysteroscopy was the 
Neodymium laser and currently BIOLITEC with Selective Light Vaporization.
4.4.3 Mini-resectoscopy
The Gubbini Mini-resectoscope which has a small diameter for outpatient 
procedures uses terminals with bipolar energy and different tips (ball, loop, blade) 
to perform the same function as traditional resectoscopes.
4.4.4 Hysteroscopic TRDs
The Hysteroscopic TRD is a hysteroscopic mechanical system used to remove 
polyps and submucosal myomas. It has a terminal with a side window and a 
mechanical cutting blade, which rotates and oscillates at the same time. It is based 
on a rotary tubular cutting system with mechanical energy based on suction instead 
of the high-frequency electric power historically used in resectoscopy.
There are two brands in the market for performing outpatient myomectomy 
with different diameters and speeds.
The Truclear 5.0 system was the first mechanical TRD for intrauterine 
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a small diameter of 5 mm, ideal for outpatient procedures without anesthesia, with 
a speed of 750 rpm.
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The MyoSure® system was the second mechanical TRD for intrauterine 
pathologies approved by the FDA in 2009. The MyoSure® suite includes four 
devices (MyoSure MANUAL, LITE, REACH, XL) allowing flexibility to treat 
a wide range of intrauterine pathologies in any setting. MyoSure works at a 
faster speed (8075 rpm), which reduces the duration of the procedure [39, 40]. 
The device can be introduced via the new generation Omni scope (diameter 
from 5.5 mm up to 6 mm) or the MyoSure hysteroscopes (from 6.25 mm up to 
7.25 mm).
5. What factors influence for a successful myomectomy?
The main limiting factor for a successful one-step myomectomy is the 
duration of the procedure because the volume of fluid deficit depends on it, 
which is the main and most serious complication in the process of performing a 
hysteroscopy.
On the one hand, the complexity of myomas (fibroids with intramural penetra-
tion) increases the risk of systemic fluid absorption because the hysteroscopist 
needs more time for the myomectomy and this type of myoma disrupts the integrity 
of the myometrium. On the other hand, the skill level and experience of the hys-
teroscopist influence the duration of the procedure [41].
5.1 Complexity of the fibroid
We must analyze all the characteristics of the myomas before performing the 
myomectomy: size, number, location and type (G0, G1, G2) in order to perform 
a successful myomectomy. Within all existing classifications of submucous 
myoma, the Lasmar classification [42, 43] is the most accurate, even more so if 
associated with the concept of CONTINENT/CONTENT proposed by Haimovich 
(Figures 6 and 7).
The five parameters of STEPW are as follows:
1. Size (S): the largest diameter found by any of the imaging methods. When the 
nodule measures <2 cm, it is given a score of 0; if it is 2.1–5 cm, it gets a score 
of 1; and if it measures >5 cm, it gets a score of 2.
2. Topography (T): defined by the third of the uterine cavity where the fibroid is 
located. If it is in the lower third, the score is 0; if in the middle third, the score 
is 1; and if in the upper third, the score is 2.
3. Extension of the base of the myoma (E): when the fibroid covers one third 
or less of the wall, it is given a score of 0; when the base of the nodule occupies 
between one and two thirds of the wall, the score is 1; and when it affects more 
than two thirds of the wall, the score is 2.
4. Penetration of the nodule into the myometrium (P): when the fibroid is 
completely within the uterine cavity it is given a score of 0; if most of it is in 
the uterine cavity the score is 1; and if most of it is in the myometrium the 
score is 2.
5. Wall (W): when the fibroid is on the lateral wall, 1 extra point is added regard-
less of the third that is affected.
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5.2 Skill level and experience of the hysteroscopist
While the skill set required for outpatient hysteroscopy is still state-of-the-art 
gynecological competence, global progress in this procedure has been irregular. 
Currently, entities such as the Royal College of Obstetrics and Gynecology (RCOG) 
and the International Society of Gynecologic Endoscopy (ISGE) have developed a 
ranking of hysteroscopic procedures, in terms of surgical complexity, guiding the 
accreditation and training in hysteroscopic surgery (Figures 8 and 9) [29, 31].
The resection of fibroids with intramural extension is advisable only for expert 
surgeons as it is technically difficult and has a higher risk of complications than other 
hysteroscopic procedures. Type G1-G2 myomas need a short procedure duration for 
Figure 7. 
The concept continent/content take into consideration the relation between the continent (uterine cavity) and 
content (fibroid).
Figure 8. 
RCOG classification of operative hysteroscopy levels.
Figure 6. 
STEPW submucous fibroid classification.
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of 1; and if it measures >5 cm, it gets a score of 2.
2. Topography (T): defined by the third of the uterine cavity where the fibroid is 
located. If it is in the lower third, the score is 0; if in the middle third, the score 
is 1; and if in the upper third, the score is 2.
3. Extension of the base of the myoma (E): when the fibroid covers one third 
or less of the wall, it is given a score of 0; when the base of the nodule occupies 
between one and two thirds of the wall, the score is 1; and when it affects more 
than two thirds of the wall, the score is 2.
4. Penetration of the nodule into the myometrium (P): when the fibroid is 
completely within the uterine cavity it is given a score of 0; if most of it is in 
the uterine cavity the score is 1; and if most of it is in the myometrium the 
score is 2.
5. Wall (W): when the fibroid is on the lateral wall, 1 extra point is added regard-
less of the third that is affected.
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5.2 Skill level and experience of the hysteroscopist
While the skill set required for outpatient hysteroscopy is still state-of-the-art 
gynecological competence, global progress in this procedure has been irregular. 
Currently, entities such as the Royal College of Obstetrics and Gynecology (RCOG) 
and the International Society of Gynecologic Endoscopy (ISGE) have developed a 
ranking of hysteroscopic procedures, in terms of surgical complexity, guiding the 
accreditation and training in hysteroscopic surgery (Figures 8 and 9) [29, 31].
The resection of fibroids with intramural extension is advisable only for expert 
surgeons as it is technically difficult and has a higher risk of complications than other 
hysteroscopic procedures. Type G1-G2 myomas need a short procedure duration for 
Figure 7. 
The concept continent/content take into consideration the relation between the continent (uterine cavity) and 
content (fibroid).
Figure 8. 
RCOG classification of operative hysteroscopy levels.
Figure 6. 
STEPW submucous fibroid classification.
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complete resection that is only achieved by expert hysteroscopists. Furthermore, the 
difference in equipment does not seem to have a significant impact on surgery for 
safe hysteroscopic myomectomy for fibroids with intramural extension [44].
6. Complications
Hysteroscopic myomectomy is relatively safe, but like any other surgical proce-
dure, it is not without complications. Complication rates of 2% and 2.7% have been 
described in the literature [45, 46].
6.1 Fluid overload. Why is the operating time so important?
The estimated frequency of fluid overload is 0.2%. It is the most serious compli-
cation however not frequent; it is directly related to the duration of the procedure 
and to fibroids with a large surface due to the vascular damage associated to them 
and the subsequent intravasation of liquid due to distension. Therefore, in the exci-
sion of complex fibroids, sometimes it is better to stop and complete the operation 
during a second procedure. Whenever possible, we recommend the use of isotonic 
mediums such as normal saline. The distension mediums must be as low as possible 
while providing adequate distension with an intrauterine pressure of approximately 
70–100 mmHg. This is usually achieved when the medium is suspended for approx-
imately 1–1.5 min above the uterus with the current continuous pressure pumps. 
Garry et al. proved that intravasation of the mediums increases considerably once 
the intrauterine pressure exceeds the mean blood pressure (MBP). Most gynecolo-
gists have a termination threshold of 1000 mL for electrolyte-poor hypotonic 
mediums and 2500 mL for isotonic electrolytes.
6.1.1 How to decrease fluid overload?
There are several options to reduce systemic absorption of fluid such as intracervi-
cal injection of diluted vasopressin solution immediately prior to the procedure, the 
distension pressure in the uterine cavity should not be kept too high, it should be 
Figure 9. 
ISGE classification of operative difficulty.
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maintained below the mean blood pressure (evidence level A, stopping the procedure 
for a few minutes (10′) reduces systemic absorption of fluids by intravascular clotting) 
[35, 38]. There is consistent evidence that preoperative administration of GnRH ago-
nists reduces the risk of systemic fluid absorption and decreases the impact of hypona-
tremic hypotonic encephalopathy, especially in premenopausal women [36, 37].
6.2 Uterine perforations
The frequency is low, 0.13% to 0.76%. The uterus can be pierced with a dila-
tor, hysteroscope, or power source. Management will depend on the size, the site 
of the perforation and whether or not there is a risk of injury to another organ. 
Perforation occurs most frequently at the fundus level without significant bleeding. 
Simple perforation rarely causes further damage and can be managed conserva-
tively with hospitalization, no observation, and appropriate broad-spectrum anti-
biotics. Complex perforation can occur with a mechanical device or energy source 
and therefore can be associated with thermal injury to adjacent structures, includ-
ing the intestine or large vessels. However, the energy sources used in the outpa-
tient setting are usually monopolar or bipolar energy that decrease the propagation 
of energy through the tissue during the process and are therefore safer. Mechanical 
TRDs do not require energy and continuously aspirate resected tissue through the 
device for better visualization and thus reducing the risk of perforation.
6.3 Intrauterine bleeding during procedure
The frequency is about 0.25%. Management will depend on the site, severity, and 
cause of the bleeding. Intrauterine bleeding that occurs during the procedure should 
be immediately obvious and can usually be controlled by spot electrocoagulation. 
If clotting fails to control bleeding, the procedure may need to be terminated and a 
tamponade applied by inserting a Foley catheter and dilating the balloon. The cath-
eter must be left in place for 4–6 hours, after which the bleeding almost always stops.
6.4 Cervical trauma
Outpatient procedures can often be performed without the need to dilate the 
cervix, particularly using the vaginoscopic technique described by Bettocchi et 
al. However, operative hysteroscopy may require cervical dilation. Trauma can be 
treated with pressure, silver nitrate, or sutures. It is best to avoid over dilation of the 
cervix because this can cause the distention medium to leak through the cervix and 
around the hysteroscope.
6.5 Infection
Incidence is between 0.1% and 1.42%. Acute pelvic inflammatory disease after 
hysteroscopic surgery is rare. Diagnosis is made from classic signs and symptoms, 
and treatment should be performed with appropriate antibiotics after vaginal smear 
and blood culture.
7. Other frequent questions regarding the handling of fibroids
7.1 Cervical maturing
There have been studies evaluating the use of cervical “maturing” agents prior 
to hysteroscopy; these are typically prostaglandin analog, misoprostol, progesterone 
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tient setting are usually monopolar or bipolar energy that decrease the propagation 
of energy through the tissue during the process and are therefore safer. Mechanical 
TRDs do not require energy and continuously aspirate resected tissue through the 
device for better visualization and thus reducing the risk of perforation.
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If clotting fails to control bleeding, the procedure may need to be terminated and a 
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eter must be left in place for 4–6 hours, after which the bleeding almost always stops.
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Outpatient procedures can often be performed without the need to dilate the 
cervix, particularly using the vaginoscopic technique described by Bettocchi et 
al. However, operative hysteroscopy may require cervical dilation. Trauma can be 
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cervix because this can cause the distention medium to leak through the cervix and 
around the hysteroscope.
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Incidence is between 0.1% and 1.42%. Acute pelvic inflammatory disease after 
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7. Other frequent questions regarding the handling of fibroids
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There have been studies evaluating the use of cervical “maturing” agents prior 
to hysteroscopy; these are typically prostaglandin analog, misoprostol, progesterone 
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antagonist, mifepristone, or osmotic stents (laminaria stents). The literature 
available does not demonstrate any benefit in the use of ceramic preparations for 
patients undergoing diagnostic hysteroscopy. For patients who undergo surgical 
hysteroscopy and cervical dilation beyond 5 mm in diameter, these agents may be 
especially beneficial in premenopausal women [47, 48].
7.2 Paracervical block
Most outpatient procedures do not require analgesics or anesthesia, but if the 
patient needs any of them, paracervical anesthesia is better. According to the 
Cochrane database publication, anesthesia with paracervical block can decrease 
pain during the procedure and 30 minutes afterwards [49], while the French 
guidelines [50] do not recommend the use of analgesics or anesthesia to conduct 
outpatient hysteroscopy; in England, analgesics are administered by 62.5% of 
physicians [51].
7.3 Antibiotic prophylaxis
There are no studies that show any evidence to indicate antibiotic prophylaxis in 
hysteroscopies.
8. Adhesions
Intrauterine adhesions are frequent, especially after a myomectomy if the plane 
of the pseudocapsule is not respected or when two fibroids are located on opposite 
uterine walls; in this case, it is preferable to perform the myomectomy in multiple 
stages to avoid the formation of adhesions. The use of non-electrical devices (cold 
loop or mechanical TRDs) reduces intrauterine adhesions. Different safe and effec-
tive strategies reduce intrauterine adhesions after hysteroscopic myomectomy: early 
second revision hysteroscopy, barrier methods and, in particular, the barrier of 
non-adhesive gels, insertion of an intrauterine device and 2 months of estrogen and 
progestin therapy (in the form of combined oral contraceptives) [45, 52].
9. Future expectation
9.1  Should we treat small asymptomatic submucosal fibroids in patients who 
want to become?
Small myomas, given that they are benign hormone-dependent tumors, have 
a high growth potential and become symptomatic or cause complications during 
natural or assisted conception and pregnancy. Physicians must always take into 
account the biological effects of hormonal changes and/or high levels of estrogen 
during the reproductive life of a woman.
Even if a submucous myoma is small, it may affect the implantation potential 
of an embryo due to the changes produced in the myometrium, or just by causing 
mechanical compression.
Given that myomas are usually spherical, linear growth in the diameter of a 
myoma corresponds to the squared growth in surface and the cubic growth in 
volume [53].
The Global Congress on Hysteroscopy Scientific Committee [54] recommends 
the following:
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When immediate fertility is not desired and in the presence of 1 asymptomatic 
submucous myoma smaller than 15 mm, hysteroscopic myomectomy is recom-
mended, but expectant management is acceptable. If expectant management is 
favored, clinical surveillance of symptoms and serial transvaginal pelvic ultra-
sounds to monitor growth of the myomas are recommended.
When immediate fertility is a priority and in the presence of 1 asymptomatic 
submucous myomas 15 mm, hysteroscopic myomectomy is recommended.
9.2 Hysteroscopic resection of myoma type 3 (FIGO classification), is it feasible?
Type 3 fibroids are intramural fibroids in contact with the endometrium, but 
lack deformation of the cavity. There is no guideline for this type of fibroids. A 
primary goal of treating fibroid type 3 by hysteroscopic resection is to avoid open or 
laparoscopic myomectomy.. Hysteroscopic resection is a potential alternative to tra-
ditional surgery for this type of fibroids. This procedure should be limited to expert 
surgeons because it is a difficult procedure. These fibroids are not visible within 
the uterine cavity, but can be located by ultrasound at the beginning of surgery and 
resected with one of the techniques described in this chapter. The choice of hys-
teroscopic technique depends mainly on the intramural extension of the myoma, as 
well as personal experience and the available technique. The ultrasound guide is the 
main element to guide a safe resection [55].
10. Conclusions
Submucosal fibroids are a health problem for women and a great economic 
burden for National Health Systems (NHS). Nowadays, hysteroscopic myomectomy 
is the most cost-effective treatment because it can be performed on an outpatient 
setting. This type of minimally invasive surgery requires skill and an experienced 
hysteroscopist and new generation devices.
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Bleeding and Hysteroscopy in 
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Abstract
Uterine leiomyomas are one of the most common diseases in women. However, 
there is still much about them we do not know. These tumours, also known as 
fibroids or myomas, affect women mainly during their reproductive years, and they 
are diagnosed in up to 70% to 80% of women during their lives. The most relevant 
part of this disease is the profound impact in the quality of life of women, in the 
provision of health services, and on the costs all around the world. Even though, the 
majority of women with fibroids are asymptomatic, approximately 30% of them 
will present severe symptoms, with a broad range of problems such as: abnormal 
uterine bleeding, infertility, and obstetric complications. There are multiple factors 
involved in the biology of fibroids: genetic, epigenetic, hormonal, proinflamma-
tory, angiogenic and growth factors, growth factors that are capable of inducing 
and promoting de development of fibroids. The leiomyoma is surrounded by a 
pseudocapsule generated by compression and ischaemia of the tumour towards the 
myometrium and is composed by multiple elements that that promote healing and 
tissue repair of the myometrium after myomectomy. Therefore, its conservation in 
the myometrium is essential, regardless of the surgical technique used. Resection by 
hysteroscopy can be performed in an office or in an operating room, depending on 
the characteristics of the fibroid, it is required a good diagnosis and experience.
Keywords: bleeding, hysteroscopy, pseudocapsula, submucosa fobroids
1. Introduction
Uterine leiomyomas are one of the most common diseases in women. However, 
there is still much about them we do not know. These tumours, also known as 
fibroids or myomas, affect women mainly during their reproductive years, and they 
are diagnosed in up to 70% to 80% of women during their lives. The most relevant 
part of this disease is the profound impact in the quality of life of women, in the 
provision of health services, and on the costs all around the world.
Even though, the majority of women with fibroids are asymptomatic, approxi-
mately 30% of them will present severe symptoms, with a broad range of problems 
such as: abnormal uterine bleeding, infertility, and obstetric complications.
There are multiple factors involved in the biology of fibroids: genetic, epigenetic, 
hormonal, proinflammatory, angiogenic and growth factors, growth factors that are 
capable of inducing and promoting de development of fibroids.
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Abstract
Uterine leiomyomas are one of the most common diseases in women. However, 
there is still much about them we do not know. These tumours, also known as 
fibroids or myomas, affect women mainly during their reproductive years, and they 
are diagnosed in up to 70% to 80% of women during their lives. The most relevant 
part of this disease is the profound impact in the quality of life of women, in the 
provision of health services, and on the costs all around the world. Even though, the 
majority of women with fibroids are asymptomatic, approximately 30% of them 
will present severe symptoms, with a broad range of problems such as: abnormal 
uterine bleeding, infertility, and obstetric complications. There are multiple factors 
involved in the biology of fibroids: genetic, epigenetic, hormonal, proinflamma-
tory, angiogenic and growth factors, growth factors that are capable of inducing 
and promoting de development of fibroids. The leiomyoma is surrounded by a 
pseudocapsule generated by compression and ischaemia of the tumour towards the 
myometrium and is composed by multiple elements that that promote healing and 
tissue repair of the myometrium after myomectomy. Therefore, its conservation in 
the myometrium is essential, regardless of the surgical technique used. Resection by 
hysteroscopy can be performed in an office or in an operating room, depending on 
the characteristics of the fibroid, it is required a good diagnosis and experience.
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1. Introduction
Uterine leiomyomas are one of the most common diseases in women. However, 
there is still much about them we do not know. These tumours, also known as 
fibroids or myomas, affect women mainly during their reproductive years, and they 
are diagnosed in up to 70% to 80% of women during their lives. The most relevant 
part of this disease is the profound impact in the quality of life of women, in the 
provision of health services, and on the costs all around the world.
Even though, the majority of women with fibroids are asymptomatic, approxi-
mately 30% of them will present severe symptoms, with a broad range of problems 
such as: abnormal uterine bleeding, infertility, and obstetric complications.
There are multiple factors involved in the biology of fibroids: genetic, epigenetic, 
hormonal, proinflammatory, angiogenic and growth factors, growth factors that are 
capable of inducing and promoting de development of fibroids.
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The leiomyoma is surrounded by a pseudocapsule generated by compression 
and ischaemia of the tumour towards the myometrium and is composed by mul-
tiple elements that that promote healing and tissue repair of the myometrium after 
myomectomy. Therefore, its conservation in the myometrium is essential, regard-
less of the surgical technique used.
Resection by hysteroscopy can be performed in an office or in an operating 
room, depending on the characteristics of the fibroid, it is required a good diagnosis 
and experience.
2. The relevant of fibroids
Abnormal uterine bleeding (AUB) refers to uterine bleeding that, by its charac-
teristics in duration, volume, frequency, and regularity, are outside the 5th and 95th 
percentiles for the female population in reproductive age and non-pregnant. In such 
manner that range of variation in the menstrual bleeding pattern can be very wide 
affecting one or more characteristics at the same time.
The abnormal uterine bleeding is divided into acute and chronic — acute when, 
according to a medical evaluation, the amount of bleeding justifies an immediate 
intervention to avoid complications secondary to blood loss. It is defined as chronic 
when this symptom occurs persistently in last 6 months [1].
The widespread term of heavy menstrual bleeding, refers to a sub-category of 
AUB, and it refers to a subjective symptom expressed by the woman as the excessive 
loss of blood and impacts her physical, emotional and social well-being as well as 
her quality of life. This term moves away from an objective measurement of volume 
of more than 80 ml, or a specific score and focuses on the perception of the patient, 
therefore, it has a better clinical focus [2].
One important aspect of AUB is that it is one of the main causes for seeking 
gynaecological care among 5% and 30% of women in reproductive age, and 
approximately one third of that population will suffer from AUB at one moment 
in their lives, which represents high direct and indirect costs in their medical 
attention [3].
The aetiology of AUB is broad since various pathophysiological mechanisms are 
involved, requiring the physician to have an individualised approach and a clear 
understanding of the systematised study and treatment options.
In 2011, the International Federation of Gynaecology and Obstetrics (Fédération 
Internationale de Gynécologie et d’Obstétrique, FIGO), in contribution with a large 
group of clinical and non-clinical researchers of 17 countries of six continents, 
published a system and a set of clinical recommendations about AUB to provide 
a detailed update with the objective of standardising different terminologies and 
definitions used up to that date to refer to symptoms of altered menstrual bleeding 
and to establish a correlation with possible underlying causes, so as to facilitate 
research, education and standardised and replicable medical care [4].
An AUB classification was introduced, with nine categories based on the 
PALM-COEIN acronym, which divides causes into structural and non-structural 
pathologies.
Structural pathologies can be evaluated by imaging studies and/or defined 
histopathologically (polyps, adenomyosis, leiomyomas and malignancy or atypical 
endometrial hyperplasia: PALM).
Regarding non-structural causes, these cannot be detailed by means of 
imaging studies, these require a detailed clinical evaluation, and an appropriate 
physical examination supported by laboratory tests. In most cases, a diagnosis 
can be established, one which corresponds to the COEIN acronym (coagulopathy, 
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ovulatory dysfunction, primary endometrial dysfunction, iatrogenesis and not 
otherwise classified) [4, 5].
In 2018, FIGO recommendations were updated, including clarifications on 
terminologies and definitions, as well as modifications in the PALM-COEIN system 
which include the reassignment of some entities and orientation for subclasses of 
leiomyomas [5].
Leiomyomas are monoclonal tumours comprised of muscle tissue of the uterus, 
also referred in literature as fibroids or myomas. These represent the pelvic tumour, 
frequently benign, more common in women in reproductive age. At age 50, almost 
70% of white women and 80% of African American women will have developed at 
least one fibroid [6].
There are many risk factors associated with myomatosis, and these are still 
being described. Among these: African American race, age, delayed pregnancy, 
nulliparity, early menarche, caffeine, genetic alterations, obesity, a diet rich in red 
meat and, recently discovered, the crucial role of progesterone and its receptors in 
pathophysiology, growth and development of these tumours [7, 8].
Even though myomatosis has a high prevalence in women, most of them are 
asymptomatic and are diagnosed as an incidental finding in a routine gynaecologi-
cal examination. The main symptom of patients with leiomyomas is AUB, referred 
by women as profuse and prolonged bleeding, bleeding between periods, and 
frequent and irregular periods. These menstrual alterations are frequently used to 
being accompanied by the presence of pelvic tumours, dysmenorrhoea, chronic 
pelvic pain, infertility, compressive symptoms, and obstetric complications.
Other relevant aspects in the detriment of the quality of life of women with 
myomatosis are a negative impact in their sex life (42.9%), bad performance at 
work (27.7%), and impaired couple and family relations (27.2%). In this way, a third 
of women with leiomyomas will seek medical attention. Symptomatic cases will 
depend on size, number, and localisation of these [7, 9].
Several uterine fibroids classifications have been described. Most of them have 
considered the degree of extension in the myometrium and/or the distortion of 
the uterine cavity. Currently, this has changed, and several factors are considered 
in order to establish a better therapeutic approach, its possibility of success, the 
complete removal of fibroids and lower risk of complications.
The classification adopted by the ESGE (European Society for Gynaecological 
Endoscopy) based on Wamsteker’s, proposes a classification of submucous fibroids 
according to the depth within the myometrium, classified as: G−0 is an intrauterine 
pedunculated fibroid, G-1 fibroid is majorly in the uterine cavity or has less than 
50% of penetration inside of myometrium, and G-2 is mostly (> 50%) inside of the 
myometrium [10].
The classification proposed by Lasmar, takes into consideration, the depth of the 
fibroid in addition to other characteristics such as size, placement inside of the cavity, 
the extension of the injury in the endometrium, and the uterine wall involved, grant-
ing a rating that gives a prognosis on the difficulty or complexity of the removal, as 
well as the therapeutic options for its management (Figure 1) [11].
Another classification that also gives a rating according to size, localiza-
tion, myometrium penetration and base extension is the STEPW classification. 
(Figure 2).
The FIGO classification considers any location of the fibroids and describes 
eight types, as well as a hybrid class (an association of two types of fibroids). It is 
common for different types of fibroids to be present at the same time (depending on 
the site), and with this classification, a more representative “map” of the distribu-
tion of the fibroids can be made. However, this classification can have difficulties 
when applied to very big uteri and with multiple fibroids.
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and ischaemia of the tumour towards the myometrium and is composed by mul-
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myomectomy. Therefore, its conservation in the myometrium is essential, regard-
less of the surgical technique used.
Resection by hysteroscopy can be performed in an office or in an operating 
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and experience.
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teristics in duration, volume, frequency, and regularity, are outside the 5th and 95th 
percentiles for the female population in reproductive age and non-pregnant. In such 
manner that range of variation in the menstrual bleeding pattern can be very wide 
affecting one or more characteristics at the same time.
The abnormal uterine bleeding is divided into acute and chronic — acute when, 
according to a medical evaluation, the amount of bleeding justifies an immediate 
intervention to avoid complications secondary to blood loss. It is defined as chronic 
when this symptom occurs persistently in last 6 months [1].
The widespread term of heavy menstrual bleeding, refers to a sub-category of 
AUB, and it refers to a subjective symptom expressed by the woman as the excessive 
loss of blood and impacts her physical, emotional and social well-being as well as 
her quality of life. This term moves away from an objective measurement of volume 
of more than 80 ml, or a specific score and focuses on the perception of the patient, 
therefore, it has a better clinical focus [2].
One important aspect of AUB is that it is one of the main causes for seeking 
gynaecological care among 5% and 30% of women in reproductive age, and 
approximately one third of that population will suffer from AUB at one moment 
in their lives, which represents high direct and indirect costs in their medical 
attention [3].
The aetiology of AUB is broad since various pathophysiological mechanisms are 
involved, requiring the physician to have an individualised approach and a clear 
understanding of the systematised study and treatment options.
In 2011, the International Federation of Gynaecology and Obstetrics (Fédération 
Internationale de Gynécologie et d’Obstétrique, FIGO), in contribution with a large 
group of clinical and non-clinical researchers of 17 countries of six continents, 
published a system and a set of clinical recommendations about AUB to provide 
a detailed update with the objective of standardising different terminologies and 
definitions used up to that date to refer to symptoms of altered menstrual bleeding 
and to establish a correlation with possible underlying causes, so as to facilitate 
research, education and standardised and replicable medical care [4].
An AUB classification was introduced, with nine categories based on the 
PALM-COEIN acronym, which divides causes into structural and non-structural 
pathologies.
Structural pathologies can be evaluated by imaging studies and/or defined 
histopathologically (polyps, adenomyosis, leiomyomas and malignancy or atypical 
endometrial hyperplasia: PALM).
Regarding non-structural causes, these cannot be detailed by means of 
imaging studies, these require a detailed clinical evaluation, and an appropriate 
physical examination supported by laboratory tests. In most cases, a diagnosis 
can be established, one which corresponds to the COEIN acronym (coagulopathy, 
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ovulatory dysfunction, primary endometrial dysfunction, iatrogenesis and not 
otherwise classified) [4, 5].
In 2018, FIGO recommendations were updated, including clarifications on 
terminologies and definitions, as well as modifications in the PALM-COEIN system 
which include the reassignment of some entities and orientation for subclasses of 
leiomyomas [5].
Leiomyomas are monoclonal tumours comprised of muscle tissue of the uterus, 
also referred in literature as fibroids or myomas. These represent the pelvic tumour, 
frequently benign, more common in women in reproductive age. At age 50, almost 
70% of white women and 80% of African American women will have developed at 
least one fibroid [6].
There are many risk factors associated with myomatosis, and these are still 
being described. Among these: African American race, age, delayed pregnancy, 
nulliparity, early menarche, caffeine, genetic alterations, obesity, a diet rich in red 
meat and, recently discovered, the crucial role of progesterone and its receptors in 
pathophysiology, growth and development of these tumours [7, 8].
Even though myomatosis has a high prevalence in women, most of them are 
asymptomatic and are diagnosed as an incidental finding in a routine gynaecologi-
cal examination. The main symptom of patients with leiomyomas is AUB, referred 
by women as profuse and prolonged bleeding, bleeding between periods, and 
frequent and irregular periods. These menstrual alterations are frequently used to 
being accompanied by the presence of pelvic tumours, dysmenorrhoea, chronic 
pelvic pain, infertility, compressive symptoms, and obstetric complications.
Other relevant aspects in the detriment of the quality of life of women with 
myomatosis are a negative impact in their sex life (42.9%), bad performance at 
work (27.7%), and impaired couple and family relations (27.2%). In this way, a third 
of women with leiomyomas will seek medical attention. Symptomatic cases will 
depend on size, number, and localisation of these [7, 9].
Several uterine fibroids classifications have been described. Most of them have 
considered the degree of extension in the myometrium and/or the distortion of 
the uterine cavity. Currently, this has changed, and several factors are considered 
in order to establish a better therapeutic approach, its possibility of success, the 
complete removal of fibroids and lower risk of complications.
The classification adopted by the ESGE (European Society for Gynaecological 
Endoscopy) based on Wamsteker’s, proposes a classification of submucous fibroids 
according to the depth within the myometrium, classified as: G−0 is an intrauterine 
pedunculated fibroid, G-1 fibroid is majorly in the uterine cavity or has less than 
50% of penetration inside of myometrium, and G-2 is mostly (> 50%) inside of the 
myometrium [10].
The classification proposed by Lasmar, takes into consideration, the depth of the 
fibroid in addition to other characteristics such as size, placement inside of the cavity, 
the extension of the injury in the endometrium, and the uterine wall involved, grant-
ing a rating that gives a prognosis on the difficulty or complexity of the removal, as 
well as the therapeutic options for its management (Figure 1) [11].
Another classification that also gives a rating according to size, localiza-
tion, myometrium penetration and base extension is the STEPW classification. 
(Figure 2).
The FIGO classification considers any location of the fibroids and describes 
eight types, as well as a hybrid class (an association of two types of fibroids). It is 
common for different types of fibroids to be present at the same time (depending on 
the site), and with this classification, a more representative “map” of the distribu-
tion of the fibroids can be made. However, this classification can have difficulties 
when applied to very big uteri and with multiple fibroids.
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The FIGO classification updated in 2018 is as follows:
Submucous fibroids — those located exactly below the endometrium and that 
protrude, disrupting the uterine cavity in different degrees are types 0, 1, 2 and 3.
Type 0: Pedunculated or with its base on the endometrial wall, but the fibroid is 
completely located inside of endometrial cavity.
Types 1 and 2 require that a portion of the injury is intramural (Type 1 < 50% of 
the average diameter and Type 2 > 50%).
Type 3 are completely intramural but are also in contact with the endometrium. 
Type 3 formally distinguishes itself of Type 2 by means of a hysteroscopy, using the 
lowest intrauterine pressure possible to allow visualisation.
Intramural fibroids (Type 4) are completely located inside of the myometrium 
without protruding into the endometrial nor the serosal surface.
Subserosal fibroids (Types 5, 6 and 7) represent the mirror image of the sub-
mucousal ones — type 5 with more than 50% of intramural penetration, type 6 less 
than 50% intramural and type 7 is attached to the serosal surface by a stalk.
In another place (Type 8): The localization must be specified, for example: 
cervical, intraligamentary, and so on.
Hybrid or transmural fibroids are classified by their relation to the endometrial 
and serosal surfaces. In these cases, one must refer first to the portion that is in 
contact with the endometrium [4, 5, 12].
3. The relation between the fibroid and the bleeding
The relationship between AUB and uterine myomatosis is still not fully 
understood, and there is a contradiction that many women with fibroids have a 




Adapted of STEPW classification. SC: Score. Size: Larger diameter by any image study. Topography: It refers to 
where the fibroid is placed in the uterus. Extension of the base: How much of the uterine wall is covered by the 
fibroid compared to thirds. Penetration: Depth of the fibroid within the myometrium. Wall: When the fibroid 
is in the lateral wall, add one point to the total score.
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submucousal fibroids is observed in the context of the degree of distortion and 
penetration into the uterine cavity that can generate submucousal fibroids and the 
possible occurrence of AUB. According to literature, fibroids (FIGO 0, 1, 2 y 3) are 
the most symptomatic [7].
Diverse mechanisms have been proposed to explain the relationship between 
the AUB caused by myomatosis, however, these do not explain clearly how all these 
facts are intimately involved.
Previously, the most described mechanisms were the increase in the endometrial 
surface and the presence of fragile and congested vascularity around the perimy-
ome, currently, it is believed that the effect of fibroids on the endometrial function 
represents a change in the surface inside of the uterine cavity that is not limited to 
areas that cover the fibroid or fibroids. Some of these changes can have an impact in 
the responsiveness and endometrial implantation, as well as in AUB.
An increase in uterine vascularity with larger calibre vessels that can overcome 
the action of platelets has also been proposed. As well as changes in the patterns of 
myometrial contractility, ulceration of the surface of the fibroid, degeneration of 
the fibroid and venous ectasia by due to of compression of the fibroid [3, 13].
In recent years, more knowledge has been gained about complex the cellular 
and molecular changes associated with fibroids and the AUB, with an impact in 
angiogenesis, alteration of vasoactive substrates and growth factors, as well as 
alterations in coagulation, that highlight complex interactions among coagulation, 
neoangiogenesis and vasoconstriction [14].
Fibroids will behave as one independent functional unit with the capacity to 
secrete different bioactive factors, which generate changes in situ and produce an 
effect on the uterus. One of these changes is the increase in the secretion of TGF-β3 
(transforming growth factor beta 3), which is involved in the alteration of the homeo-
static and fibrinolytic normal pathways in the endometrium since it reduces the 
plasminogen activator-1 (PAI-1), thrombomodulin and antithrombin III, which could 
explain one of mechanisms associated with AUB — an increased quantity of TGF-β 
has also been related to the remodelling and proliferation of extracellular matrix that 
could modulate the growth of fibroids [1, 15].
Regarding the causes related to the increased in bleeding in women with 
fibroids, different angiogenic factors have been described, such as the vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), heparin-
binding epidermal growth factor (HB-EGF), platelet-derived growth factor 
(PDGF), parathyroid hormone-related protein (PTHrP) and prolactin [2, 14].
On the other hand, there is an alteration of endothelin-1 (ET-1) and prostaglan-
din F2 alpha (PGF2α), both strong vasoconstrictors that intervene in the amount 
of menstrual bleeding by regulating the contractility of the myometrium and the 
vasoconstriction of the spiral artery (ET-1) [16].
4. Endometrial changes
Understanding changes generated by fibroids at the endometrial level is very 
complex, since it is not only a physical effect on the anatomy of the uterus exerted 
by intramural and submucosal fibroids, but a significant effect in the endometrial 
physiology and the expression and function of endometrial genes [17].
An important phenomenon to understand endometrial changes, is inflammation. 
It is well established that an inflammatory component is involved in most physi-
ological processes, specifically in the reproductive process, inflammation has direct 
interference with follicular development, ovulation, implantation, pregnancy, labor, 
and menstruation are not exempt.
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protrude, disrupting the uterine cavity in different degrees are types 0, 1, 2 and 3.
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submucousal fibroids is observed in the context of the degree of distortion and 
penetration into the uterine cavity that can generate submucousal fibroids and the 
possible occurrence of AUB. According to literature, fibroids (FIGO 0, 1, 2 y 3) are 
the most symptomatic [7].
Diverse mechanisms have been proposed to explain the relationship between 
the AUB caused by myomatosis, however, these do not explain clearly how all these 
facts are intimately involved.
Previously, the most described mechanisms were the increase in the endometrial 
surface and the presence of fragile and congested vascularity around the perimy-
ome, currently, it is believed that the effect of fibroids on the endometrial function 
represents a change in the surface inside of the uterine cavity that is not limited to 
areas that cover the fibroid or fibroids. Some of these changes can have an impact in 
the responsiveness and endometrial implantation, as well as in AUB.
An increase in uterine vascularity with larger calibre vessels that can overcome 
the action of platelets has also been proposed. As well as changes in the patterns of 
myometrial contractility, ulceration of the surface of the fibroid, degeneration of 
the fibroid and venous ectasia by due to of compression of the fibroid [3, 13].
In recent years, more knowledge has been gained about complex the cellular 
and molecular changes associated with fibroids and the AUB, with an impact in 
angiogenesis, alteration of vasoactive substrates and growth factors, as well as 
alterations in coagulation, that highlight complex interactions among coagulation, 
neoangiogenesis and vasoconstriction [14].
Fibroids will behave as one independent functional unit with the capacity to 
secrete different bioactive factors, which generate changes in situ and produce an 
effect on the uterus. One of these changes is the increase in the secretion of TGF-β3 
(transforming growth factor beta 3), which is involved in the alteration of the homeo-
static and fibrinolytic normal pathways in the endometrium since it reduces the 
plasminogen activator-1 (PAI-1), thrombomodulin and antithrombin III, which could 
explain one of mechanisms associated with AUB — an increased quantity of TGF-β 
has also been related to the remodelling and proliferation of extracellular matrix that 
could modulate the growth of fibroids [1, 15].
Regarding the causes related to the increased in bleeding in women with 
fibroids, different angiogenic factors have been described, such as the vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), heparin-
binding epidermal growth factor (HB-EGF), platelet-derived growth factor 
(PDGF), parathyroid hormone-related protein (PTHrP) and prolactin [2, 14].
On the other hand, there is an alteration of endothelin-1 (ET-1) and prostaglan-
din F2 alpha (PGF2α), both strong vasoconstrictors that intervene in the amount 
of menstrual bleeding by regulating the contractility of the myometrium and the 
vasoconstriction of the spiral artery (ET-1) [16].
4. Endometrial changes
Understanding changes generated by fibroids at the endometrial level is very 
complex, since it is not only a physical effect on the anatomy of the uterus exerted 
by intramural and submucosal fibroids, but a significant effect in the endometrial 
physiology and the expression and function of endometrial genes [17].
An important phenomenon to understand endometrial changes, is inflammation. 
It is well established that an inflammatory component is involved in most physi-
ological processes, specifically in the reproductive process, inflammation has direct 
interference with follicular development, ovulation, implantation, pregnancy, labor, 
and menstruation are not exempt.
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Inflammation is understood as the presence of leukocytes (immune cells) of 
different within the reproductive tract tissue, without being associated with an 
infectious process. This invasion of leukocytes alters function by having specific 
role in local regulation.
Specific sequential changes in different kinds of leukocytes can be proven inside 
of the human endometrium during the different phases of normal and abnormal 
menstrual cycles. Leukocytes are very scarce in number throughout the prolifera-
tive phase, but significantly increase all through the secretory phase, taking into 
consideration that around 40% of all stromal cells in the premenstrual phase are 
leukocytes, mostly natural killer cells (NK) and granulocytes.
The decrease in progesterone increases the expression of inflammatory media-
tors, including Il-8, MCP-1 and nitric oxide which promote the recruiting of 
endometrial leukocytes. Macrophages and neutrophils are important in the defence 
of the epithelium when the epithelial barrier is broken because of any reason, for 
example, menstrual bleeding.
Leukocytes also have the potential to release regulatory molecules that stimu-
late the mechanisms of endometrial repair, consequently, so the alteration of 
immune cells and cytokine mediators are related to the symptoms of abnormal 
uterine bleeding and pelvic pain, always starting from the inflammatory process 
produced by the menstrual cycle, fibroids, and endometriosis among other 
pathologies [18, 19].
Besides endometritis and endometrial micro-erosions, vascular alterations are 
another important factor in the causes of bleeding and endometrial alterations [20].
From the complex onset of fibroid tumorigenesis, induced among others by 
the t (12-14) translocation, the deletion of 7q, HMGA2 gene of the locus 12q14-q15, 
that, under the oestrogen-progesterone promoter stimulus, the micro-environment, 
growth factors with mitotic activity such as growth factor 3, fibroblast growth 
factor, epidermal growth factor, and insulin-like growth factor, besides promoting 
tumour growth, are leukocyte chemoattractans, generating an accumulation of 
inflammatory cells inside of the fibroid tissue and the corresponding endometrium 
that could affect the function from menstruation to fertility [21, 22].
Another aspect related to leukocytes is the relation between the vascular 
endothelial growth factor (VEGF) of intravascular neutrophils and the prolifera-
tion of endometrial cells from the subendometrial capillary plexus that develops 
small vessels in the capillary plexus — this angiogenic process is present alongside 
functional activity in the proliferative phase and in pathological states [22].
Among the effects that fibroids exert on the endometrium, are the altered 
genetic expression and changes in the immune environment and vasoconstrictive 
factors, generating from a decrease in production of transcription factors neces-
sary for implantation, within the window of implantation (WOI) to the altered 
production of coagulation factors during menstruation [17].
To understand these changes, it is necessary to understand how human endo-
metrial stromal cells (HESC) regulate the expression of the tissue factor (TF), 
which is the main promoter of coagulation at this level, complemented by the effect 
of progesterone which increases a second haemostatic factor in the HESC, the 
plasminogen activator inhibitor-1 (PAI-1) — if this order is altered, the stability 
of the stromal endometrial matrix and the vascular extracellular matrix are lost by 
the action of the matrix metalloproteinase (MMP) -1, 3 and 9. This increases the 
inflammatory activity and an uncontrolled angiogenesis, with an endometrium that 
loses its homeostatic and proteolytic ability, and being highly vascularised.
An increase in TF expression accompanied by decreased endometrial blood 
flow produces hypoxia and reactive oxygen species (ROS) induce an aberrant 
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angiogenesis and inflammation. Hypoxia produces the release of endometrial cells’ 
apoptosis inducers secreted by human endometrial stromal cells (HESC) [23].
An altered angiogenesis due to the presence of fibroids produces fragile, hyper 
dilated, thinned vessels that bleed easily. The alteration of endometrial blood flow 
produces local hypoxia and the generation of ROS that increase the production of 
angiogenic factors such as the vascular endothelial growth factor (VEGF) in human 
endometrial stromal cells and Angiopoietin-2 (Ang-2) in endometrial cells with a 
decrease in HESC of angiostatic (Ang-1) [24].
5. The pseudo-capsule
In order to understand more about fibroids, it is essential to understand the 
myometium as a structure comprised of bundles of smooth muscle fibres sur-
rounded by connective tissue with a network of blood and lymphatic vessels — this 
is the place where fibroids grow, comprised of intertwined fascicles of disor-
dered smooth muscle cells, abundant fibrous tissue with type I and III collagen 
(Figure 3).
During its growth, fibroids compress the myometrium forming a pseudo-
capsule composed of collagen fibres, neurofibres and blood vessels. Occasionally, 
bridges of collagen fibres and vessels that join the myometrium with the fibroid can 
be formed (Figures 4 and 5) [25].
The pseudocapsule vessels that come from the surrounding myometrium are 
grouped in a vascular network and the veins surrounding the fibroid in the shape 
of a plexus forming the image of a “ring of fire”, easily detectable with a Doppler 
ultrasound (Figure 6) [26].
Figure 3. 
Showing the uterine wall (UW) with th dissected pseudocapsule (PS) and the myoma at the bottom.
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Inflammation is understood as the presence of leukocytes (immune cells) of 
different within the reproductive tract tissue, without being associated with an 
infectious process. This invasion of leukocytes alters function by having specific 
role in local regulation.
Specific sequential changes in different kinds of leukocytes can be proven inside 
of the human endometrium during the different phases of normal and abnormal 
menstrual cycles. Leukocytes are very scarce in number throughout the prolifera-
tive phase, but significantly increase all through the secretory phase, taking into 
consideration that around 40% of all stromal cells in the premenstrual phase are 
leukocytes, mostly natural killer cells (NK) and granulocytes.
The decrease in progesterone increases the expression of inflammatory media-
tors, including Il-8, MCP-1 and nitric oxide which promote the recruiting of 
endometrial leukocytes. Macrophages and neutrophils are important in the defence 
of the epithelium when the epithelial barrier is broken because of any reason, for 
example, menstrual bleeding.
Leukocytes also have the potential to release regulatory molecules that stimu-
late the mechanisms of endometrial repair, consequently, so the alteration of 
immune cells and cytokine mediators are related to the symptoms of abnormal 
uterine bleeding and pelvic pain, always starting from the inflammatory process 
produced by the menstrual cycle, fibroids, and endometriosis among other 
pathologies [18, 19].
Besides endometritis and endometrial micro-erosions, vascular alterations are 
another important factor in the causes of bleeding and endometrial alterations [20].
From the complex onset of fibroid tumorigenesis, induced among others by 
the t (12-14) translocation, the deletion of 7q, HMGA2 gene of the locus 12q14-q15, 
that, under the oestrogen-progesterone promoter stimulus, the micro-environment, 
growth factors with mitotic activity such as growth factor 3, fibroblast growth 
factor, epidermal growth factor, and insulin-like growth factor, besides promoting 
tumour growth, are leukocyte chemoattractans, generating an accumulation of 
inflammatory cells inside of the fibroid tissue and the corresponding endometrium 
that could affect the function from menstruation to fertility [21, 22].
Another aspect related to leukocytes is the relation between the vascular 
endothelial growth factor (VEGF) of intravascular neutrophils and the prolifera-
tion of endometrial cells from the subendometrial capillary plexus that develops 
small vessels in the capillary plexus — this angiogenic process is present alongside 
functional activity in the proliferative phase and in pathological states [22].
Among the effects that fibroids exert on the endometrium, are the altered 
genetic expression and changes in the immune environment and vasoconstrictive 
factors, generating from a decrease in production of transcription factors neces-
sary for implantation, within the window of implantation (WOI) to the altered 
production of coagulation factors during menstruation [17].
To understand these changes, it is necessary to understand how human endo-
metrial stromal cells (HESC) regulate the expression of the tissue factor (TF), 
which is the main promoter of coagulation at this level, complemented by the effect 
of progesterone which increases a second haemostatic factor in the HESC, the 
plasminogen activator inhibitor-1 (PAI-1) — if this order is altered, the stability 
of the stromal endometrial matrix and the vascular extracellular matrix are lost by 
the action of the matrix metalloproteinase (MMP) -1, 3 and 9. This increases the 
inflammatory activity and an uncontrolled angiogenesis, with an endometrium that 
loses its homeostatic and proteolytic ability, and being highly vascularised.
An increase in TF expression accompanied by decreased endometrial blood 
flow produces hypoxia and reactive oxygen species (ROS) induce an aberrant 
61
Bleeding and Hysteroscopy in Uterine Myomatosis
DOI: http://dx.doi.org/10.5772/intechopen.94174
angiogenesis and inflammation. Hypoxia produces the release of endometrial cells’ 
apoptosis inducers secreted by human endometrial stromal cells (HESC) [23].
An altered angiogenesis due to the presence of fibroids produces fragile, hyper 
dilated, thinned vessels that bleed easily. The alteration of endometrial blood flow 
produces local hypoxia and the generation of ROS that increase the production of 
angiogenic factors such as the vascular endothelial growth factor (VEGF) in human 
endometrial stromal cells and Angiopoietin-2 (Ang-2) in endometrial cells with a 
decrease in HESC of angiostatic (Ang-1) [24].
5. The pseudo-capsule
In order to understand more about fibroids, it is essential to understand the 
myometium as a structure comprised of bundles of smooth muscle fibres sur-
rounded by connective tissue with a network of blood and lymphatic vessels — this 
is the place where fibroids grow, comprised of intertwined fascicles of disor-
dered smooth muscle cells, abundant fibrous tissue with type I and III collagen 
(Figure 3).
During its growth, fibroids compress the myometrium forming a pseudo-
capsule composed of collagen fibres, neurofibres and blood vessels. Occasionally, 
bridges of collagen fibres and vessels that join the myometrium with the fibroid can 
be formed (Figures 4 and 5) [25].
The pseudocapsule vessels that come from the surrounding myometrium are 
grouped in a vascular network and the veins surrounding the fibroid in the shape 
of a plexus forming the image of a “ring of fire”, easily detectable with a Doppler 
ultrasound (Figure 6) [26].
Figure 3. 




Magnified image of the pseudocapsule (PC) and fibroid (F).
Angiogenesis of the fibroid’s pseudo-capsule leads to the formation of a 
protective vascular capsule, in addition, to being responsible for the blood supply 
to the central nucleus of the tumour.
The biological genesis of the pseudo-capsule is not well described, however, 
there is evidence that is originated from the myometrium that surrounds the 
fibroid, therefore, the fibroid is not originated from the pseudo-capsule, but it is 
part of the myometrium that compresses it [27].
The pseudo-capsule is a structure rich in neuropeptides and neurotransmit-
ters, which have a very important role in wound healing and innervation repair-
ing besides being key in sexual and reproductive functions and being the study 
objective for new future treatments.
Figure 4. 
Image with two fibroids at the ends (F), two pseudocapsules (PC) and the myometrium in the center (my).
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Neurotransmitters such as: Substance P (SP), Vasoactive Intestinal Peptide 
(VIP), Neuropeptide Y, Oxytocin, Vasopressin, PGP 9.5, calcitonin gene-related 
peptide and Growth hormone releasing hormone play an important role in the 
wounds’ inflammatory and healing cascades [28].
The neurofibres of the pseudo-capsule contain SP and VIP just as the myome-
trium without pregnancy.
It is possible that these neuropeptides have influence in the physiology of the 
uterine contraction, cervix dilation and during labour [29].
Other research focused on the opioid neuropeptides enkephalin (ENK) and 
oxytocin (OXT). The study revealed the lack of positive ENK neurofibres at the 
bottom of the uterus and in the fibroid’s pseudo-capsule in the body of the uterus, 
and presence of these in the isthmic-cervical area. Fibres positive for OXT were 
observed in the pseudo-capsule in all uterine regions, lesser at the bottom, and a 
higher quantity in the cervical isthmus. This indicates a larger research of neuro-
peptides about the impact in neurofibres in obstetric complications such as sponta-
neous miscarriage and cervical dystocia during labour [30].
Literature mentions the importance of knowing the fibroid’s pseudo-capsule 
during a myomectomy, since performing a correct technique enhances the progno-
sis of quality of life and fertility rate in women affected by uterine myomatosis [31].
The objective of the myomectomy is to enucleate the fibroid, always preserv-
ing the pseudo-capsule. Myomectomy’s technique takes prostate cancer surgery 
as a base, a procedure that preserves the neurovascular bundles that surround the 
prostate with the objective of reducing the probability of post-operative impotence 
and incontinence.
Taking into account these findings according to the prostatic capsule and the 
importance of nerve-spearing surgery, these were implemented in the surgery known 
as intracapsular myomectomy, preserving the fibroid’s pseudo-capsule and neurovas-
cular bundle with the objective of improving reproductive function. It is performed 
by coagulating, cutting, and breaking the pseudo-capsule’s fibrous bridges, then 
extracting the fibroid directly dissecting the fibromuscular skeleton that surrounds 
it, always using low energy instruments (less than 30 watts). The closing of the 
Figure 6. 
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myometrium is performed depending on the type of fibroid found — in subserosal 
fibroids it is performed in one plane, and in intramuscular fibroids two planes are 
closed (Figure 7). This surgical principle can be applied to all myomectomies: lapa-
rotomy, laparoscopy, and caesarean myomectomy. In comparison with intracapsular 
myomectomy through laparotomy or laparoscopy, laparoscopic myomectomy proved 
to have more benefits: lesser intraoperative and postoperative bleeding, reduced 
bladder pain after the removal of the Foley catheter, less use of analgesic medication 
and a shorter hospital stay — reduced appearance of fever, myometrial scar, bruising, 
ileus, and use of antibiotics were also observed during the post-operative period in 
comparison with laparotomy [32].
6. Leiomyomatosis and infertility
Most of leiomyomas are asymptomatic, symptoms are usually correlated with 
the number, size, location, and degenerative changes that these suffer — these are 
considered hormone-dependent. It is estimated that 30% of cases cause abnormal 
uterine bleeding, chronic pelvic pain and other symptoms that can affect the 
patients’ quality of life. Leiomyomas also cause anaemia, recurrent pregnancy loss, 
preterm birth, urinary incontinence, subfertility, and infertility [33, 34].
The relation between leiomyomas and infertility has been a concern for a 
long time. The American Society for Reproductive Medicine (ASRM) mentions that 
these uterine tumours are associated with infertility from 5% to 10% of cases and 
are catalogued as directly responsible for infertility from 2% to 3% of patients. 
However, the exact mechanism, by which these cause infertility, is still in debate. 
Consequently, several mechanisms have been proposed to explain the possible 
Figure 7. 
Miomectomy image with dissection of fibroma (F), pseudocapsule (PC) and between fibroconnective 
bridges (FB).
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adverse effects of fibroids on fertility, such as: alteration of the endometrial 
contour that interferes with implantation, alteration of endometrial blood flow 
that affects endometrial responsiveness, ulceration, thinning, endometrial inflam-
mation and atrophy, endometrial biochemical alterations, triggering of uterine 
contractility dysfunction that alters the embryonic movement and tube obstruc-
tion. According to the American Fertility Society Guideline for Practice, fibroids can 
be associated with 5% to 10% of infertility cases, although as a sole factor, these 
only influence from 2% to 3% [35].
Normally, the uterus presents uterine contractions, these begins in the uterine 
fundus and continue towards the cervix, and their frequency increases in the early 
follicular phase. In the periovulatory and luteal phase, the direction of contractions 
is inverted, that is to say, from the cervix to the fundus, favouring the fertilisation 
process [36].
Fibroids as a mechanical factor is one of the simplest mechanisms that would 
explain infertility in this group of patients with larger and intracavitary fibroids 
being those that interfere in the process of transporting eggs and sperm, as well as 
implantation [37]. Another mechanism is through the production of cytokines and 
chronic inflammation — these underlying mechanisms are the ones that increase the 
uterine contractility mainly due by overproduction of cytokines. One study showed a 
considerable increase in uterine peristalsis in the presence of fibroids and after myo-
mectomy in this group of patients, a pregnancy rate of 40% was obtained [38, 39].
The implantation process is one of the most complex and perfectly orchestrated 
processes in the human being. The foetal success depends on immunological 
changes in the mother, and it is based on modifications in the innate and adaptive 
immune system, in which embryo implantation and placenta development are 
presented thanks to immune reactions mediated by the following cytokines: TNF 
(tumour necrosis factor) -α and β, interleukin 1, 2, 10 and 6, among others [40].
In patients with submucous fibroids, it has been proven that a significant decrease 
in IL-10 and glycodelin levels, the latter being a key protein to promote angiogenesis 
and supress NK (natural killer) cells in the implantation process [41]. The presence 
of fibroids has shown alterations in the subendometrial area, a region highly rich in 
macrophages and NK cells. In patients with leiomyomatosis, a decrease in concentra-
tions of these two cell populations has been proven, altering the steroid receptors at 
the endometrial level that are essential for the implantation process [42].
Pregnancy, live births, and implantation rates are significantly lower in 
patients with leiomyomatosis [43]. The presence of submucosal leiomyomas 
decreases the birth rate by 70%, while intramural fibroids show a decrease in the 
birth rate by 30% [44].
It is known that the presence of fibroids shows a deleterious effect upon the uter-
ine contractility, depending on its location and size, particularly those that distort 
the submucosal and intramural uterine cavity in 60% of women younger than 
40 years of age, and in 80% of women younger than 50 years of age.
One of fibroids subtypes tha most affects fertility is leiomyoma with bizarre 
nuclei (LBNs) which, in turn, is linked with higher concentrations of MIB1 (mind-
bomb E3 ubiquitin protein ligase 1, which is an apoptosis regulator, also known as 
Ki-67) in the endometrium. This means, that not only the size and location of the 
fibroid plays a role in the subfertility observed in patients withe leiomyomatosis, 
but also the morphological subtype of fibroids. Furthermore, this shows that 
regardless of the location of the fibroids, the fertility rate was lower compared 
with the controls. Showing a relative risk of clinical pregnancy of 0.85 with CI 
95%: 0.73–0.98 and a live birth rate with a RR: 0.69 with CI 95% 0.59–0.82 and 
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7. Hysteroscopical management of submucous fibroids
The coming of hysteroscopy in gynaecologic surgery has offered a new conser-
vative approach to the treatment of pathologies of the uterine cavity.
Going back to the FIGO classification adopted by ESGE (European Society 
of Gynaecological Endoscopy) of submucous fibroids, describing the extent 
of miometrial involvement of submucosal fibroids visualised by hysteroscopy. 
According to the degree of myometrial penetration: submucosal fibroids grade 0, 
grade 1 and sometimes grade 2 submucous fibroids are candidates for this  
management (Figure 8).
The criteria for scheduling the surgical procedure must be clear, and these 
include a pre-operative evaluation that considers in detail the size, location, myo-
metrial depth, distance from the fibroid to the serosa layer of the uterus, and the 
number of fibroids with possible degree of tissue degeneration with ultrasound or 
MRI, knowledge of the management of electrolytic or non-electrolytic distension 
fluids, and hysteroscopic irrigation pump, experience in the use of monopolar or 
bipolar resectoscopes, diode laser or mechanic resectors and when to select each one 
of them, and surgical judgement to use different techniques and to know when to 
stop the procedure or program it in two sessions [46].
Contraindications for a resectoscopy are: pelvic inflammatory disease or herpes 
infection, a distance of less than 5 mm from the fibroid to the uterine serosa, large 
size uterine cavity that does not allow the suitable distension and view of tumours, 
and a lack of surgical ability of the surgeon.
The success rate of 90% in myomectomies depends on the appropriate selection 
of the patient and being within the range of possible complications — from 1% to 
5% in fibroids of less than 3 cm in diameter.
The entire fibroid must be removed without leaving any residual tissue and 
respecting the dissection plane of the pseudocapsule, which is part of the myome-
trium and favours the appropriate healing of the uterine wall.
The myomectomy can be performed in the office or in the operating the-
atre according to patient’s characteristics, intra-wall extension of the tumour, 
Figure 8. 
ESGE classification of submucous leiomyomas.
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estimated surgical time since office procedures should not exceed more than 
20 minutes, the diameter of the instrument, and if anaesthesia is required to 
improve the conditions and results of the surgery [47].
As decision criteria G-0 and G-1 fibroids with a minimum myometrial compo-
nent and smaller than 15 mm can be treated in the office. Hysteroscopic resections 
can still be attempted in G-1 fibroids of less than from 4 to 5 cm and G-2 fibroids of 
less than from 5 to 6 cm of diameter in the operating theatre and with anaesthesia 
since pain occurs when surgically working in the myometrium that has sensory 
innervation.
In order to calculate the volume of the fibroid, the V = 4/3πr [3] formula must 
be used.
Using a 4 mm resectoscope loop, 0.5 cm [3] is removed per minute and a 5 cm 
diameter fibroid has 65.4 cm [3], so on average the procedure will require two 
hours, being within the pertinent time limit for a hysteroscopy [48].
In the office, scissors and 5 Fr grasper clamps can be used in fibroids of less than 
15 mm, sectioning the pedicle in order to extract it and, if it is not possible to, wait 
from 30 to 45 days for the uterus to spontaneously expel it, or the tumour can also 
be divided into two parts in order to extract fragments.
There is the, OPPIuM technique in G2 myomas, consisting in performing a 
cut with monopolar energy alongside the intracavitary fibroid’s peripheral line of 
reflection, and in a second surgery in 30 days, resecting the leiomyoma that has 
emerged into the uterine cavity with a resectoscope, facilitating the procedure.
There is also the possibility of using a 45-watt diode laser with wavelengths 
of 980 nm and 1470 nm to cut or vaporise the fibroid with a lower rate of com-
plications and a better vision without generating bubbles. The cutting depth is 
1 mm and with special fibres, vaporisation and selective clotting of the tissue are 
achieved.
The gold standard is the resection with 15 Fr bipolar loop mini-resectoscope and 
3 mm loop in the office and in the operating theatre, 27 Fr bipolar resectoscope with 
a 4 mm loop in order to completely the fibroid, while preserving the pseudocapsule. 
The “cut” must be programmed from 60 Watt to 70 Watt to avoid post-operative 
adherences. It is convenient to have the Collins loop and the cold Mazzon loops 
to enucleate the residual tissue, complete the surgery, and completely remove the 
leiomyoma.
There are mechanic tissue resection devices of different thicknesses — 15 Fr to 
24 Fr with a reciprocating cutting blade and a 0 degree vision with better liquid 
control, that cut and aspirate the tissue by using saline solution, avoiding thermal 
damage to endometrium/myometrium and fluid overload. The surgeon must have 
the experience to align the instrument which is straight and does not allow much 
mobilitiy, with the fibroid in a peripheric way, and in case any vein or artery pres-
ents haemorrhage, remove the device a few millimetres from the surgical site and 
wait that the continuous flow clears the vision and then directs it towards the vessel 
and completely resects it towards its origin.
No prophylactic or post-operative antibiotic is needed, it is only used if there is a 
history of pelvic inflammatory disease.
The success of the hysteroscopic myomectomy depends on a personalised 
study of each patient and its therapeutic goals, performing a complete diagnosis 
both clinical and with laboratory and imaging studies including an ultrasound or 
magnetic resonance to perfectly locate the type and number of fibroids, their depth 
within the myometrium, and the distance to the serosa layer of the uterus.
Correctly selecting if the procedure can be performed in an office or in an 
operating theatre, because one of the main goals is the complete removal of all the 
Fibroids
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bipolar resectoscopes, diode laser or mechanic resectors and when to select each one 
of them, and surgical judgement to use different techniques and to know when to 
stop the procedure or program it in two sessions [46].
Contraindications for a resectoscopy are: pelvic inflammatory disease or herpes 
infection, a distance of less than 5 mm from the fibroid to the uterine serosa, large 
size uterine cavity that does not allow the suitable distension and view of tumours, 
and a lack of surgical ability of the surgeon.
The success rate of 90% in myomectomies depends on the appropriate selection 
of the patient and being within the range of possible complications — from 1% to 
5% in fibroids of less than 3 cm in diameter.
The entire fibroid must be removed without leaving any residual tissue and 
respecting the dissection plane of the pseudocapsule, which is part of the myome-
trium and favours the appropriate healing of the uterine wall.
The myomectomy can be performed in the office or in the operating the-
atre according to patient’s characteristics, intra-wall extension of the tumour, 
Figure 8. 
ESGE classification of submucous leiomyomas.
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estimated surgical time since office procedures should not exceed more than 
20 minutes, the diameter of the instrument, and if anaesthesia is required to 
improve the conditions and results of the surgery [47].
As decision criteria G-0 and G-1 fibroids with a minimum myometrial compo-
nent and smaller than 15 mm can be treated in the office. Hysteroscopic resections 
can still be attempted in G-1 fibroids of less than from 4 to 5 cm and G-2 fibroids of 
less than from 5 to 6 cm of diameter in the operating theatre and with anaesthesia 
since pain occurs when surgically working in the myometrium that has sensory 
innervation.
In order to calculate the volume of the fibroid, the V = 4/3πr [3] formula must 
be used.
Using a 4 mm resectoscope loop, 0.5 cm [3] is removed per minute and a 5 cm 
diameter fibroid has 65.4 cm [3], so on average the procedure will require two 
hours, being within the pertinent time limit for a hysteroscopy [48].
In the office, scissors and 5 Fr grasper clamps can be used in fibroids of less than 
15 mm, sectioning the pedicle in order to extract it and, if it is not possible to, wait 
from 30 to 45 days for the uterus to spontaneously expel it, or the tumour can also 
be divided into two parts in order to extract fragments.
There is the, OPPIuM technique in G2 myomas, consisting in performing a 
cut with monopolar energy alongside the intracavitary fibroid’s peripheral line of 
reflection, and in a second surgery in 30 days, resecting the leiomyoma that has 
emerged into the uterine cavity with a resectoscope, facilitating the procedure.
There is also the possibility of using a 45-watt diode laser with wavelengths 
of 980 nm and 1470 nm to cut or vaporise the fibroid with a lower rate of com-
plications and a better vision without generating bubbles. The cutting depth is 
1 mm and with special fibres, vaporisation and selective clotting of the tissue are 
achieved.
The gold standard is the resection with 15 Fr bipolar loop mini-resectoscope and 
3 mm loop in the office and in the operating theatre, 27 Fr bipolar resectoscope with 
a 4 mm loop in order to completely the fibroid, while preserving the pseudocapsule. 
The “cut” must be programmed from 60 Watt to 70 Watt to avoid post-operative 
adherences. It is convenient to have the Collins loop and the cold Mazzon loops 
to enucleate the residual tissue, complete the surgery, and completely remove the 
leiomyoma.
There are mechanic tissue resection devices of different thicknesses — 15 Fr to 
24 Fr with a reciprocating cutting blade and a 0 degree vision with better liquid 
control, that cut and aspirate the tissue by using saline solution, avoiding thermal 
damage to endometrium/myometrium and fluid overload. The surgeon must have 
the experience to align the instrument which is straight and does not allow much 
mobilitiy, with the fibroid in a peripheric way, and in case any vein or artery pres-
ents haemorrhage, remove the device a few millimetres from the surgical site and 
wait that the continuous flow clears the vision and then directs it towards the vessel 
and completely resects it towards its origin.
No prophylactic or post-operative antibiotic is needed, it is only used if there is a 
history of pelvic inflammatory disease.
The success of the hysteroscopic myomectomy depends on a personalised 
study of each patient and its therapeutic goals, performing a complete diagnosis 
both clinical and with laboratory and imaging studies including an ultrasound or 
magnetic resonance to perfectly locate the type and number of fibroids, their depth 
within the myometrium, and the distance to the serosa layer of the uterus.
Correctly selecting if the procedure can be performed in an office or in an 
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tumour tissue in one or two surgical sessions, remembering that the office surgery 
limit is 25 minutes and that the ability to work comfortably depends on the patient’s 
pain threshold, in addition the use of the appropriate 5 mm surgical material.
Both in the case of surgery in an office and in an operating theatre, being familiar 
with more than one instrument allows a better selection of the type of energy to use 
and guarantee the safety of the patient and avoid possible complications [49].
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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Abstract
Uterine fibroids have remarkably heterogeneous clinical characteristics with 
unknown exact etiology. The treatment of fibroids should be individualized based 
on their size, location, growth rate, the symptoms that they cause, the desire 
to have children and the age of the woman. Embolization is currently the most 
advanced non-surgical technique. The majority of women report satisfactory 
post-treatment results like shorter hospitalization period and recovery time in 
comparison to hysterectomy and improvement or complete remission of clinical 
symptoms. Complications include amenorrhea (in the majority of cases: recur-
rence after three months) and infections that are generally treated with antibiotics. 
The results from most clinical studies and our published experience indicate that 
embolization improves pelvic symptoms related to uterine fibroids. Collaborative 
efforts between gynecologists and interventional radiologists are necessary in 
order to optimize the safety and efficacy of this procedure. In the future, emboli-
zation could be generally recommended as treatment option for women who desire 
future fertility/pregnancy.
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Uterine fibroids are high prevalent benign tumors that originate from muscle 
cells of the uterus with remained incompletely understood incidence, progression 
disease and natural history [1]. The above mentioned tumors may appear single or 
multiple but usually remain asymptomatic [1, 2]. Fibroids appear in various areas 
of uterus, different sizes and exist not a general accepted classification system for 
fibroid evaluation [3, 4]. They represent a tremendous public health problem with 
multiple difficulties and financial cost on society [1–4].
Treatment strategies to prevent the fibroid limit growth and non-surgical treat-
ment are needed [5–8]. Minimally invasive methods like uterine artery embolization 
(UAE) as treatment option of fibroids by retaining the uterus among the women dur-
ing middle or late reproductive years is the summarized goal of this literature review 
with detailed 12 years results report of Department Obstetrics and Gynecology 
in cooperation with Interventional Radiology Unit of Radiology Department, 
Democritus University of Thrace in Greece. The aim of this retrospective study was 
to investigate the contribution of UAE and the occurrence of transient, or permanent 
amenorrhea as well as reappearance of regular menstruation, inflammation, pain in 
premenopausal women up to one year of postoperative follow-up UAE.
2. Incidence
The fibroids occur in a phenotype in wide of genetic diseases, clinically not as 
single disease entity and their progression varies and based on the various types 
of disease in different national groups [9, 10]. The incidence of asymptomatic but 
sonographically fibroids detected as remarkably high and the incidence depending 
on women age and race. Their prevalence is 9% in white women, three to nine times 
higher prevalence in African American, diagnosed in 3.3% of 25 to 32 year olds, 7.8% 
of the 33 to 40 year olds and increased 20-fold to 6.20 per 1000 women years by ages 
45to 50 [9–14]. Familial aggregation studies confirm heritability of fibroids 2.5 times 
more at risk in first degree relatives, increasing to 5.7 for women with an affected 
first degree relative of less than 45 years old. The grow and recur rate of fibroids after 
abdominal myomectomy reported as 5 year risk 62% with 9% risk an additional 
major surgical procedure. Relapses of 27% over a period of 10 years are reported 
with increasing frequency rate approaching to premenopausal period [9, 14, 15].
The recurrence risk is lower in women with single fibroid with small size and in 
those women who noticed a subsequent successful pregnancy. Oral contraceptives 
administration decreased the occurrence of fibroids depending to the duration of 
oral contraceptives use [16–18]. Moreover, early menarche and high body mass 
index (approximately 18% for each 19 kg increase) are some other factors that 
lead to the development of fibroids [9, 14, 15, 19]. Clinically fibroids occur at least 
three distinct phenotypes like: single, multiple varying size and in association with 
adenomyosis or alone [9]. Fibroids interfere not only with implantation but also 
with successful labor and if there are not existing, is for a woman more likely to be 
pregnant. Pregnancy prevents the development of fibroids, because is associated 
with fibroid inflated effect [9, 14, 16–18]. The risk of fibroids decrease with parity 
up to fivefold [9, 14]. Although subfertility may be caused by fibroids, however the 
detected fibroids during pregnancy not influence the age of delivery of the first 
child, but change the age of last term labor. The presence of fibroids in the major-
ity are not associated to any symptoms but is poorly explain their contribution to 
symptoms menstrual disorders heavy menstrual flow or longer duration of menses, 
pelvic pain and infertility. Based on the published literature is demonstrated a 
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relationship between diastolic pressure and fibroids [9, 16–20]. High diastolic blood 
pressures led to atherogenesis, cause injury and damage of muscle cells like a similar 
mechanism as in vascular muscle system, release cytokine in uterus muscle, which 
led to promotion of fibroid growth [9, 16–20]. Approximately 10 mm Hg increas-
ing of blood pressure led to 8–10% increased fibroid risk. Myometrial injury based 
either on ischemia, hypertension or atheromatic type mechanisms are associated 
positively also to pelvic inflammatory disease [9, 16–20]. The risk of fibroids is low, 
if the estrogen levels are low and this could be explain the low risk associated with 
smoking, alcohol and caffeine consumption.
3. Heritable disease associated to fibroids
Some fibroids reflected genetic syndromes feature fibroids development such 
Reed’s, Bannayan Zonana, Cowden syndrome, herediatary leiomatosis and renal 
cell cancer (HLRCC). Reed’s syndrome is well known as familial leiomyomatosis 
cutis and uteri (MIM150800) is an autosomal dominant trait with reduced pen-
etrance associated with cutaneous fibroids. Bannayan Zonana (MIM153480), 
Cowden (MIM158350) syndromes are autosomal dominant hamartomatous pol-
yposis disorders included lipomas, interstinal hamartomatous polyps and various 
nonneoplastic manifestations [21–24].
Intracellular mutation such as chromosomal translocations and deletions are 
reported. None of the mentioned patterns of inheritance have been clearly proved 
in fibroids as a solitary phenotype.
In addition, different genetic subtypes can be found in different fibroids of the 
same patient. Many fibroids in a uterus may be of different cytological origin. The 
heterogeneity from growth and development of fibroids based on enzyme glucose-
6-phosphate dehydrogenase (G6PD) isoenzyme analysis and using androgen recep-
tor (AR) gene assays reveal that fibroids are monoclonal lesions arise independently 
from the same uterus and may associated to various chromosomal abnormalities 
which results in a distinct fibroid is a monocyte in the origin of the monoclonal 
independent lesion [25–28].
In uterus referred high rate of estrogen receptors, which comprised spiral linear 
muscle fibers separated from the natural surrounding uterine muscle tissue by a 
pseudocapsule of connective tissue.. Many distinct factors contribute to tumor 
progression [25–28].
Approximately 40% of fibroids are karyotypically abnormal which compared to 
normal fibroids are generally more cellular and have a greater mitotic index lower 
DNA content. The most prevalent types of chromosomal aberrations are as fol-
lowing: t(12,14), (q14-q15,q23-q24), rearrangement of 6p21, del(7)(q22q32), 1p36, 
10q22, 13q21–22 nad of x chromosome partial deletion 3q, trisomy 12. [29–32]. 
Fibroids with abnormal karyotypes are associated to anatomically positions 12% of 
submucosal, 29% of subserosal and 35% of intramural. Based on low frequency of 
karyotypic rearrangement is the explanation that submucosal fibroids are highly 
symptomatic and led to menorrhagia. Further research in the genetics of fibroids is 
needed to investigate the heritability based on their clonal mosaic nature to corre-
late genotypic and clinically characteristics [29–34].
4. Adenomyosis
In UAE practice for therapy of symptomatic types adenomyosis either of pure 
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respectively depending on size and number of fibroids (adenomyosis dominance, 
fibroid dominance) is reported a ratio 7:2:1 between the treated women [35].
Adenomyosis is characterized by the development of ectopic endometrial glands 
and a stroma in the myometrium, at a depth > 2.5 mm from the endometrial-
myometrial separation surface and moreover by hypertrophy or hyperplasia of 
the smooth muscles of the myometrium [36–39]. An older description is given 
by Rokintasky 1860 adenoid cystosarcoma of the uterus and for the first time by 
Frankl 1925 the term of adenomyosis of the uterus [36–39]. Clinical diagnosis of 
adenomyosis is only hypothetical, histological examination poses diagnosis of the 
disease after hysterectomy [36–39]. It is diffuse (adenomyosis) or focal (adeno-
myoma), asymmetrically affects the uterine wall of premenopausal women (usually 
the posterior) and often coexists with myomas [36–39]. The disease is common 
(5% - 70% in the surgical series, using strict criteria 10% - 18%), progressing and 
manifested with non-specific symptoms, which are similar to the symptoms caused 
by myomas (bleeding - anemia, pain, dysmenorrhea, dyspareunia, pelvic load (bulk 
symptoms) - sensitive uterus or a combination of the above), so it is difficult to 
diagnose only by clinical criteria [36–39]. An incidence of 10% -30% is described, 
in hysterectomy preparations it was found in a percentage of 10% - 18%. 80% of 
women with adenomyosis have another uterine condition like pelvic endometriosis 
and endometrial polyps (2% - 20%) endometrial hyperplasia, adenocarcinoma 
[36–39]. In 35% of women with adenomyosis do not show any symptoms and 
the diagnosis of the disease is random [38–41]. The pathogenesis of adenomyosis 
remains unknown. Etiology: According to various studies the endometrial glands 
of the disease express more in immunochemical examinations the ratio of HCG/
LH receptors found in endometrial cancers and trophoblastic disease, compared 
to natural [36–39]. Other theories of pathogenesis include elevated estrogen 
levels, endometrial injuries in surgeries such as scraping, fibromyectomy, cesarean 
section, and residual of Muller Duct. Adenomyosis occurs mainly in multiparas 
with an incidence of 5–70%. Symptoms of adenomyosis (menorrhagia (50%), 
dysmenorrhea (30%), uterine bleeding (20%), dyspareunia (sporadic additional 
symptom) [38–41]. The clinical diagnosis of adenomyosis is only hypothetical and 
only histological diagnosis makes the diagnosis of the disease after hysterectomy. 
Preoperative transvaginal ultrasonography (TVUS) and magnetic resonance (MRI) 
are useful diagnostic examinations Main diagnostic TVUS criteria are as following: 
asymmetrical uterine enlargement, subendometrial halo thickening, indistinct 
endometrial myometrial border, myometrium is thickened ventrally and associated 
to heterogeneous echotexture. MRI is another recommend imaging examination 
preprocedural of UAE with higher specificity compared to TVUS approximately 
(86–96%)and excellent to recognize fibroids,adenomyomas if the myometrial 
thickness is increased or the myometrium occur anatomical area changes In focal 
adenomyosis occurs low signal intensity within the myometrium, while in diffuse 
adenomyosis appear the junctional zone diffuse thickening also with low signal 
intensity in T2 weighted MRI The treatment options are: Drug treatment (usually 
ineffective), Presence of estrogen receptors in fibroids promote the increase in 
fibroid size. Progesteroids such as medroxyprogesterone acetate, norethindrone in 
GnRH-suppressed patients may increase in size. Stimulation of fibroid enlargement 
is a complex process involving the interaction of estrogen-progestogens in combi-
nation with local growth factors [38–41]. Antiprogesteroids such as mifepristone 
RU-486 reduce fibroid size. Invasive treatment of fibroids: myomectomy (open 
- intra-abdominal, laparoscopic, hysteroscopic), hysterectomy, myolysis - catalysis 
cryocatalysis, thermal catalysis by microwave or radio frequency (RF-ablation), 
ultrasound focus catalysis (FUS) and laser photocatalysis] and uterine artery 
percutaneous embolization (UAE) [38–42].
79
The Contribution of Uterine Artery Embolization as a Safe Treatment Option for Uterine Fibroids
DOI: http://dx.doi.org/10.5772/intechopen.93999
5. Clinical symptoms of fibroids
The majority of 60–70% are asymptomatic. The clinical recognized significantly 
underestimates the true occurrence due to the fact that the routine ultrasound 
screening in not obligatory indicated [43–46].
Approximately 62% of women with symptomatic fibroids visit the gyne-
cologists due to multiple symptoms depending on their anatomical location, 
(subserosal, intramural, submucosal or intracavity) size number and associated 
degenerative morphological changes [43–46]. The referred symptoms are as fol-
lowing: abnormal vaginal bleeding (most common), anemia, pelvic mass, frequent 
urination, possible incontinence constipation tenesmus rectal pressure, pelvic 
pain and infertility [43–46]. Pregnancy related fibroid behavior: growth which is 
reported controversy concerning to increasing or remain the same the uterus size, 
degeneration, pain, spontaneous abortions, obstetric complication (premature 
labor in 15%, intrauterine restriction in 10% and malpresentation in 20%) .[43–46]. 
The pregnancy in coesting of fibroids depending on their anatomical location 
and the distance to placental site. Other rare associations are as following: Ascites 
development due the transudation of fluid after torsion and obstruction of vessels 
in floating fibroids, Polycythemia secondary detected, familial syndromes with 
renal cell carcinoma, intravenous leiomatosis and benign matastasizing uterine 
fibroids [43–46].
The most common symptom in the majority of cases in clinical practice is the 
abnormal vaginal bleeding. This symptom in association with myomas occurs either 
as menorrhagia or hypermenorrhea, while metrorrrhagia is not typical for fibroids 
and need more investigation to rule out malignancies. The exact mechanism of 
abnormal bleeding from fibroids is not yet well known. Fibroids alter the nature 
of uterine muscle contractions and prevent the uterus from controlling the degree 
and intensity of bleeding during menstruation. The submucosal fibroids due to 
total or partial protrusion in uterus cavity led most likely to menorrhagia while the 
intramural myomas have obstructive effect on uterine vessels and subsequent led to 
endometrial vessels ectasia with profuse menstrual bleeding [43–46].
Hypermenorrhea occur most likely in endometritis in association to submucous 
myomas. The palpation of myomas based on enlarged irregular uterine contour 
can be useful to clinically diagnosis of fibroids and the findings described as uterus 
size like in pregnancy [43–48]. If the uterus size is more than 12–20 week can be 
palpated on abdominal examination. In cases of increased size of uterus arise 
pelvic pressure on adjacent organs like urinary tract, rectosigmoid with frequent 
urination, ureteral obstruction tenesmus due to incarceration of enlarged uterus in 
Douglas pouch and dysmenorrhea [43–48].
The incidence of malignant mutation in sarcomas is reported to be 0.1–0.29% 
of diagnosed fibroids [43, 49, 50]. Leiomyosarcoma is an independent malignant 
tumor in the absolutely majority and arises de novo, however recently published 
studies reveal that in very rare cases is possible in fibroids with chromosome dele-
tions to develop in leiomyosarcoma most common in the 5th–6th decade of life. 
Γλωσσική επιμέλεια.
It is characterized by extensive abnormal bleeding and a rapid increase in 
uterine size in postmenopausal patients [43, 49, 50]. The main microscopic fea-
tures which are significant predictors of leiomyosarcoma clinical course included: 
coagualtive tumor cell necrosis, degenerating hyperchromatic, pleomorphic nuclei, 
cytologic atypia, mitotic index MI (MI denotes definite mitotic figures (mf) per 
10 high power field (hpf) MI ≥ 5mf/10hpf, differentiation. In case of fibroids, the 
MI < 5mf/10hpf no atypia and necrosis and in the subgroup of leiomyosarcoma or 
smooth muscle of uncertain malignant potential (STUMP) [43, 49, 50]. In STUMP 
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(subserosal, intramural, submucosal or intracavity) size number and associated 
degenerative morphological changes [43–46]. The referred symptoms are as fol-
lowing: abnormal vaginal bleeding (most common), anemia, pelvic mass, frequent 
urination, possible incontinence constipation tenesmus rectal pressure, pelvic 
pain and infertility [43–46]. Pregnancy related fibroid behavior: growth which is 
reported controversy concerning to increasing or remain the same the uterus size, 
degeneration, pain, spontaneous abortions, obstetric complication (premature 
labor in 15%, intrauterine restriction in 10% and malpresentation in 20%) .[43–46]. 
The pregnancy in coesting of fibroids depending on their anatomical location 
and the distance to placental site. Other rare associations are as following: Ascites 
development due the transudation of fluid after torsion and obstruction of vessels 
in floating fibroids, Polycythemia secondary detected, familial syndromes with 
renal cell carcinoma, intravenous leiomatosis and benign matastasizing uterine 
fibroids [43–46].
The most common symptom in the majority of cases in clinical practice is the 
abnormal vaginal bleeding. This symptom in association with myomas occurs either 
as menorrhagia or hypermenorrhea, while metrorrrhagia is not typical for fibroids 
and need more investigation to rule out malignancies. The exact mechanism of 
abnormal bleeding from fibroids is not yet well known. Fibroids alter the nature 
of uterine muscle contractions and prevent the uterus from controlling the degree 
and intensity of bleeding during menstruation. The submucosal fibroids due to 
total or partial protrusion in uterus cavity led most likely to menorrhagia while the 
intramural myomas have obstructive effect on uterine vessels and subsequent led to 
endometrial vessels ectasia with profuse menstrual bleeding [43–46].
Hypermenorrhea occur most likely in endometritis in association to submucous 
myomas. The palpation of myomas based on enlarged irregular uterine contour 
can be useful to clinically diagnosis of fibroids and the findings described as uterus 
size like in pregnancy [43–48]. If the uterus size is more than 12–20 week can be 
palpated on abdominal examination. In cases of increased size of uterus arise 
pelvic pressure on adjacent organs like urinary tract, rectosigmoid with frequent 
urination, ureteral obstruction tenesmus due to incarceration of enlarged uterus in 
Douglas pouch and dysmenorrhea [43–48].
The incidence of malignant mutation in sarcomas is reported to be 0.1–0.29% 
of diagnosed fibroids [43, 49, 50]. Leiomyosarcoma is an independent malignant 
tumor in the absolutely majority and arises de novo, however recently published 
studies reveal that in very rare cases is possible in fibroids with chromosome dele-
tions to develop in leiomyosarcoma most common in the 5th–6th decade of life. 
Γλωσσική επιμέλεια.
It is characterized by extensive abnormal bleeding and a rapid increase in 
uterine size in postmenopausal patients [43, 49, 50]. The main microscopic fea-
tures which are significant predictors of leiomyosarcoma clinical course included: 
coagualtive tumor cell necrosis, degenerating hyperchromatic, pleomorphic nuclei, 
cytologic atypia, mitotic index MI (MI denotes definite mitotic figures (mf) per 
10 high power field (hpf) MI ≥ 5mf/10hpf, differentiation. In case of fibroids, the 
MI < 5mf/10hpf no atypia and necrosis and in the subgroup of leiomyosarcoma or 
smooth muscle of uncertain malignant potential (STUMP) [43, 49, 50]. In STUMP 
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tumors the main diagnostic criterion associated to prognosticate biologic behavior 
is the MI < 5mf/10hpf but is presence of moderate to severe atypia without necrosis 
[43, 49, 50]. The least subgroup of tumors is accompanied by lymph nodes in the 
lung or other sites with histopathological occurrence similar to the original tumor 
approximately 15 years after hysterectomy. Immunostaining for expression of cell 
cycle regulatory proteins like Ki-67,cyclins E,A,cdks (cdk2,cdc2), p16, progesterone 
receptors, p53 Her-2/neu based on significant elevated levels in leiomyosarcomas 
can be useful in discriminating and identifying STUMP tumors, leiomyosarcoma 
and fibroids [43, 49, 50].
6. Treatment options
The uterine fibroids is the most common uterine pathology with a prevalence 
more than 25% of all reproductive years and approximately 1.6 million women in 
United States diagnosed with uterus myomatosus. Asymptomatic fibroids could 
be found incidentally on pelvic imaging and management therapeutical strategy 
depending on their causing clinical symptoms [51]. If cases which are asymptomatic 
need not any treatment and after menopause due to their regression expectant 
management is the recommended therapy option. In symptomatic fibroids based on 
the most common symptoms, heavy menstrual bleeding and painful menstruation 
is very useful. Fibroid classification system based on the fact that the above men-
tioned symptoms caused by fibroids which distort the uterine cavity [49].
Fibroid classification system is referred as following:
Type 0 completely intracavity fibroids.
Type1 ≥ 50% in the cavity intramural.
Type 2 < 50% in the cavity intramural.
Type 3 intramural but approach endometrium.
Type 4 intramural.
Type 5 subserosal but at least 50% intramural.
Type 6 subserosal but less than 50% intramural.
Type 7 subserosal pedunculated.
Type 8 cervical [51].
According to Donnez [52, 53] staging, submucosal fibroids are classified as 
following:
Grade I Fibroids with the largest diameter in the endometrial cavity.
Grade II Fibromyomas with the largest diameter in the myometrium.
Grade III Appearance of multiple fibroids>2.
7. Medical treatment
Medical therapies based on therapeutical manipulating the fibroid hormonal 
environment. Steroid hormones, especially estrogen and progesterone are associ-
ated to fibroids behavior, proved by clinical molecular biological pharmacological 
models and play an important role to their medical treatment. The combination of 
estrogen progestin or progestin alone is the first line medical therapy for uterine 
fibroids.
GnRH (gonadotropin releasing hormone)-agonists led to down regulation of 
GnRH receptors at level of pituitary after initially increase the release of gonado-
tropins flare effect of heavy vaginal bleeding, reduce the FSH (follicle stimulating 
hormone) LH (luteinizing hormone) and ovarian steroid hormone and produce 
a hypoestrogenic menopause state [52–56]. Subsequent results amenorrhea and 
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reduction of the size of fibroids pronounced within three months after beginning of 
treatment [54–58]. The reduction can reach 40–50% of the tumor in 3 months but is 
reversible after stopping treatment. This effect is more pronounced in submucosal 
fibroids due to a higher number of estrogen and progesterone receptors.
GnRH antagonists often used to treat myomas before surgical procedure, 
block pituitary receptors and led immediately to declination of FSH, LH levels 
and fibroid, uterus volume reduction within 3 weeks of therapy beginning. Their 
directly promptly block gonadotropin effect has rapid clinical character and is 
associated to initial flare effect. They are currently indicated only for ovulation 
induction [54–58].
The presence of aromatase in fibroids and additional to ovarian estrogen activ-
ity, interleukin 1βc AMP analoque, prostaglandin E2 led to estrogen production in 
fibroids cells [54–58]. Fibroids express aromatase higher levels compared to sur-
rounding intact myometrium. In these cells occur significant conversion of andros-
tendione to estrone and subsequent to estradiol which has full biologic activity and 
act positively to significant stimulation of proliferation of fibroids cells [54–58].
Aromatase inhibitors inhibit ovarian and peripheral estrogen production due 
to cellular proliferation inhibition, androstendione inhibition and reduce estradiol 
levels after 24 hours of treatment. SERMs (selective estrogen receptor modulator) 
are nonsteroidal agents who bind estrogen receptor and based on target tissue show 
estrogen agonist or antagonist effect [51, 59, 60]. While the SERM Tamoxifen has 
agonist effect in endometrium, Raloxifen exhibit no agonist activity and decrease 
the fibroid size. Antiprogesterone agents act at the level of progesterone receptors 
(PR-A PR-B), which are abundant in the fibroid. It is reported that progesterone 
induce proliferation, up regulate growth factors, antiapoptotic proteins like EGF in 
fibroid cells [51, 59, 60]. Mifepristone is the most studied antagonist of progester-
one and due to high progesterone affinity led to amenorrhea, reduction of fibroid 
size and improvement the clinical symptoms [51, 59, 60]. The administration of 
ulipristal acetate, who is a selective progesterone receptor modulator, has proved 
successful effects on therapy of fibroids with clinical symptoms reduction of their 
size and endometrium cystic glandular changes. Danazol (19a nortestosterone 
derivate) inhibits pituarity gonadotropin secretion, led to ovarian steroid produc-
tion and suppression of endometrial growth after 6 months treatment [51, 59, 60]. 
The use of progestin containing intrauterine contraceptive device (LNG -IUDs) as 
local therapy for menorrhagia and symptomatic uterine fibroids has been studied 
and confirmed a significant reduction in bleeding and fibroid size. However uterus 
myomatosus with a distorted uterine cavity or a submucosal fibroid is a contarindi-
cation for LNG –IUD [51, 59, 60].
8. Surgical treatment
Although the traditional treatment for uterine fibroids remains the hyster-
ectomy either abdominal or vaginal classical, total laparoscopic assisted vaginal 
hysterectomy, robotic assisted laparoscopic hysterectomy as the predominant 
surgical procedure, however is preferred only in women who have completed their 
family planning [61–65].
In late reproductive age and premenopausal period available therapeutic options 
to preserve the uterus allow possible an attempt at conception and are surgical or 
conservative options. Over the past decade, the hysterectomy rate has decreased 
while alternative therapy options for symptomatic fibroids have been increased. The 
surgical procedures include myomectomy, abdominal myomectomy, laparoscopic 
myomectomy, laparoscopic thermal ablation, percutaneous ablative methods, 
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reduction of the size of fibroids pronounced within three months after beginning of 
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fibroids due to a higher number of estrogen and progesterone receptors.
GnRH antagonists often used to treat myomas before surgical procedure, 
block pituitary receptors and led immediately to declination of FSH, LH levels 
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associated to initial flare effect. They are currently indicated only for ovulation 
induction [54–58].
The presence of aromatase in fibroids and additional to ovarian estrogen activ-
ity, interleukin 1βc AMP analoque, prostaglandin E2 led to estrogen production in 
fibroids cells [54–58]. Fibroids express aromatase higher levels compared to sur-
rounding intact myometrium. In these cells occur significant conversion of andros-
tendione to estrone and subsequent to estradiol which has full biologic activity and 
act positively to significant stimulation of proliferation of fibroids cells [54–58].
Aromatase inhibitors inhibit ovarian and peripheral estrogen production due 
to cellular proliferation inhibition, androstendione inhibition and reduce estradiol 
levels after 24 hours of treatment. SERMs (selective estrogen receptor modulator) 
are nonsteroidal agents who bind estrogen receptor and based on target tissue show 
estrogen agonist or antagonist effect [51, 59, 60]. While the SERM Tamoxifen has 
agonist effect in endometrium, Raloxifen exhibit no agonist activity and decrease 
the fibroid size. Antiprogesterone agents act at the level of progesterone receptors 
(PR-A PR-B), which are abundant in the fibroid. It is reported that progesterone 
induce proliferation, up regulate growth factors, antiapoptotic proteins like EGF in 
fibroid cells [51, 59, 60]. Mifepristone is the most studied antagonist of progester-
one and due to high progesterone affinity led to amenorrhea, reduction of fibroid 
size and improvement the clinical symptoms [51, 59, 60]. The administration of 
ulipristal acetate, who is a selective progesterone receptor modulator, has proved 
successful effects on therapy of fibroids with clinical symptoms reduction of their 
size and endometrium cystic glandular changes. Danazol (19a nortestosterone 
derivate) inhibits pituarity gonadotropin secretion, led to ovarian steroid produc-
tion and suppression of endometrial growth after 6 months treatment [51, 59, 60]. 
The use of progestin containing intrauterine contraceptive device (LNG -IUDs) as 
local therapy for menorrhagia and symptomatic uterine fibroids has been studied 
and confirmed a significant reduction in bleeding and fibroid size. However uterus 
myomatosus with a distorted uterine cavity or a submucosal fibroid is a contarindi-
cation for LNG –IUD [51, 59, 60].
8. Surgical treatment
Although the traditional treatment for uterine fibroids remains the hyster-
ectomy either abdominal or vaginal classical, total laparoscopic assisted vaginal 
hysterectomy, robotic assisted laparoscopic hysterectomy as the predominant 
surgical procedure, however is preferred only in women who have completed their 
family planning [61–65].
In late reproductive age and premenopausal period available therapeutic options 
to preserve the uterus allow possible an attempt at conception and are surgical or 
conservative options. Over the past decade, the hysterectomy rate has decreased 
while alternative therapy options for symptomatic fibroids have been increased. The 
surgical procedures include myomectomy, abdominal myomectomy, laparoscopic 
myomectomy, laparoscopic thermal ablation, percutaneous ablative methods, 
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hysteroscopic myomectomy, myolysis, laparoscopic morcellation and finally uterine 
artery ligation and occlusion performed either as surgical ligation during laparos-
copy [61–65]. (παρακάτω θα μπορούσε να μπεί παράγραφος για τους κινδύνους της σε 
περίπτωση STUMP tu).
In cases of laparoscopic morcellation is of great importance to exclude based 
on evaluations criteria like presence of coagulations necrosis, no significant atypia 
and mitotic index ≤10 STUMP tu due to unknown malignant potential behavior. 
Minimally invasive therapies non-surgical procedures are as following: Magnetic 
resonance guided focused ultrasound ablation (MRgFUS) and UAE. MRgFUS 
based on ultrasound energy through the abdominal layers without requirement 
of incisions under real time MRI monitoring to reduce fibroid size [66]. Γλωσσική 
επιμέλεια UAE blocks selective the uterine artery blood flow led to shrink of fibroids 
[67]. The goal of this review was to report our 12 years of experience from the 
impact of UAE on ovarian reserve (OR) (which refer to number and quality of the 
follicles left in the ovaries) of normal menstruating premenopausal women and to 
estimate the degree of pain and inflammation caused by UAE in our patients based 
on AMH levels and inflammatory parameters (CRP, temperature, white blood cells) 
respectively.
9. UAE uterine artery embolization as treatment option
UAE to treatment of fibroids as alternative to surgical procedure was reported 
for first time by Ravina in 1995 [67]. This is not only treatment option for fibroids 
but used successfully also in refractory postpartum bleeding, or after gynecologic 
surgery, abnormal malignancy suspicious vaginal bleeding or in cases with uterine 
arteriovenous malformation. Although several reports confirm satisfactory results 
of treatment of symptomatic fibroids without necessity of surgical procedure based 
on the optimal cooperation between gynecologist and interventional radiologist, 
however the absolutely majority is retrospective and exist no prospective random-
ized trials to prove the effectiveness of this procedure compared to other therapy 
options [67–70]. The UAEs were performed in the Department of Radiology by an 
experienced interventional radiologist.
9.1 Preprocedureal management
All study participants were normal menstruating premenopausal women aged 
between of 38–50 years old (42.6 ± 7 years on average), had attended the depart-
ment of obstetrics and gynecology of our University hospital complaining of serious 
symptoms of uterine fibroids (menorrhea, anemia, pelvic pain, bulky symptoms, 
pressure effects) underwent UAE for uterus fibromyomas and/or adenomyosis 
(pure or mix type). The enrolled premenopausal women diagnosed with and normal 
ovarian reserve as defined by AMH and FSH measurements (serum FSH concentra-
tion > 10 IU/L (on day 3 of menstrual cycle), serum AMH (2–8 pg./l). In all patients 
were available cervical pap smear test and previously performed fractional curettage. 
Exclusions criteria: Women with pelvic infection, pregnant (or willing to be preg-
nant) women, cases suspicious of any pelvic malignancy, postmenopausal women, 
women with resistant clotting disorders or severe allergy to contrast media, ovula-
tory problems, previous ovarian surgery, PCOS (polycystic ovarian syndrome) or 
coagulopathy, immunocompromised, previous pelvic irradiation or women who had 
been offered hormonal therapy for fibroids with GnRh agonists, were excluded. All 
patients underwent MR Imaging on a 1.5 Tesla (Multiva, Koninklijke Philips N.V.) or 
an 1 Tesla equipment (GE Healthcare, Milwaukee, USA) up to 60 days before UAE, 
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using phased-array pelvic coils (Figure 1a-f). MR imaging included at least sagittal, 
coronal and transverse T2-weighted images, T2*-weighted images, T2-weighted fat 
saturated images, Diffusion-weighted images, T1-weighted images, and sagittal, 
coronal and transverse fat saturated T1-weighted images pre and post contrast. 
AMH, FSH, TSH, LH, fT 4 E, PROG, PROL, TESTOST and DHEAS were measured 
on day 3 of the menstrual cycle before UAE. C reactive protein (CRP) and white 
blood cell count lab exams were carried out prior to and after UAE. Two patients 
that had undergone fibromyectomy and with fibromyoma recurrence were included. 
Preoperative imaging management enhances the ability to diagnosis and to identify 
pathology induced anatomic changes and is crucial in optimizing information to 
treatment.
Transvaginal ultrasonography (TVUS) has an efficacy of 65–99% and consists 
the gold standard for imaging of the woman’s pelvis. MRI is crucial in the diagnosis. 
Differential diagnosis with MRI has a sensitivity of 88% - 93% and a specificity of 
66% - 91%. MRI examination is important to rule out malignancy in the uterus, 
eg sarcoma and to identify nondegenerated fibroids. Degenarated fibroids occur 
as hyalinized fibroids, cystic changes as hypertense, myxoid degeneration as high 
signal intensity, necrotizing has components of necrotizing or coagulative necrosis.
9.2 UAE
All patients had signed a written consent before the UAE. The UAE procedures 
were performed in the hybrid angiography suite of Radiology Department using a 
biplane angiography system (Philips Allura Xper Cath/angio system, Koninklijke 
Philips N.V.).
Bilateral UAE was performed, under local anesthesia, i.v. antibiotic prophy-
laxis, and sedation when required. In all cases a bladder catheter has been placed. 
Figure 1. 
Description of UAE procedure course.
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The procedure included a single percutaneous puncture of the right common femoral 
artery, selective crossover contralateral and unilateral advance of a 4-French flush 
angiographic catheter (Simmons 1 or Cobra 1) to both uterine arteries. When the 
catheter bypassed the arteries for the vagina and cervix, administration of the 
embolic particles started. In the most of the cases a 2.7-Frence or 2.8-Frence micro-
catheter (Progreat, Terumo Europe, Leuven, Belgium) has then been positioned 
away from the cervicovaginal branches (Figure 2a-f).
Special radiation protection care was taken, using fluoroscopic guidance of the 
catheterizations, fluoroscopy time reduction to the minimal possible and, mostly, 
fluoroscopic imaging of contrast angiography opacifications.
Fibroid ischemia was achieved by using of spherical, tightly calibrated, bio-
compatible, non-resorbable, hydrogel coated microspheres, 700 μm and 900 μm in 
diameter (Embozene, CeloNova BioSciences Inc./Boston Scientific, San Antonio, 
USA). The angiographic embolization endpoint was defined as complete stasis of 
contrast agent in the ascending segment of the uterine artery during selective digi-
tal subtraction angiography at the end of the embolization procedure. Adenomyosis 
patients were embolized with the use of 500 μm and/or 700 μm Embozene micro-
spheres. Criterion for the particle administration stop in adenomyosis cases was the 
fluoroscopic finding of “almost complete stasis”.
9.3 Postprocedureal management
Regarding pain treatment, post-intervention 50 mg of pethidine was intramus-
cular administered, and after 4 hours the dosage was repeated by intramuscular 
injection in the first 24 hours. 100 mg tramadol was taken every 6 hours and anti-
inflammatory tablets were taken every 12 hours for a week. Pain assessment results 
were determined based on a visual analogue scale (0 min-10max). After daily stay 
Figure 2. 
MRI imaging of fibroid course pre- and post embolization.
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at the hospital, patients were discharged and administered broad spectrum anti-
biotics for one week. Clinical, laboratory and imaging follow up examinations by 
trans–vaginal ultrasonography and MRI scans of the patients were performed at the 
1rst, 3rd, 6th and 12th month after the procedure (Figure 1e-f).
Main outcome measures were menstruation, hormonal status and presence of 
menopausal symptoms. Hormonal status and ovarian reserve were evaluated by 
means of AMH and FSH serum levels on 1st, 3rd, 6th and 12th month after UAE. 
Subsequently, FSH and LH levels began to decrease and reached the base line values 
on the 12th month after UAE (Figure 3) [71]. The AMH levels showed a decrease 
on the 1st month, reaching the minimum values on the 3rd month and retaining 
the base line values on the 3rd month in contrary to the other examined hormones. 
No Case of amenorrhea was noted in women ≤45 years old, while 0.6% of women 
>45 years old experienced amenorrhea only the first 3 months after UAE 
(Figure 4) [71] According to our findings, a leukocytosis value of up to 16,000  
Κ/μl and an increase in CRP level of up to 8 mg/dl, are not alarming [70]. In our 
study were included only premenopausal women and especially women who com-
pleted their family planning. However, reported two unplanned pregnancy cases, 
which they have decided to terminate the pregnancy. We have no noticed no case 
for emergency hysterectomy. In Table 1 are summarized the complications in our 
participants and according to international literature with the maximally respec-
tively referred complications rate. The first column of the table refers to our results 
in the time from 2008 to 2020 while in the second column are shown the respec-
tive values of the examinated parameters in average concerning to  international 
 literature [72–76].
The course of myoma size according to a follow up for a period of 1 year post 
UAE was mean reduction 75% of fibroid volume compared to fibroid size before 
beginning of treatment. The percentage of technical success of the performed UAEs 
was estimated at 100% and the MRI examinations revealed that the uterine volume 
continues to shrink over follow up time. In no case was noticed continuity of wors-
ening preprocedure symptoms, permanent amenorrhea, necessity of subsequent 
hysterectomy or minimal shrinkage of fibroid size after 6 months postprocedural. 
The positive results expressed as clinical included: Reduce of bleeding and pressure 
symptoms and as imaging reduction in uterine size and fibroids. According to our 
Figure 3. 
Hormonal changes (FSH,LH) during the follow up period (Tsikouras et al. [71]).
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Figure 2. 
MRI imaging of fibroid course pre- and post embolization.
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at the hospital, patients were discharged and administered broad spectrum anti-
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1rst, 3rd, 6th and 12th month after the procedure (Figure 1e-f).
Main outcome measures were menstruation, hormonal status and presence of 
menopausal symptoms. Hormonal status and ovarian reserve were evaluated by 
means of AMH and FSH serum levels on 1st, 3rd, 6th and 12th month after UAE. 
Subsequently, FSH and LH levels began to decrease and reached the base line values 
on the 12th month after UAE (Figure 3) [71]. The AMH levels showed a decrease 
on the 1st month, reaching the minimum values on the 3rd month and retaining 
the base line values on the 3rd month in contrary to the other examined hormones. 
No Case of amenorrhea was noted in women ≤45 years old, while 0.6% of women 
>45 years old experienced amenorrhea only the first 3 months after UAE 
(Figure 4) [71] According to our findings, a leukocytosis value of up to 16,000  
Κ/μl and an increase in CRP level of up to 8 mg/dl, are not alarming [70]. In our 
study were included only premenopausal women and especially women who com-
pleted their family planning. However, reported two unplanned pregnancy cases, 
which they have decided to terminate the pregnancy. We have no noticed no case 
for emergency hysterectomy. In Table 1 are summarized the complications in our 
participants and according to international literature with the maximally respec-
tively referred complications rate. The first column of the table refers to our results 
in the time from 2008 to 2020 while in the second column are shown the respec-
tive values of the examinated parameters in average concerning to  international 
 literature [72–76].
The course of myoma size according to a follow up for a period of 1 year post 
UAE was mean reduction 75% of fibroid volume compared to fibroid size before 
beginning of treatment. The percentage of technical success of the performed UAEs 
was estimated at 100% and the MRI examinations revealed that the uterine volume 
continues to shrink over follow up time. In no case was noticed continuity of wors-
ening preprocedure symptoms, permanent amenorrhea, necessity of subsequent 
hysterectomy or minimal shrinkage of fibroid size after 6 months postprocedural. 
The positive results expressed as clinical included: Reduce of bleeding and pressure 
symptoms and as imaging reduction in uterine size and fibroids. According to our 
Figure 3. 
Hormonal changes (FSH,LH) during the follow up period (Tsikouras et al. [71]).
Fibroids
86
findings after UAE the fibroids shrank by 60–70% and the size of the uterus by 
50–60%. In particular, mild symptoms of metabolic syndrome in four cases were 
observed. Over time, shrinkage increases. The reduction in symptoms is expected to 
be close to 98%.
Specifically, menstruation improved in 95–100% of cases, while symptoms 
(flatulence, pelvic pressure and frequency) are reduced to 91–100% depending on 
how the result is calculated. High satisfaction rates for women. The recurrence of 
fibroids reaches 4%, but is thought to be due to an increase in the size of old incom-
plete embolized myomas and adenomyosis. The main cause of failure was not the 
initial size of the fibroids, but their failure shrank below 30% of the original size. In 
three cases it was mandatory to repeat the procedure of UAE due to the anatomical 
location of the fibroids, intra-ligamentally.
Figure 4. 






< 45 years old 0.2–0.5% 1–2%
> 45 years old 1.5% 2–4%
Permanent amenorrhea 0
< 45 years old 0 2–3%
> 45 years old 0 5–6%
Fibroma protrusion 0.3%
Aseptic endometritis 0.1–0.2% 2%
Septic endometritis 0 1.2%
Uterine necrosis 0 <1%
Unsuccessful UAE 0 <1%
Table 1. 
UAE complications: our results and various published reports.
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10. Discussion
UAE is a minimally invasive procedure which improves symptoms by inter-
rupting the blood flow uterine vessel branches to fibroids after bilateral (from 
right and left) hyper-selective catheterization of the myometric feeder arteries and 
embossing of pistons induceing irreversible ischemic damage and degeneration/
shrinkage in the fibroids [65, 75–80]. According to bibliography, therapy success 
rate during menorrhagia, was is 80–100% and at? pressure phenomena 60–100%. 
A decrease in fibroid size by 40–70% was noted in the first 6 months, followed by 
50–80% in the months that ensued [67, 77–82]. There are various reports regard-
ing uterus size course [67, 77–82]. Some authors mention uterus size as criteria, 
whilst others use both fibroids and uterus size as successful therapy assessment 
criteria. Inflammation appearance rate is 1–2% based on tissue reactions due to post 
interventional ischemia is an interaction between cells and cytokine and should be 
diagnosed at an early stage so that sepsis, hysterectomy and death can be avoided 
[81–84]. There have been reports of 100.000 successful UAEs in total so far [84–87].
Patients should be notified in detail and contact their doctor. Fundamental is the 
co-operation between gynecologist and interventional radiologist before, during 
and after UAE. In general, complications include either catheterization or the 
effects of uterine ischemia that can cause fibrotic necrosis, pain and septic imaging. 
The ovaries may be affected. The reported deaths following UAE are extremely rare 
(approximately 1: 1600) and are mainly related to pulmonary embolism, which may 
be due to the effect of necrotic tissue on activation of the coagulation mechanism 
and on inflammation. The complications of catheterization are rare (<1%), such 
as hematoma, allergy to contrast media and pseudo-aneurysm or vascular separa-
tion [75, 76, 87–90]. Elimination of uterine fibroids occurs in 5% of cases and can 
cause inflammation requiring scanning or hysterectomy. The necrotic tissue, if not 
removed in time, can become infected and the condition becomes severe. Cases 
with submucosal fibroids should be treated hysteroscopically [75, 76, 87–90]. 
Ischemia may cause endometritis, pelvic inflammation and pyometra with poor 
outcome if hysterectomy does not occur. According to the literature, menorrhagia  
is successfully treated in 91–100% of cases, while symptoms such as flatulence, 
pressure on organs of the pelvis and loss of urine are reduced to 92–100%  
[67, 75, 76, 87–90]. Uterine size does not appear to be a determinant, as remission of 
symptoms is also common in patients with a uterus greater than 24 weeks gestation. 
These results are also confirmed by studies of the last four years, which show that 
patients are 98–1000% satisfied [67, 75, 76, 87–90]. UAEs also have a beneficial 
effect in cases of adenomyosis, although there is not much experience. In a series of 
28 patients with genuine adenomyosis an improvement of 95.3% was recorded  
[67, 75, 76, 87–90]. Although there are no long-term data, follow-up of up to 
72 months shows postembolization syndrome include: pain and cramps (eliminated 
in the first hours after procedure with good/systemic analgesic treatment), nausea 
and fever (controlled with appropriate medications), aseptic or (rarely) septic 
inflammation (in a few patients, total 4 in our study controlled with anti-inflam-
matory/antibiotics) for 3–6 months) or (rare) menopause after UAE (small number 
of patients, almost always aged>45 years) [67, 75, 76, 87–90]. In these cases were 
diagnosed large fibroids and the reported complications affect range according to 
published literature 2–15% needed readmission for monitoring of symptoms. The 
necessity of hysterectomy after UAE approximately reported in 1% of cases. In our 
study participants reintervention was necessary only in 4 cases due the anatomical 
fibroid positions. According to international literature reintervention’s rate is by 
9% at 1 year and 28% at 5 years [67, 75, 76, 87–90]. Pregnancies in the majority after 
the UAE reported and delivered at term without serious complications, however 
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the cesarean section rate is high approximately 33–50% [67, 75, 76, 87–91]. Based 
on current medical knowledge concerning genetics and molecular biology of 
uterine fibroids will be the basis of development microarray analysis to investigate 
genes, which involved in fibroid formation and provide more specific and effective 
minimally preventive fibroid therapies to early intervention and improve the life 
impact of women.
11. Conclusion
UAE is a safe and effective treatment option for uterine fibroids with inter-
national recognition, however further multicentric studies required to provide 
clinical data and participate in randomized control trial to compare with the known 
surgical procedures.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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Physiopathology and Management 
of Uterine Fibroids
Joel Noutakdie Tochie, Gaelle Therese Badjang, 
Gregory Ayissi and Julius Sama Dohbit
Abstract
Uterine fibroid is the most encountered benign tumour in women of 
reproductive age. It causes spontaneous abortions, missed abortions, painful red 
degeneration or infarction of the fibroids, abnormal foetal presentation, obstructed 
labour, and an increased likelihood of premature deliveries, caesarean deliveries, 
postpartum haemorrhage in pregnancy, whereas, in the non-pregnant women 
it is associated an irregular menstrual cycle sometimes associated with heavy 
menstrual bleeding, infertility, constipation, urinary incontinence, and leiosarcoma 
transformation. Till date is pathophysiology and management both in the non-
pregnant and pregnant woman have not been well described. In this chapter, we 
present contemporary evidence to help elucidate this enigma.
Keywords: uterine fibroid, leiomyoma, pathophysiology, management
1. Introduction
Leiomyomas also called uterine myomas, uterine fibroids, or fibromyomas are 
discrete, rounded, firm, white to pale pink, benign myometrial tumours composed 
mostly of smooth muscle with varying amounts of fibrous connective tissues [1]. 
Uterine fibroids or leiomyomas are benign tumours of the uterine smooth muscles. 
They are benign clonal neoplasms that contain an increased amount of extracellular 
collagen, elastin and are surrounded by a thin pseudo-capsule. They may enlarge to 
cause significant distortion of the uterine surface or cavity. Their size will then be 
described in menstrual weeks, as in a pregnant uterus [2].
Most fibroids are asymptomatic; usually asymptomatic in pregnancy but may 
interfere with conception and may cause spontaneous abortion, missed abortions, 
painful red degeneration or infarction of the fibroids, abnormal foetal presenta-
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Abstract
Uterine fibroid is the most encountered benign tumour in women of 
reproductive age. It causes spontaneous abortions, missed abortions, painful red 
degeneration or infarction of the fibroids, abnormal foetal presentation, obstructed 
labour, and an increased likelihood of premature deliveries, caesarean deliveries, 
postpartum haemorrhage in pregnancy, whereas, in the non-pregnant women 
it is associated an irregular menstrual cycle sometimes associated with heavy 
menstrual bleeding, infertility, constipation, urinary incontinence, and leiosarcoma 
transformation. Till date is pathophysiology and management both in the non-
pregnant and pregnant woman have not been well described. In this chapter, we 
present contemporary evidence to help elucidate this enigma.
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1. Introduction
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described in menstrual weeks, as in a pregnant uterus [2].
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tion, obstructed labour, and an increased likelihood of premature deliveries, 
caesarean deliveries, postpartum haemorrhage and, whereas, in the non-pregnant 
state its signs and symptoms are menorrhagia, metorrhagia, menometorrhagia, 
infertility, constipation, urinary incontinence, and leiosarcoma transformation 
[3]. Uterine fibroids can occur in the non-pregnant woman and then continue 
into pregnancy/may develop de novo in pregnancy. In both circumstances, the 





Evidence from the contemporary literature reports that the prevalence rate of 
uterine fibroid varies between 16.7% - 30% of reproductive-age women and there 
is a two-fold increase in the prevalence in Afro American women [4, 5]. Also, their 
incidence tends to peak at the age of 35 years and almost 50% of African women 
will have uterine fibroid by their 5th decade of life [1]. Leiomyomas are the most 
frequent pelvic tumours and occur in about 20 to 25% of reproductive-age women. 
Uterine fibroids and the severity of their symptoms have a predilection for the black 
ethnicity. Huyck KL et al. in 2008 demonstrated that the odds of having severe 
symptoms from uterine fibroids are more than five times greater in black African 
women than in Caucasians [6]. Furthermore, black women develop the disease five 
to six years earlier and their peak age at diagnosis is 40–44 years [7] as opposed to a 
to peak age of incidence of 35 years observed in Caucasians [1]. Also, almost 50% of 
African women will have uterine fibroid by their 5th decade of life [1].
Risks factors of uterine fibroids include African-American ethnicity, early 
menarche (less than 11 years) and high body mass index [8, 9]. Moreover, the length 
of the menstrual cycle has an inversely proportional relationship with fibroids: a 
shorter cycle is positively correlated with an increased likelihood to develop fibroids 
[10, 11]. A similar inverse association is observed with use of oral contraceptives, 
the duration of tobacco smoking and the development of fibroids [12]. On the other 
hand, multiparity and the late ages of last pregnancy are other protective factors for 
uterine fibroids [11].
3. Anatomical Classification of Uterine Fibroids
According to their anatomic locations, there are three different types of 
leiomyomas:
• Subserosal or subperitoneal leiomyomata are the most common and are 
usually asymptomatic unless very large. They originate in the myometrium 
and grow out toward the serosal surface of the uterus, lying beneath the 
peritoneum [1]. They may lie just at the serosal surface of the uterus or may 
become pedunculated. They become parasitic when they derive their entire 
blood supply outside of the uterus, from omental vessels. Sometimes, their 
pedicles may atrophy and resorb. When they arise laterally, subserous tumours 
may extend between the two peritoneal layers of the broad ligament to become 
intraligamentary leiomyomas.
• Intramural or interstitial myomas are located within the uterine wall of the 
myometrium and may distort the shape of the uterine cavity and surface. They 
may manifest with swelling of the abdomen, menorrhagia and infertility.
• Submucosal fibroids are the most symptomatic. They originate in the 
 myometrium and grow toward the endometrial cavity, protruding into the 
uterine cavity that they tend to compress. Their impact on the endometrium 
and its blood supply most often lead to irregular uterine bleeding. Other 
symptoms commonly associated are dysmenorrhea, infertility and recurrent 
abortions [13]. This type of fibroids may also develop pedicles and protrude 
fully into the uterine cavity. Occasionally they pass through the cervical canal 
while still attached within the corpus by a long stalk. There, they are subject to 
torsion or infection.
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• Cervical leiomyomas are a rare type. They are sometimes mistaken to vaginal 
leiomyomas, which may present with the same clinical features [14]. They 
cause early pressure effects in regions of bladder neck, infection, dyspareunia 
and infertility.
• With respect to the location of the fibroids, 89.4% submucous, 10.6% subse-
rous and 74.5% were intramural according to a study done in Cameroon [15].
FIGO classification of uterine fibroids (PALM-COEIN)
Stage 0: a sub-mucosal pedunculated intra-uterine cavity fibroid
Stage 1: a sub-mucosal located less than 50% intra-murally
Stage 2: a sub-mucosal located greater than 50% intra-murally
Stage 3: a fibroid which is 100% interstitially or intra-murally located in contact 
with the endometrium
Stage 4: a fibroid which is completely interstitially or intra-murally located
Stage 5: a sub-serosal fibroid which is greater than or equall to 50% intra-
murally located
Stage 6: a sub-serosal fibroid which is less than 50% intra-murally located
Stage 7: a sub-serosal pedunculated fibroid
Stage 8: others, parasite (round cervical ligament, large ligament).
4. Physiopathology of Uterine Fibroids
The cause of uterine leiomyomata is idiopathic till date. However, several 
hypotheses have been postulated, namely:
i. Glucose-6-phosphate dehydrogenase studies suggest that each individual 
leiomyoma is unicellular in origin that is monoclonal [2]. Hence, this implies 
a genetic probability for the growth of uterine.
ii. In increment in the exposure of circulating oestrogens is another hypothesis 
for the growth of uterine fibroids. Effectively, leiomyomas contain oestrogen 
receptors in higher concentrations than the surrounding myometrium. But at 
lower concentrations than the endometrium, this oestrogen may contribute to 
tumour enlargement by increasing the production of extracellular matrix. On 
the other hand, progesterone increases the mitotic activity of myomas in young 
women. It may allow for tumour enlargement by down-regulating apoptosis in 
the fibroids [16]. They usually decrease in size after menopause and whenever 
myomas grow after menopause, malignancy must be seriously considered [17].
Malignant transformation of leiomyomas is very rare, seen in 0.04% women 
having uterine fibroids. In a review of 13,000 leiomyomas, 38 cases (0.29%) dem-
onstrated malignant manifestations. A second study reported that malignant change 
developed in less than 0.13% of uterine leiomyomas [17]. The diagnosis of leiomyosar-
comas is based on the counts of 10 or more mitotic figures per 10 HPFs. Atypical leio-
myoma is differentiated from leiomyosarcoma by a lack of necrotizing tumour cells 
and a mitotic count less than 7 per 10 HPFs. Nuclear atypia makes the difference with 
mitotically active leiomyoma [18]. Secondary changes may occur when the fibroids 
tend to outgrow their blood supply. These degenerations include necrotic, haemor-
rhagic (red degeneration) or septic for the acute ones. Chronic degeneration may be 
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Most at times, leiomyomas are asymptomatic. Symptoms are found only in about 
35–50% of the patients. They vary according to the type, location, size, number and 
vascular supply of the fibroids. These include:




Bleeding from the uterus is the most common symptom. It may either be  during 
the menstrual periods when the patient will have heavy and prolonged menses 
called menometorrhagia [16] or it may manifest as light spotting before and after 
the menses. The incidence of abnormal uterine bleeding was 47.7% in a study done 
by Okogbo et al. in 2011 in Nigeria [19]. This abnormal bleeding is due to the devel-
opment or dilatation of endometrial venules which increase the flow during cyclical 
sloughing or to the increase in size of the uterine cavity by the fibromyomas [17].
Pain may either be due to red degeneration, infarction or torsion of a uterine 
fibroid, or mat stem from attempts to expel a pedunculated submucousal fibroid 
[1]. A sensation of pelvic heaviness or fullness or a feeling of a mass in the pelvis is 
particularly characteristic of large tumours. These may press on nerves within the 
bony pelvis, creating pain that radiates to the back or lower extremities.
Pressure effects may either be anteriorly on the bladder, causing mainly fre-
quent micturation, and urinary incontinence. Laterally, myomas may compress the 
ureters, leading to hydroureters. When the base of the bladder is involved, urinary 
retention may occur. Posteriorly, fibroids may increase the rectal pressure or cause 
constipation or tenesmus. It should be noted that these pressure symptoms are quite 
unusual and are difficult to directly relate to fibroids.
The relationship between fibroids and infertility is not clear. Fibroids may have 
a detrimental effect on fertility in up to 10% of the cases [20]. Infertility may result 
because of impaired implantation, tubal function or sperm transport.
5.2 Diagnostic tests
The diagnosis of uterine fibroids is made from the signs and symptoms, pelvic 
examination, laboratory investigations and imaging.
Most leiomyomas are discovered by routine pelvic examination, when a firm 
mass of an irregular shape is felt in the uterus. To confirm the diagnosis different 
types of imaging techniques are used:
• A Pelvic ultrasound scan is the test of first choice. Here, three-dimensional 
scan is preferred to a two-dimensional scan due its higher resolution which 
helps to rule out a pregnancy, other pelvic masses, a congenital uterine 
 malformation [21].
• A magnetic resonance imaging is the gold standard test which is highly 
accurate in depicting the size, number and location of myomas to choose the 
therapeutical modality.
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• Saline sonohysterography can identify and characterise the location of 
submucosal myomas missed on classical abdominal or transvaginal ultrasound.
• Plain X-Rays of the lower abdomen and pelvis usually identify only calcified 
fibroids and sometimes large fibroids may be seen as soft tissue or calcified 
masses displacing bowel gas [22].
• Hysterosalpingography may be useful in the infertile patient. It evaluates the 
contour of the uterine cavity and the patency of fallopian tubes but does not 
evaluate the exact location of fibroids.
• CT scan is not the investigation of choice, fibroids may be detected inciden-
tally while investigating for another condition.
Laboratory investigations may reveal anaemia as a consequence of the 
 menometrorrhagia of fibroids and depletion of iron stores or leucocytosis and 
raised C-reactive proteins in case of acute degeneration or infection.
Differential diagnoses of leiomyomas include pregnancy, adenomyosis, 
 leiomyosarcoma, or solid ovarian neoplasms. Other conditions to be considered 
include sub involution, congenital anomalies, adherent adnexa, omentum or bowel 
benign hypertrophy, and sarcoma or carcinoma of the uterus [1]. The most common 
symptom of leiomyomata, recurrent abnormal bleeding, may be caused by any of the 
numerous conditions that affect the uterus. The definitive diagnosis in cases of uterine 
bleeding usually can be established by endometrial biopsy or fractional D&C [16].
6. Management
When uterine fibroids become symptomatic, medical or surgical treatment is 
offered to the patient, depending on her age, symptoms and future fertility desires.
A. Medical therapy includes:
• Progestins: Progestational therapy using norethindrone, medrogestone, 
and medroxyprogesterone acetate has been successful. These compounds 
produce a hypo-estrogenic effect by inhibiting gonadotropin secretion and 
suppressing ovarian function [17]. A small randomised controlled trial pre-
sented weak evidence of a reduction in fibroid size among women receiving 
lynestrenol compared with women receiving leuprolide acetate [13].
• 25 mg mifepristone produces reduction in leiomyoma size and uterine vol-
ume and produces symptomatic improvement in women with fibroids [23].
• Gonadotrophin Releasing Hormone (GnRH) agonists have proven very 
useful for limiting growth or temporarily decreasing uterine fribroid’s 
size. GnRH agonists induce hypogonadism through pituitary desensitisa-
tion, down-regulation of receptors, and inhibition of gonadotropins. They 
are however not suitable for long term use because they are associated 
with menopausal symptoms and bone loss but are likely to be beneficial 
preoperatively [24].
• Oestrogen Receptors Modulators and Antagonists: Because co-admin-
istration of oestrogen with progesterone was essential for growth and 
maintenance, inhibition of oesytogen receptors should also be an effective 
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B. Surgical therapies include:
• Myomectomy: There may be a beneficial effect of surgical resection of 
myomas to enhance fertility or successful pregnancy outcome [25]. It 
can be achieved using the following surgical procedures: open surgery, 
laparoscopy, robotic, transvaginal, and hysteroscopic surgery. The loca-
tion and size of the myoma(s) dictates the specific surgical approach. 
Total abdominal myomectomy maintains fertility compared with 
 hysterectomy but increases recovery time and postoperative pain com-
pared with laparoscopic myomectomy [24]. However, there is high chance 
of recurrence with myomectomy, while hysterectomy is definitive. A rare 
complication of laparoscopic myomectomy is the occurrence of parasitic 
leiomyomas. They usually regress after menopause but in extremely rare 
cases they can calcify and present in a post-menopausal woman with 
atypical signs and symptoms [26].
• Hysterectomy: It is the procedure of choice whenever surgery is indicated 
for leiomyomas and when childbearing has been completed. It should 
also be considered in the event of a rapidly enlarging fibroids, in which a 
reasonable likelihood of malignancy exists. Different types of hysterec-
tomies exist: laparoscopically-assisted vaginal hysterectomy, total vaginal 
hysterectomy, total abdominal hysterectomy and total laparoscopic 
hysterectomy. Total abdominal hysterectomy is considered to be beneficial 
in reducing fibroid-related symptoms, but total vaginal hysterectomy and 
total laparoscopic hysterectomy may have lower risks of complications, 
and shorter recovery times [18]. In 2010 Demir RH and Marchand GJ pub-
lished a case report in which they resected a huge uterus weighing 3200 g 
via laparoscopic-assisted hysterectomy, laparotomy can be avoided in 
almost all instances of hysterectomy for benign disease for an experienced 
laparoscopic surgeon [27].
• Uterine artery embolization (UAE): It is the occlusion of the uterine 
artery, which reduces the blood supply to the uterus and ultimately to 
the uterine fibroids. There is evidence that uterine artery embolization 
patients are more likely to report greater improvements in symptoms, 
fewer complications and less additional interventions than myomectomy. 
Meanwhile, patients who undergo a myomectomy are more likely to have 
a conserved fertility [28, 29]. Complications of the technique include 
infections, complications of angiography and very rarely, uterine isch-
emia. However, there are no increased serious complications after UAE in 
patients with a large fibroid burden [30].
• Laparoscopic occlusion of the uterine vessel: It consists of cauterising the 
uterine artery at laparoscopy, with or without concurrent myomectomy. 
Based on the study of Helal et al. in 2010, both laparoscopic occlusions of 
the uterine vessel and embolization improve symptoms associated with 
uterine fibroids [31]. The laparoscopic procedure resulted in less postop-
erative pain and nausea and shorter hospital stays, although significantly 
more participants experienced heavy menstrual bleeding six months after 
laparoscopic occlusion, indicating a more favourable effect after uterine 
leiomyoma embolization. Thus, laparoscopic uterine artery occlusion is 
likely to attract considerable interest as an effective alternative to hysterec-
tomy treatment of symptomatic uterine leiomyomata.
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• MRI- guided focused ultrasound surgery. It was approved by the Food 
and Drug Administration (FDA) in October 2004 for the treatment of 
leiomyoma in premenopausal women who have completed childbearing. 
This outpatient procedure uses MRI for real-time thermal monitoring 
of the thermoablative technique, which concentrates multiple waves 
of ultrasound energy on a small volume of tissue to be destroyed [16]. 
Careful patient selection and use of pre-treatment imaging are important 
components for predicting the success of MR-guided focused ultrasound 
surgery of uterine leiomyomas [32]. Overall, there is reasonable toler-
ance, improvement in quality of life, and modest change in fibroid size. 
However, 11% of women experience worsened symptoms during more 
than a year of follow-up and 28% elect further treatment including 
myomectomy and hysterectomy [13].
7. Uterine Fibroids and Pregnancy.
The prevalence of leiomyomas in pregnancy varies between 10.7% to 16.7% 
[5, 33]. It’s higher in African American women followed by Caucasians, Hispanic 
and Asian women [33]. According to a study done by Hasan et al. in 2010, fibroids 
are part of the factors predictive of bleeding in the first trimester of pregnancy and 
are also potential important predictors of heavy menstrual bleeding heaviness [34]. 
This is due to the oedema, increased vascularity and hypertrophy of uterine muscles 
that lead to the increase in size of fibroids during pregnancy. However, Laughlin et 
al. in 2010 think there could be a direct protective effect of pregnancy on fibroids 
after delivery. In their study of 171 postpartum women, they found that 36% of 
fibroids resolved to an undetectable level and those that remain were reduced in 
diameter by a median of 0.5 cm [35].
Generally, the effects of fibroids on pregnancy and labour are:
• Spontaneous abortion, especially with sub-mucousal leiomyomas due to the 
distortion of the uterine cavity and impairment of the vascular supply to the 
implanted ovum [36].
• Ectopic pregnancy if it interferes with the passage of the ovum.
• Incarceration of a retroverted gravid uterus in case of posterior wall uterine 
fibroid.
• Placenta praevia due to interference with implantation of the ovum in the 
upper uterine segment.
• Malpresentations; in the study of Tchente et al. in 2008, breech presentation 
was two times more encountered in pregnant women with fibroids [15].
• Abdominal discomfort if the tumour is large.
• Torsion of the uterus which is very rare and is found in subserousal fundal 
myoma.
• Premature or threatening premature delivery probably due to the stretching of 
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• Myomectomy: There may be a beneficial effect of surgical resection of 
myomas to enhance fertility or successful pregnancy outcome [25]. It 
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Meanwhile, patients who undergo a myomectomy are more likely to have 
a conserved fertility [28, 29]. Complications of the technique include 
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leiomyoma embolization. Thus, laparoscopic uterine artery occlusion is 
likely to attract considerable interest as an effective alternative to hysterec-
tomy treatment of symptomatic uterine leiomyomata.
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• MRI- guided focused ultrasound surgery. It was approved by the Food 
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myomectomy and hysterectomy [13].
7. Uterine Fibroids and Pregnancy.
The prevalence of leiomyomas in pregnancy varies between 10.7% to 16.7% 
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This is due to the oedema, increased vascularity and hypertrophy of uterine muscles 
that lead to the increase in size of fibroids during pregnancy. However, Laughlin et 
al. in 2010 think there could be a direct protective effect of pregnancy on fibroids 
after delivery. In their study of 171 postpartum women, they found that 36% of 
fibroids resolved to an undetectable level and those that remain were reduced in 
diameter by a median of 0.5 cm [35].
Generally, the effects of fibroids on pregnancy and labour are:
• Spontaneous abortion, especially with sub-mucousal leiomyomas due to the 
distortion of the uterine cavity and impairment of the vascular supply to the 
implanted ovum [36].
• Ectopic pregnancy if it interferes with the passage of the ovum.
• Incarceration of a retroverted gravid uterus in case of posterior wall uterine 
fibroid.
• Placenta praevia due to interference with implantation of the ovum in the 
upper uterine segment.
• Malpresentations; in the study of Tchente et al. in 2008, breech presentation 
was two times more encountered in pregnant women with fibroids [15].
• Abdominal discomfort if the tumour is large.
• Torsion of the uterus which is very rare and is found in subserousal fundal 
myoma.
• Premature or threatening premature delivery probably due to the stretching of 




• Prolonged labour due to inertia from interference with normal uterine 
contractions.
• Obstructed labour in cervical myoma or pedunculated subserous myoma 
impacted in the pelvis.
• Postpartum haemorrhage due to interference with sub involution of the uterus 
and increased vascularity.
• Puerperal sepsis.
The management of uterine fibroids in pregnancy depends on the signs and 
symptoms:
In the majority of cases, no treatment is required. In case of pain, bed rest and 
narcotics are almost always successful [16]. Tocolytics may be necessary to control 
the uterine contractions in threatening premature labour. Myomectomy is generally 
contraindicated during pregnancy due to increased vascularity that may lead to 
haemorrhagic complications. However, laparoscopic myomectomy may be consid-
ered safe if done in early pregnancy but only in the hands of experienced laparo-
scopic surgeons [37]. Indications for it include red degeneration not responding to 
medical therapy, torsion of a pedunculated myoma or internal haemorrhage from 
rupture of a surface vein [36]. In case of obstructed labour, caesarean section is 
indicated but myomectomy is contraindicated. In the post-partum period, prophy-
lactic antibodies should be given. Also, the women should be carefully observed for 
post-partum haemorrhage.
8. Conclusion
Uterine fibroids are the most frequent benign uterine tumours in females of 
reproductive age. Although benign in character they are associated with adverse 
outcomes such as miscarriages, aseptic necrobiosis, foetal mal-presentation, 
obstructed labour, premature births, caesarean sections, postpartum haemorrhage 
in pregnancy, and an altered menstrual cycle, heavy menstrual bleeding, infertility, 
constipation, urinary incontinence, and malignant transformation in non-pregnant 
women. Through this chapter the authors sought to contribute to the scarce evi-
dence on its idiopathic pathophysiology and present all its available management 
options.
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women. Through this chapter the authors sought to contribute to the scarce evi-
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tumor of the uterus found in women of reproductive age. Uterine fibroids are the 
cause of major quality-of-life issues for approximately 25% of all women who suffer 
from clinically significant symptoms of uterine fibroid. Despite the prevalence of 
fibroid, currently, there are no effective treatment options for fibroid. The lack 
of understanding of the etiology of fibroid contributes to the scarcity of medical 
therapies available. Sex steroid hormones, dysregulation of cell signaling pathways, 
miRNA expression, and cytogenetic abnormalities may all implicate in fibroid 
etiology. Several herbal medicines have been used as anti-inflammation and antitu-
mor agents. All of them have a common capability to inhibit expression of pro-
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1. Background
Uterine fibroids are common benign muscle tumors of the uterus. It affects the 
normal life of thousands of women of childbearing age, especially non-Caucasian 
women, which can be caused by genetic and environmental factors. It is not usually 
fatal but can produce serious clinical symptoms. The prevalence of uterine fibroids is 
predicted to be approximately 70% depending on the population [1]. Clinical symp-
toms caused by uterine fibroid include pelvic pain or compression, abnormal uterine 
bleeding, gastrointestinal and voiding problems. It also produces pregnancy compli-
cations as well as fertility impairment. Since there are no effective medical therapies, 
invasive surgeries have become a clear option for the treatment of this tumor.
Studies on the whole genome of uterine fibroid indicate that there are many new 
signal transduction pathways and how gene nets play a role in uterine fibroid devel-
opment. Not only in its origin, the transcriptomic, and epigenetic profiles, as well 
as the impact of the inter-cell matrix are all involved in uterine fibroid growth [2]. 
Additionally, microRNA plays a role in regulating uterine fibroid pathogenesis [3]. 
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Nowadays, numerous treatments for fibroids are available. Therapies include con-
servative medications to invasive surgeries. Up to now, the regular therapy of uterine 
fibroid is surgery, but its negative impact on future fertility is evidenced. Therefore, 
selecting appropriate individualized therapy and augmented modifications to fit 
patient’s expectations are readily important. However, newly developing pharmaceu-
tical prospects have significant adverse effects, such as liver function impairment, hot 
flashes, bone density loss, endometrial changes, and inability to attempt conception 
during treatment [4].
Numbers of natural compounds are demonstrated effectively to treat uterine 
fibroids and to relieve their symptoms. In this review, we will discuss potential 
available herbal medicine compounds that may be beneficial for uterine fibroid 
patients, particularly those who plan to conceive during therapy or desire to pre-
serve their future fertility. Nonetheless, there is still no significant clinic evidence 
available so far. Therefore, it is highly recommended to obtain more clinical trials 
utilizing these compounds before endorsing widespread usage [5].
2. Mechanisms and signal transductions in uterine fibroid
As the pathogenesis of uterine fibroids has not been fully elucidated, many stud-
ies have been carried out in mechanisms involved in this area and are still ongoing. 
The involved mechanisms affect several categories of cellular and tissue functions. 
The presumptive identification of progenitor stem cells of uterine fibroids has 
produced fibroids and maternal junctions, providing new clues about the etiology 
of uterine fibroids [2]. There are two hypotheses raised for the development mecha-
nisms of uterine fibroid. However, they may cross-talk with each other intimately. 
The genetic hypothesis is focused primarily on the mutant mediator complex 
subunit 12 (MED12) genes [6], suggesting it onsets in the side population of the 
female reproductive system embryonic myoblasts and contributed rise to multiple 
small and medium fibroids later on [2]. Most studies on uterine fibroids have 
focused specifically on somatic mutations in the MED12 gene [6, 7]. According to 
the available data, this mutation has been confirmed in more than 70% of patients 
with uterine fibroids depending on different populations [6, 8]. Alternatively, the 
single and usually large-size fibroids are induced by predominantly epigenetic 
disorders in uterine fibroid steam cells, provoked by enhanced expression of the 
DNA hypomethylation in HMGA2 gene and epigenetic deregulation enhanced by 
hypoxia, muscle tension, or chromosome instability/aberrations (Table 1).
The life cycle of uterine fibroid is divided into two stages: transformation and 
benign tumor development [7, 57]. Mutations are sources for normal myometrial 
stem cells to transform into abnormal cells. Additionally, some other factors may 
also cause immunological changes [58] to lead to altered DNA repair and cell muta-
tion [59]. Finally, a mixture of early environmental exposure and hyperreactivity to 
estrogen may also play a role in fibroid development [60].
Reactive oxygen species (ROS) formed after exposure to oxidative stress and/or 
hypoxia are linked to the activation of a variety of signal molecules [61–66]. Various 
enzyme systems produce ROS, including the mitochondrial electron transport 
chain, cytochrome P450, lipoxygenase, cyclooxygenase, NADPH oxidase complex, 
and peroxisomes [61]. Hypoxia triggers many key adaptive changes that enable cell 
survival, including inhibition of apoptosis, changes in glucose metabolism, and 
angiogenic phenotypes [61]. Recent studies have shown that oxygen depletion pro-
motes mitochondria to increase more ROS production, and then activate signaling 
transduction pathways, such as hypoxia-inducible factor (HIF)-1α to promote cell 
survival and increase fibrotic growth sequentially [61].
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Remarkably, ovarian sex hormones play an important role in uterine fibroid 
pathophysiology [7, 67, 68]. Primarily under the influences of sex hormone, 
myometrial stem cells transform into pathological cells and develop into uterine 
lesions [69]. Tumor growth occurs by a large number of cell growth and extracel-
lular matrix (ECM) building up [70, 71]. Accumulation and remodeling of ECM 
are believed to be crucial for fibrotic diseases such as uterine fibroid. Indeed, ECM 
plays an important role in forming the bulk structure of fibroids. Rigid ECM-rich 
structure may cause abnormal bleeding and pelvic pain [70, 72]. Therefore, a better 
understanding of ECM accumulation and remodeling is critical for developing new 
therapeutics for uterine fibroid. The ECM is approximate twice the volume in uter-
ine fibroid compared to those in healthy myometrium. ECM is mainly composed 
of different types of collagen, fibronectin, and proteoglycan [70, 71]. It has been 
found in ultrafiltration that different fibers forming the ECM have abnormal struc-
tures and are different from the corresponding fibers in the unchanged tissue [73].
Estrogen has been shown to stimulate proliferation in a dose- and time-
dependent manner in uterine fibroid cell lines [68, 74]. Estrogen (17β-estradiol) 
binds to the nuclear estrogen receptor (ER)-α to modulate the expression of proto-
oncogenes, cytokines, and growth factors [75–77]. Uterine fibroid cells are more 
accessible to actions of 17β-estradiol than normal myometrial cells [78]. Although 
estrogen is essential for uterine fibroid growth, progesterone now is considered 
the key hormone to initiate uterine fibroid pathological differentiation and growth 
[7]. Estradiol has a tolerant effect on the growth of uterine fibroids mediated by 
progesterone. Additionally, the combination of estrogen and progesterone signifi-
cantly increased cellular expression of the proliferation marker Ki-67 [79] and the 
accumulation of ECM due to the accelerated synthesis of type 1 and type 3 collagen 
[80]. Studies of Ishikawa et al. have shown that combined estrogen and proges-
terone increased uterine fibroid size more than 3-fold higher than those treated 
with estradiol alone or untreated controls in a xenograft model [67]. These results 
highlight the significant role of progesterone in uterine fibroid growth.
Furthermore, disturbance of steroid hormone receptors may be a primary 
pre-requisite for development of uterine fibroid [81]. Adenovirus-mediated a 
dominant-negative ER-α gene delivery eliminates the expression of estrogen and 
progesterone-regulated genes in uterine leiomyoma cells in vitro and shrinks uterine 
fibroids in vivo [82, 83]. Steroid hormones can affect uterine fibroid cells by differ-
ent mechanisms including paracrine [7]. Steroid hormones stimulate expression 
of cytokines and growth factors. Sequentially, the induced cytokines and growth 
factors affect signal pathways, growth, and survival of uterine fibroid cells. They 
also regulate angiogenesis and ECM formation [84]. Consequently, this influences 
uterine fibroid cells to grow and survive and ECM to accumulate. ECM may serve 
as a reservoir for growth factors and cytokines to increase their stability and extend 
their influence [70].
Different growth factors and signal pathways are involved in uterine fibroid 
formation processes [71, 84]. As one of the most important growth factors affect 
development of uterine fibroid, transforming growth factor-β (TGF-β) stimulates 
uterine fibroid progress [71]. TGF-β signaling connects with other different path-
ways such as Smad pathway, phosphoinositide 3-kinase (PI3K)/Akt/mammalian 
target of rapamycin (mTOR), the mitogen-activated protein kinases (MAPK, 
ERK1/2) signaling cascade, and focal adhesion kinase (FAK) [71]. Expression 
of TGF-β is significantly increased in myometrial cells when they are directly 
in contact with the uterine fibroid tumor [85]. TGF-β1 stimulates expression of 
metalloproteinase-2 (MMP-2), MMP-9, and membrane-associated MMP inhibitor 
(RECK) [86]. TGF-β also modulates ECM production via cross-talk with growth 
factor and integrins [87, 88].
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In addition to TGF-β, insulin-like growth factor–1 (IGF-1) is another growth 
factor that plays a vital role in the pathogenesis of uterine fibroid [89]. Studies 
of Boehm et al. indicated that more IGF-1 expression increases in uterine fibroid 
than in normal myometrium [90]. An animal model from Eker rat also showed 
upregulation of IGF-1 in uterine fibroid tissue [91]. We have shown how IGF-1R 
accumulated in uterine fibroid primary cell lines in response to IGF-1 to regulate 
cell proliferation [12]. Estrogen induces ERK1/2 activation and IGF-I, cell cycle 
regulating transcriptional factor A-Myb accumulation to stimulate uterine fibroid 
cell cycle progression in human uterine leiomyoma cell lines [92]. Additionally, 
growth hormone stimulates IGF-1 production to promote cell proliferation and to 
inhibit apoptosis in uterine fibroid [93, 94].
Wingless-type (Wnt)/β-catenin signaling also plays a role in somatic stem-cell 
function in both myometrium and uterine fibroid tissue [7]. Paracrine activation of 
the Wnt/β-catenin pathway in uterine fibroid stem cells can stimulate tumor growth 
[95]. Activin A, a product of macrophages, may also play a crucial role in uterine 
fibroid biology. Activin A is response for different immunological actions including 
cell transformation to lead to tumor development [58, 96]. Interactions between 
Wnt/β-catenin and TGF-β pathways, as well as with steroids and growth factors, 
give rise to the clonal formation of uterine fibroid tumors and are believed to be the 
basis of modern uterine fibroid biology hypothesis [7, 97].
The genetics of uterine fibroids and the etiology of epigenetic procedures have 
many peculiarities at first, then become quite similar and partially overlap due to 
the proximity of their genetic network and epigenetic environment. Research on 
the etiology of uterine fibroids to elucidate new strategies for the prevention and 
treatment of this common disease [2].
3. Treatment of uterine fibroid
Because the natural cause of uterine fibroid is not known, it makes the myomec-
tomy or selected conditions hysterectomy to become the mainstay of management 
[98]. Genetic factors, epigenetic factors, and several pathogenic factors such as 
sex hormones, growth factors, cytokines, chemokines, and extracellular matrix 
components all of them have been implicated in development and growth of uterine 
fibroid [99, 100]. Although surgery has been suggested, it is not an attractive choice 
due to its serious consequences, especially with patients desiring to preserve their 
fertility potential [100].
Studies of El Andaloussi et al. [101] indicate that MED12 mutation presents a 
potential of dysregulating Wnt4/β-catenin to transform cells [101]. The dysregulat-
ing Wnt4/β-catenin affects mTOR signaling and caused autophagy abrogation, cell 
proliferation, and tumorigenesis [101]. Silenced MED12 gene reduces the prolifera-
tion of uterine fibroid cells [97]. In 2020, Ali et al. also found that β-catenin nuclear 
translocation contributes to uterine fibroid phenotype, and β-catenin signaling is 
modulated by estradiol and histone deacetylases activity [102]. Additionally, the 
Wnt/β-catenin pathway leads to increased levels of TGF-β3 [7, 71]. As we discussed 
above, different isoforms of TGF-β may play a crucial role in uterine fibroid 
development. Studies that used anti-uterine fibroid agents cause the attenuation 
of this pathway by reducing TGF-β3 signal and protein expression, resulting in a 
reduction in TGF-β canonical signaling [103]. Therefore, canonical Wnt pathway 
has been suggested to be a potential therapeutic target for the treatment of uterine 
fibroids [104].
It has been shown the proliferation of uterine fibroid is sensitive to the GnRH 
agonists [105, 106] or estrogen receptor antagonists. For those patients can be 
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applied with hormone treatment with GnRH agonists including Lupron, Synarel, 
and Zoladex and/or aromatase inhibitors such as anastrozole (Arimidex®), letro-
zole (Femara®), exemestane (Aromasin®), vorozole (Rivizor®), formestane 
(Lentaron®), fadrozole (Afema®), and testolactone (Teslac®). Treatment with 
medications such as tamoxifen may also reduce uterine fibroid size [106]. In addi-
tion, using an adenovirus-expressing dominant-negative ER-α reduces ER-α to 
arrest fibroid growth in a mouse model which may provide an optional treatment 
[107]. Besides, alternative medicine has been shown to improve the symptom of 
uterine fibroids [108–110].
Alternatively, several natural products have been suggested for the treatment 
of uterine fibroids based on their natural activities of anti-inflammation, anti-
proliferation, and anti-angiogenesis. We will discuss mechanisms in the following 
sections.
3.1 Curcumin
Curcumin is a yellow active natural polyphenol of the perennial herb Curcuma 
longa, commonly known as turmeric. In addition, curcumin is commonly found as 
ingredients in food seasoning, cosmetics, or herbal supplements. It has tradition-
ally been used for decades in Asian countries as a medical herb due to its anti-
microbial, anti-inflammatory, anti-tumorigenic, and anti-mutagenic properties 
[111]. Curcumin has many medical effects such as suppression of thrombosis [112], 
reduction of blood cholesterol [113, 114], and reduction of myocardial infarction 
[115]. Evidence indicates that curcumin suppresses the growth of several tumor 
cell lines [116, 117]. All in all, curcumin is effective against a variety of inflamma-
tory illnesses and modulates multiple cell signaling pathways. However, it is still 
not well understood which binding site or receptor for it. In vitro studies indicate 
that curcumin can interact with integral components of cell signaling pathways 
and therefore may be pharmacologically relevant. However, only limited studies 
have shown functional consequences of curcumin interaction [118]. The tumor 
suppression mechanisms of curcumin are accredited by modulation of numer-
ous targets playing important roles in tumor growth [119–122]. Those targets 
include transcription factors, receptors, kinases, cytokines, enzymes, and growth 
factors. Therefore, curcumin has been demonstrated to suppress the growth of 
several tumor cell lines [123]. It also inhibits the growth of uterine fibroid cells, 
even though there has yet to be a report describing the precise mechanism of its 
inhibition.
Curcumin inhibits phorbol ester-induced activation of NF-κB and ERK1/2  
[9, 10]. Alternatively, it induces apoptosis via activation of ERK1/2 or SAPK/JNK 
in cancer cells [11]. Role of ERK1/2 activation in curcumin-treated cancer cells is 
controversial [124]. Curcumin down-regulates endothelial cell fibrosis and inhibits 
uterine fibroid cell proliferation via regulation of the apoptotic pathway, and it also 
reduced production of the ECM component fibronectin (Figure 1). Curcumin has 
also been shown to attenuate TGF-β-induced endothelial-to-mesenchymal transi-
tion [125]. Extracts from Curcuma zedoaria inhibits uterine fibroid cell prolifera-
tion compared to normal myometrial cells [126]. On the other hand, it stimulates 
caspase-3 and caspase-9 expression in uterine fibroid cells. Curcumin provides a 
novel direction for uterine fibroid therapies [127].
Peroxisome proliferator-activated receptor (PPAR) is a ligand-dependent 
transcription factor of the nuclear hormone receptor superfamily. It is expressed 
in a tissue-specific manner and plays an important role in the differentiation of 
adipocytes [128, 129]. PPARγ exerts anti-inflammatory, anticancer, and insulin 
sensitivity effects and participates in the control, proliferation, and differentiation 
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of the cell cycle. Hepatic stellate cells are the type of hepatocyte responsible 
for fibrosis in liver damage and can lead to chronic liver damage and cirrhosis. 
Curcumin induces and activates PPARγ in rat hepatic stellate cells [40]. Curcumin 
considerably increases the proliferative inhibition of stellate cells by PPARγ. [40]. 
Besides, curcumin also enhances the activity of PPARγ in human colon cancer 
cell lines by reducing the expression of cyclin D1 and epidermal growth factor 
receptor (EGFR), thereby disrupting the cell cycle [130]. These two inhibitory 
effects depend on PPARγ activation. The study by Takashi Takeda et al. showed 
that uterine fibroids can share pathogenic characteristics with the development of 
metabolic syndrome [131]. PPARγ is also virtually involved in insulin signaling. 
A PPARγ agonist, thiazolidinedione, has been used to treat patients with type II 
diabetes [129]. Thiazolidinedione may be used to prevent the progression of ath-
erosclerosis and metabolic syndrome [132]. On the other hand, curcumin directly 
inhibits fibroid proliferation, and curcumin-induced PPARγ activation can also 
prevent metabolic syndrome and indirectly inhibit fibroid growth [132]. However, 
since these findings were based on in vitro experiments, it raised concerns about 
Figure 1. 
Signaling pathways by which curcumin induces biological activities in cells. Curcumin binds to an unidentified 
cell surface binding site to activate the ERK1/2 cascade. On the other hand, in addition, to downregulate NF-κB 
activation, it inhibits phorbol ester-induced activation of NF-κB and ERK1/2. Curcumin also activates SAPK/
JNK activation and Caspase-3 and -9-dependent apoptosis in cancer cells, may also including uterine fibroid 
cells. Curcumin inhibits TGF-β-induced ECM production. It also reduces inflammation and induces apoptosis.
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applied with hormone treatment with GnRH agonists including Lupron, Synarel, 
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zole (Femara®), exemestane (Aromasin®), vorozole (Rivizor®), formestane 
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suppression mechanisms of curcumin are accredited by modulation of numer-
ous targets playing important roles in tumor growth [119–122]. Those targets 
include transcription factors, receptors, kinases, cytokines, enzymes, and growth 
factors. Therefore, curcumin has been demonstrated to suppress the growth of 
several tumor cell lines [123]. It also inhibits the growth of uterine fibroid cells, 
even though there has yet to be a report describing the precise mechanism of its 
inhibition.
Curcumin inhibits phorbol ester-induced activation of NF-κB and ERK1/2  
[9, 10]. Alternatively, it induces apoptosis via activation of ERK1/2 or SAPK/JNK 
in cancer cells [11]. Role of ERK1/2 activation in curcumin-treated cancer cells is 
controversial [124]. Curcumin down-regulates endothelial cell fibrosis and inhibits 
uterine fibroid cell proliferation via regulation of the apoptotic pathway, and it also 
reduced production of the ECM component fibronectin (Figure 1). Curcumin has 
also been shown to attenuate TGF-β-induced endothelial-to-mesenchymal transi-
tion [125]. Extracts from Curcuma zedoaria inhibits uterine fibroid cell prolifera-
tion compared to normal myometrial cells [126]. On the other hand, it stimulates 
caspase-3 and caspase-9 expression in uterine fibroid cells. Curcumin provides a 
novel direction for uterine fibroid therapies [127].
Peroxisome proliferator-activated receptor (PPAR) is a ligand-dependent 
transcription factor of the nuclear hormone receptor superfamily. It is expressed 
in a tissue-specific manner and plays an important role in the differentiation of 
adipocytes [128, 129]. PPARγ exerts anti-inflammatory, anticancer, and insulin 
sensitivity effects and participates in the control, proliferation, and differentiation 
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of the cell cycle. Hepatic stellate cells are the type of hepatocyte responsible 
for fibrosis in liver damage and can lead to chronic liver damage and cirrhosis. 
Curcumin induces and activates PPARγ in rat hepatic stellate cells [40]. Curcumin 
considerably increases the proliferative inhibition of stellate cells by PPARγ. [40]. 
Besides, curcumin also enhances the activity of PPARγ in human colon cancer 
cell lines by reducing the expression of cyclin D1 and epidermal growth factor 
receptor (EGFR), thereby disrupting the cell cycle [130]. These two inhibitory 
effects depend on PPARγ activation. The study by Takashi Takeda et al. showed 
that uterine fibroids can share pathogenic characteristics with the development of 
metabolic syndrome [131]. PPARγ is also virtually involved in insulin signaling. 
A PPARγ agonist, thiazolidinedione, has been used to treat patients with type II 
diabetes [129]. Thiazolidinedione may be used to prevent the progression of ath-
erosclerosis and metabolic syndrome [132]. On the other hand, curcumin directly 
inhibits fibroid proliferation, and curcumin-induced PPARγ activation can also 
prevent metabolic syndrome and indirectly inhibit fibroid growth [132]. However, 
since these findings were based on in vitro experiments, it raised concerns about 
Figure 1. 
Signaling pathways by which curcumin induces biological activities in cells. Curcumin binds to an unidentified 
cell surface binding site to activate the ERK1/2 cascade. On the other hand, in addition, to downregulate NF-κB 
activation, it inhibits phorbol ester-induced activation of NF-κB and ERK1/2. Curcumin also activates SAPK/
JNK activation and Caspase-3 and -9-dependent apoptosis in cancer cells, may also including uterine fibroid 
cells. Curcumin inhibits TGF-β-induced ECM production. It also reduces inflammation and induces apoptosis.
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the observation limitations. Later, Kenji Tsuiji et al. have developed a new in vivo 
uterine fibroid model to study the inhibition of rat leiomyoma (ELT-3) cells by cur-
cumin [132]. The IC50 of curcumin-induced anti-proliferation in uterine fibroid 
cell lines is 20 μM, however, when patient-matched myometrial cells were exposed 
to equivalent concentrations of curcumin, there was no statistically significant 
inhibition of growth [127].
Studies indicated that curcumin absorption rate in the intestine is very low 
[133–136]. Similar raising concerns were also in other herb medicines, such as 
resveratrol discussed in next section. Thus, some modifications of curcumin need 
to be taken to keep its high blood concentration. Some studies regarding increased 
absorption and bioavailability of curcumin have been reported. For instance, the 
co-administration of curcumin and piperine can increase the bioavailability of cur-
cumin [135]. Another strategy is to develop new curcumin analogues with a higher 
cell growth inhibitory capacity. One such compound, GO-Y030, has been shown 
to exhibit an 8- to 40-fold greater growth inhibitory potential than curcumin in 
several cancer cell lines [137, 138]. It may be useful to use the compound to clinically 
treat uterine fibroids.
3.2 Resveratrol
Polyphenols have been attracting by their anti-oxidative effects during the past 
years for human chronic diseases involved in inflammation like diabetes mellitus, 
neurodegenerative diseases, cardiovascular diseases, and cancers [139]. Resveratrol 
is one of well-studied stilbenes found in peanuts, grapes, and some berries. It is a 
plant product in response to environmental stress, pathogen infection, and ultra-
violet radiation [127]. Resveratrol has been known as chemo-preventive, serving to 
suppress DMBA-induced ductal breast carcinoma [140] and ultraviolet light (UV)-
induced skin cancer [141] in mouse models. Resveratrol induces p53-dependent 
apoptosis in several human cancer cell lines, including thyroid, prostate, and breast 
cancer cells [13, 142–145]. It also induces p53-independent anti-proliferation against 
cancer cells [14, 146–148]. Resveratrol has been recommended to be a reversion 
molecule for multiple drug-resistant breast cancer [149]. Resveratrol is safe and 
well-tolerated by patients, with common adverse events including nausea, diarrhea, 
and weight loss [150].
Although surface receptors involved in the resveratrol signal transduction 
remain to be identified, resveratrol binds to cell surface integrin αvβ3 to activate 
ERK1/2 and ant-proliferation in cancer cells [13, 145, 151] (Figure 2). Integrin αvβ3 
is also involved in AKT phosphorylation [15, 152]. Resveratrol inhibits PI3K-AKT 
signal pathway to induce anti-proliferation [22] or other biological activities as 
IL-33-mediated mast cell activation [153].
Overexpression of integrin αvβ3 is observed in several types of solid tumors 
[154, 155] and highly growing endothelial cells [154, 155]. Our studies indicate 
that integrin αvβ3 overexpresses in primary uterine fibroid cell lines [12]. The 
integrin αvβ3 overexpresses in primary human uterine fibroid Case 016 and Case 
018 compared to normal Case 003 cells [12]. Therefore, it is a perfect target for 
resveratrol which has been shown to bind on integrin αvβ3 receptor [13]. Integrins 
are not classic signaling receptors in that they possess no enzymatic activity. 
Integrin signaling depends on the allosteric behavior of the receptors, their ability 
to concentrate into adhesion zones, and the recruitment to these zones of numerous 
other adhesome components to form complex integrin-based cell adhesions [156, 
157]. Many adhesome components are enzymes that interact with classic signaling 
pathways. Resveratrol regulates signal transduction via integrin αvβ3 in human 
uterine fibroid cells. Resveratrol attenuates expression of integrin αv and integrin β3 
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in primary uterine fibroid cell Case 016 and Case 018 but not in normal myometrial 
cells. Resveratrol induces ERK1/2 activation in uterine fibroid cells [12]. However, 
the constitutive phosphorylation of AKT in uterine fibroid cells was inhibited by 
resveratrol.
Integrin signaling and function are heavily dependent on cross-talk with other 
signaling pathways, especially growth factor signaling pathways [158–160]. Besides 
the aberrant integrin expression, IGF-1R highly expresses more in uterine fibroid 
compared to the normal tissues [161] indicating IGF-1 may also be involved in the 
abnormal proliferation [92, 162]. IGF-1 binds to IGF-1R to activate downstream 
AKT which is a target of resveratrol. Resveratrol did not inhibit IGF-1R phosphory-
lation in primary uterine fibroid cells [12]. These results suggest that the action of 
resveratrol on IGF-1R-dependent signal transduction is downstream IGF-1R at Akt 
level [12]. Resveratrol analogue, pterostilbene (3′,5′-dimethoxy-resveratrol) targets 
mTOR/PI3K/Akt signaling pathway to disrupt mitochondrial membrane potential, 
and induce apoptosis [163].
IGF-I mRNA is expressed significantly higher in leiomyoma cells than that in 
myometrial cells [12]. IGF-1 stimulates IGF-1R phosphorylation of but the action is 
blocked by resveratrol pre-treatment. Growth effect of IGF-1 can possibly reduce 
by resveratrol [164]. Resveratrol inhibits IGF-1-induced phosphorylated IGF-1R 
accumulation and proliferation consequently [12]. IGF-1 enhances leiomyoma 
cell proliferation and thereby accelerates uterine fibroid progression. In sum-
mary, resveratrol via a mechanism involved in crosstalk between integrin αvβ3 
Figure 2. 
Resveratrol/THSG activates signaling pathways in uterine fibroid cells. A stilbene receptor is present on 
integrin αvβ3 by which resveratrol activates ERK1/2 and induces nuclear accumulation of COX-2. On the 
other hand, 2,3,5,4′‐tetrahydroxystilbene‐2‐O‐β‐glucoside (THSG) has a similar chemical structure and 
assumedly binds to integrin αvβ3 to activate the signal transduction pathway. In resveratrol-treated cancer 
cells, pERK1/2 also translocates to the cell nucleus and complexes with inducible COX-2. Phosphorylated 
ERK1/2 also translocates into the cell nucleus and forms a complex with inducible COX‐2 in resveratrol‐
treated cancer cells. Resveratrol induces phosphorylation of the complexed p53 at Ser15 and p53‐dependent 
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molecule for multiple drug-resistant breast cancer [149]. Resveratrol is safe and 
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and weight loss [150].
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remain to be identified, resveratrol binds to cell surface integrin αvβ3 to activate 
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is also involved in AKT phosphorylation [15, 152]. Resveratrol inhibits PI3K-AKT 
signal pathway to induce anti-proliferation [22] or other biological activities as 
IL-33-mediated mast cell activation [153].
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integrin αvβ3 overexpresses in primary human uterine fibroid Case 016 and Case 
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resveratrol which has been shown to bind on integrin αvβ3 receptor [13]. Integrins 
are not classic signaling receptors in that they possess no enzymatic activity. 
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in primary uterine fibroid cell Case 016 and Case 018 but not in normal myometrial 
cells. Resveratrol induces ERK1/2 activation in uterine fibroid cells [12]. However, 
the constitutive phosphorylation of AKT in uterine fibroid cells was inhibited by 
resveratrol.
Integrin signaling and function are heavily dependent on cross-talk with other 
signaling pathways, especially growth factor signaling pathways [158–160]. Besides 
the aberrant integrin expression, IGF-1R highly expresses more in uterine fibroid 
compared to the normal tissues [161] indicating IGF-1 may also be involved in the 
abnormal proliferation [92, 162]. IGF-1 binds to IGF-1R to activate downstream 
AKT which is a target of resveratrol. Resveratrol did not inhibit IGF-1R phosphory-
lation in primary uterine fibroid cells [12]. These results suggest that the action of 
resveratrol on IGF-1R-dependent signal transduction is downstream IGF-1R at Akt 
level [12]. Resveratrol analogue, pterostilbene (3′,5′-dimethoxy-resveratrol) targets 
mTOR/PI3K/Akt signaling pathway to disrupt mitochondrial membrane potential, 
and induce apoptosis [163].
IGF-I mRNA is expressed significantly higher in leiomyoma cells than that in 
myometrial cells [12]. IGF-1 stimulates IGF-1R phosphorylation of but the action is 
blocked by resveratrol pre-treatment. Growth effect of IGF-1 can possibly reduce 
by resveratrol [164]. Resveratrol inhibits IGF-1-induced phosphorylated IGF-1R 
accumulation and proliferation consequently [12]. IGF-1 enhances leiomyoma 
cell proliferation and thereby accelerates uterine fibroid progression. In sum-
mary, resveratrol via a mechanism involved in crosstalk between integrin αvβ3 
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Resveratrol/THSG activates signaling pathways in uterine fibroid cells. A stilbene receptor is present on 
integrin αvβ3 by which resveratrol activates ERK1/2 and induces nuclear accumulation of COX-2. On the 
other hand, 2,3,5,4′‐tetrahydroxystilbene‐2‐O‐β‐glucoside (THSG) has a similar chemical structure and 
assumedly binds to integrin αvβ3 to activate the signal transduction pathway. In resveratrol-treated cancer 
cells, pERK1/2 also translocates to the cell nucleus and complexes with inducible COX-2. Phosphorylated 
ERK1/2 also translocates into the cell nucleus and forms a complex with inducible COX‐2 in resveratrol‐
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and IGF-1R-sensitive signal transduction pathways induces anti-proliferation in 
uterine fibroid.
Steroid hormones and thyroid hormone stimulate TGF-β expression [165]. 
Resveratrol blocks TGF-β expression and functions [166]. Cross talk among TGF-β 
signaling pathways, integrins, and ECM [88] is essential for uterine fibroid growth. 
Both Agarwal discussed the ability of resveratrol to infer with ECM formation and 
deposition in multiple diseases in their review article [53]. Resveratrol suppresses 
not only expression of fibronectin, fibromodulin, biglycan, and collagen types I and 
III, but also their protein levels in different cell lines [43]. Resveratrol also reduces 
MMP-9 protein accumulation but increases TIMP2 protein in ELT-3 cells and 
healthy uterine smooth muscle cells [43].
Resveratrol inhibits TGF-β signal downstream molecule AKT phosphorylation. 
Studies of confocal microscopy have shown resveratrol inhibits nuclear pAKT 
translocation in uterine fibroid cells. Alternatively, resveratrol does not interfere 
with pAKT nuclear translocation in normal uterine smooth muscle cells even 
though there are limited pAKT translocated [12]. Resveratrol reduces cellular levels 
of the phosphorylated/active form of anti-apoptotic kinase AKT in uterine cancer 
cells [167]. Sequentially, treatment of resveratrol reduces the endogenous cyclooxy-
genase-2 (COX-2) protein and produces PGE2 and PGF2α [167]. Evidence indicates 
that endogenous COX-2 is involved in inflammation, therefore, resveratrol inhibits 
AKT signaling pathway and COX-2 activity to induce anti-inflammation which 
plays vital roles in uterine fibroid cell growth.
β-catenin modulates and stimulates the stem cell renewal [168]. The regulation of 
the biologic functions for β-catenin is highly complex and not fully understood. Wnt 
proteins bind to a special cell-surface receptor, Frizzled, where it promotes activation 
of a cascade of proteins that leads to decreased β-catenin degradation in the cytosol 
and reduces nuclear β-catenin levels [7, 95]. The increased β-catenin expression is 
observed in uterine fibroids compared to the adjacent myometrium samples [169]. 
Ovarian steroids interact with the Wnt/β-catenin pathway to accelerate tumorigen-
esis [168]. Our studies also indicate that thyroid hormone increases nuclear β-catenin 
accumulation, thus β-catenin-dependent gene expression and proliferation [170, 171]. 
Resveratrol reduces expression and nuclear accumulation of β-catenin.
The expression of resveratrol-induced pro-apoptotic genes such as COX-2 and 
p21 induced in uterine fibroid cells. On the other hand, the expression of prolifera-
tive (anti-apoptotic) genes was either inhibited such as BCL2, and CDKN2 or no 
changed as Cyclin D1 and PCNA. The pro-apoptotic proteins such as caspase 3 and 
caspase 9, were also increased in resveratrol-treated cells [12]. Resveratrol-induced 
COX-2 facilitates p53-dependent anti-proliferation [172, 173]. Therefore, resveratrol 
induces anti-proliferation in uterine fibroid cells [12]. Kim et al. have also shown 
the extraction of herb medicine, Scutellaria barbata D. Don (Lamiaceae), down-
regulates the IGF-I expression [174] and inhibits the proliferation of leiomyoma 
cells. Scutellaria barbata D. Don (Lamiaceae) induces the uterine smooth muscle 
cell differentiation markers in uterine smooth muscle cells and uterine leiomyoma 
smooth muscle cells, such as α smooth muscle actin (α-SMA), calreductin h1, and 
cyclin p27-dependent kinase inhibitor. In contrast, gene products linked to the G1 
phase of the cell cycle, such as cyclin E and cdk2, are not affected by Scutellaria 
barbata D. Don (Lamiaceae) [175]. These observations agree with our studies. The 
expression of anti-apoptotic genes, such as BCL2 and CDKN2 are suppressed or 
unmodified Cyclin D1 and PCNA [12].
Estrogen stimulates proliferation in breast cancer cells [176, 177], endometrial 
cancer [178, 179] and leiomyoma cells [180]. Estrogen also stimulates cell growth in 
uterine fibroid cells [12]. Resveratrol can inhibit estrogen-dependent cancer growth 
[176] and suppresses the proliferation of six sensitive uterine fibroid cases both in 
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the absence and presence of estradiol [12]. These results indicate the suppressing 
effect of resveratrol on uterine fibroid growth may not go through ER-α.
The immunomodulatory factor, checkpoint PD-1/PD-L1 has been shown to play 
an important role in uterine fibroid pathogenesis. They also attack attention to be 
therapeutic targets. Resveratrol suppresses PD-L1 expression. In the presence of 
thyroid hormone, resveratrol traps PD-L1 in the cytosol, meanwhile, resveratrol-
induced COX-2, an inducible transcriptional co-activator [181], is trapped with 
thyroid hormone-induced PD-L1 in the cytosol [173].
Summarily, in the primary cell culture of patients with resveratrol-sensitive pri-
mary uterine fibroids, resveratrol can inhibit uterine fibroid proliferation, induce 
apoptosis, and transmit integrin-dependent signaling αvβ3. The transduction path-
way promotes uterine fibroids cell cycle arrest. Additionally, resveratrol inhibits 
the activation of IGF-1R dependent signal transduction pathways, which play an 
important role in uterine fibroid proliferation. Resveratrol may or may not inhibit 
the expression of proliferation genes. Resveratrol also induces the expression of p21 
and COX-2. Analysis of the DNA content of the PI stain indicates that resveratrol 
induces uterine fibroid cells cell cycle arrest at sub-G1 population [12]. Crosstalk 
between αvβ3 integrin and IGF-1R plays a crucial role in resveratrol-induced uterine 
fibroid anti-growth. In addition, resveratrol inhibits signal transduction pathways 
and gene expression dependent on TGF-β and β-catenin. Therefore, resveratrol can 
effectively prevent leiomyoma overgrowth and treat uterine fibroids.
3.3 Extract of He-Shou-Wu, 2,3,5,4′-Tetrahydroxystilbene-2-O-β-glucoside
The stilbene glucoside 2,3,5,4′-tetrahydroxystilbene-2-O-β-D-glucoside (THSG) 
is one of the major bioactive components of Polygonum multiflorum Thunb (He Shou 
Wu). It is glycosylated resveratrol and it has been used as antiaging medicine [182]. 
THSG suppresses experimental colitis effectively by reducing the level of oxygen 
and nitrogen free radicals [48]. It also has been shown to exert a protective effect 
on cardiotoxicity induced by doxorubicin in vitro and in vivo [183]. THSG can also 
diminish peroxidation levels in the brain of a mouse model with Alzheimer’s disease 
or cerebral ischemia–reperfusion. Administration of THSG not only prevents 
learning-memory deficits but also reverses the learning-memory deficit in disease-
like mouse models with Alzheimer’s [184].
Mechanism involved in P. multiflorum-induced anti-atherosclerosis may be 
caused by THSG-induced antagonistic effects on oxidation of lipoprotein, prolifera-
tion, and decrease of nitric oxide content of coronary arterial smooth muscle cells 
[185] which partially explains the antiatherosclerosis mechanism of Polygonum 
multiflorum. Recently, the pharmacological effects of P. multiflorum on atheroscle-
rosis have been revealed with anti-inflammation and guy microbiota regulation 
of THSG in ApoE−/− mice [186]. The protective effects of THSG are mediated by 
modulation of JNK, SirT1, and NF-κB pathways [187] (Figure 2). As resveratrol, 
THSG can activate signal transduction pathways as AMPK. Treatment with THSG 
reduces the LPS-induced neuroinflammatory response, and that the mechanism by 
which THSG induces anti-neuroinflammatory effects may include the Nrf2/AMPK 
signaling pathways [38]. Consequently, THSG treatment leads to a decrease in the 
level of iNOS, TNF-α, and IL-6 production [184]. THSG-induced neuroprotective 
effects are via Akt signaling and TrkB activity [51]. THSG possessed an anti-inflam-
matory effect that may also be related to the inhibition of COX-2 enzyme activity 
and expression [188].
As a glycosylated analogue of resveratrol, THSG has similar effects as resve-
ratrol. Studies indicate that resveratrol significantly stimulates cell proliferation 
of human gingival fibroblasts at low concentration (10 μM) but inhibited cell 
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the absence and presence of estradiol [12]. These results indicate the suppressing 
effect of resveratrol on uterine fibroid growth may not go through ER-α.
The immunomodulatory factor, checkpoint PD-1/PD-L1 has been shown to play 
an important role in uterine fibroid pathogenesis. They also attack attention to be 
therapeutic targets. Resveratrol suppresses PD-L1 expression. In the presence of 
thyroid hormone, resveratrol traps PD-L1 in the cytosol, meanwhile, resveratrol-
induced COX-2, an inducible transcriptional co-activator [181], is trapped with 
thyroid hormone-induced PD-L1 in the cytosol [173].
Summarily, in the primary cell culture of patients with resveratrol-sensitive pri-
mary uterine fibroids, resveratrol can inhibit uterine fibroid proliferation, induce 
apoptosis, and transmit integrin-dependent signaling αvβ3. The transduction path-
way promotes uterine fibroids cell cycle arrest. Additionally, resveratrol inhibits 
the activation of IGF-1R dependent signal transduction pathways, which play an 
important role in uterine fibroid proliferation. Resveratrol may or may not inhibit 
the expression of proliferation genes. Resveratrol also induces the expression of p21 
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effectively prevent leiomyoma overgrowth and treat uterine fibroids.
3.3 Extract of He-Shou-Wu, 2,3,5,4′-Tetrahydroxystilbene-2-O-β-glucoside
The stilbene glucoside 2,3,5,4′-tetrahydroxystilbene-2-O-β-D-glucoside (THSG) 
is one of the major bioactive components of Polygonum multiflorum Thunb (He Shou 
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THSG suppresses experimental colitis effectively by reducing the level of oxygen 
and nitrogen free radicals [48]. It also has been shown to exert a protective effect 
on cardiotoxicity induced by doxorubicin in vitro and in vivo [183]. THSG can also 
diminish peroxidation levels in the brain of a mouse model with Alzheimer’s disease 
or cerebral ischemia–reperfusion. Administration of THSG not only prevents 
learning-memory deficits but also reverses the learning-memory deficit in disease-
like mouse models with Alzheimer’s [184].
Mechanism involved in P. multiflorum-induced anti-atherosclerosis may be 
caused by THSG-induced antagonistic effects on oxidation of lipoprotein, prolifera-
tion, and decrease of nitric oxide content of coronary arterial smooth muscle cells 
[185] which partially explains the antiatherosclerosis mechanism of Polygonum 
multiflorum. Recently, the pharmacological effects of P. multiflorum on atheroscle-
rosis have been revealed with anti-inflammation and guy microbiota regulation 
of THSG in ApoE−/− mice [186]. The protective effects of THSG are mediated by 
modulation of JNK, SirT1, and NF-κB pathways [187] (Figure 2). As resveratrol, 
THSG can activate signal transduction pathways as AMPK. Treatment with THSG 
reduces the LPS-induced neuroinflammatory response, and that the mechanism by 
which THSG induces anti-neuroinflammatory effects may include the Nrf2/AMPK 
signaling pathways [38]. Consequently, THSG treatment leads to a decrease in the 
level of iNOS, TNF-α, and IL-6 production [184]. THSG-induced neuroprotective 
effects are via Akt signaling and TrkB activity [51]. THSG possessed an anti-inflam-
matory effect that may also be related to the inhibition of COX-2 enzyme activity 
and expression [188].
As a glycosylated analogue of resveratrol, THSG has similar effects as resve-
ratrol. Studies indicate that resveratrol significantly stimulates cell proliferation 
of human gingival fibroblasts at low concentration (10 μM) but inhibited cell 
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proliferation at high concentrations (100 and 200 μM) significantly. On the other 
hand, THSG significantly enhances growth of human gingival fibroblasts when 
the concentration is over 25 μM and does not show any cytotoxic effect in human 
gingival fibroblasts [151]. It is evidenced that THSG may not cause cytotoxicity in 
normal human cells. Although there are no studies regarding effect of THSG on 
uterine fibroid, it should be more effective than resveratrol. THSG may not enter 
cells to induce superoxide which causes cytotoxicity to cells. However, studies also 
indicate that crude extract may cause damage in hepatocellular cells.
3.4 Pycnogenol, French maritime pine bark extract
Pycnogenol is a standardized extract of the bark of French maritime pine. 
Pycnogenol is composed of flavonoids, mainly proanthocyanidins, and phenolic 
compounds. It is a known potent antioxidant [49]. Owing to the basic chemical 
structure of its components, the most obvious feature of pycnogenol is its strong 
antioxidant activity. In fact, phenolic acids, polyphenols, and in particular flavo-
noids, are composed of one or more aromatic rings bearing one or more hydroxyl 
groups. The compositions are hence potentially able to quench free radicals by 
forming resonance-stabilized phenoxyl radicals [189]. Pycnogenol is a strong 
antioxidant that may interfere with different pathways, and it plays an important 
role in diseases associated with oxidative stress. Hyperglycemia is characteristic 
of diabetic nephropathy and induces renal tubular cell apoptosis. Pycnogenol has 
been demonstrated to significantly suppress the high glucose-induced morphologi-
cal changes and the reduction in cell viability associated with cytotoxicity in high 
glucose-treated renal tubular cells [49]. Pycnogenol is able to protect high glucose-
induced apoptosis increasing Bcl2/Bax protein ratio level. Combination treatment 
of pycnogenol and metformin improves blood glucose levels, vascular reactivity, 
and left ventricular hypertrophy in induced diabetic rats [33]. Furthermore, com-
bined treatment increases expression of AMPK, glucose transporter 4 (GLUT4), 
and calcium/calmodulin-dependent protein kinase II (CaMKII) in left ventricle of 
the hearts. However, the combination of these interventions has failed to possess 
higher efficacy [33].
Pycnogenol has anti-oxidative and anti-inflammatory efficacy in suppressing 
lipid peroxidation, total reactive species, superoxide ·O2, nitric oxide NO·, per-
oxynitrite (ONOO−), pro-inflammatory inducible nitric oxide synthase (iNOS) and 
COX-2 [49]. It also inhibits NF-κB nuclear translocation [49]. The safety of use of 
pycnogenol is demonstrated by the lack of side effects or changes in blood biochem-
istry and hematologic parameters. Therefore, pycnogenol has been recommended 
both for prevention and treatment of chronic venous insufficiency and related 
veno-capillary disturbances [190].
3.5 Therapeutic orchid Anoectochilus formosanus extract
Traditional herb medicine, golden thread (Anoectochilus formosanus Hayata) has 
been used to treat various diseases in Asia. A. formosanus extracts (AFEs) have been 
reported to possess hepatoprotective, anti-inflammatory, and anti-tumor activates. 
AFEs reduced blood glucose in hyperglycemic mice while there was no change in 
control group [191]. AFE and metformin at the same administrated dose of 50 mg/
kg showed a similar effect on intraperitoneal glucose tolerance test in hyperglyce-
mic mice. Free-radical scavenger capacity of AFE was concentration-dependent 
and 200 μg/ml of AFE was able to reduce more than 41% of the free radical [191]. 
The immunomodulatory protein from A. formosanus (IPAF) stimulated the TNF-α 
and IL-1β production, upregulated the expression of CD86, MHC II, IL-12, and 
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Th1-associated cytokines/chemokines [28]. It also enhanced the phagocytic activity 
of macrophages [28]. AFE inhibited constitutive PD-L1 expression and its protein 
accumulation in cancer cells. AFE also induced expression of pro-apoptotic genes 
but inhibited proliferative and metastatic genes. Furthermore, it induced anti-
proliferation in cancer cells. The results suggested that AFE not only reduced blood 
glucose concentration as metformin but also showed its potential use in cancer 
immune chemoprevention/therapy via hypoglycemic effect, ROS scavenging, and 
PD-L1 suppression [191]. In addition, IPAF stimulated expressions of TLR signal-
related genes and the activation of NF-κB. IPAF could induce classically activated 
macrophage differentiation via TLR4-dependent NF-κB activation and had poten-
tial of IPAF to modulate the Th1 response [28].
3.6 Epigallocatechin gallate
The green tea polyphenol epigallocatechin gallate (EGCG) has not shown cyto-
toxicity to normal cells but induces apoptosis and growth inhibition of cancer cells 
[192, 193]. EGCG inhibits uterine leiomyoma cell growth in vitro and in vivo. The 
use of a green tea extract with 45% EGCG content has demonstrated clinical activ-
ity without side effects in women with uterine fibroid symptoms [194]. However, 
there are several shortcomings of EGCG including low stability, poor bioavailabil-
ity, and high metabolic transformations under physiological conditions. All present 
challenges for its development as a therapeutic agent [194].
The signal transduction pathway by which EGCG exerts cell cycle arrest and 
induction of apoptosis remains to be clarified. Several mechanisms of cell-cycle 
arrest by EGCG have been postulated [195]. Transcription factor, p53 regulates 
downstream genes important in cell cycle arrest, DNA repair, and apoptosis. Loss 
of p53 in many cancers leads to genomic instability, impaired cell cycle regulation, 
and inhibition of apoptosis [196]. EGCG-treated HuLM cells exhibited increased 
expression of several genes that represent p53 pathway such as BAX, p21, trans-
formed 3 T3 cell double minute 2 (MDM2) and tumor protein p53 inducible protein 
3 (TP53I3) [30]. The NF-κB signal pathway was impaired by EGCG and the expres-
sion of bcl2A1, a key factor in NF-κB pathway, was reduced 11.8-fold in 100 μM 
EGCG-treated uterine fibroid HuLM cells [30] compared to untreated control.
The BCL family includes proapoptotic members and antiapoptotic members, such 
as BAX and BCL-2, respectively. The effects of apoptosis or anti-apoptosis supple-
mentary depend on the balance between BCL2 and BAX rather than on the BCL2 
quantity alone [197]. EGCG treatment causes BCL2 to dramatically decrease while 
BAX up-regulates [30]. Additionally, the D-type cyclins, through the interaction with 
CDKs-forming cyclin d1-CDK4/6 complexes, are mainly responsible for driving the 
cell cycle from G1 to S phase [198]. A significant decrease was observed in the expres-
sion of CDK4 and PCNA in EGCG treated uterine fibroid HuLM cells [30].
4. Conclusion remarks
The current clinical uterine fibroid therapies are restricted to their short-term 
efficacy and unpleasant side effects. Unless the patients are postmenopausal, hys-
terectomy is generally not recommended. In terms of expanding medical options, 
alternative therapies for uterine fibroids have been explored. In addition to herbal 
medicines we discussed, natural products such as vitamin D, berberine, and others 
are being used for alternative uterine fibroid treatments. Moreover, it may be more 
effective when natural compounds combined with hormonal agents for uterine 
fibroid therapy. We have shown that resveratrol combined with thyroid hormone 
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of p53 in many cancers leads to genomic instability, impaired cell cycle regulation, 
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expression of several genes that represent p53 pathway such as BAX, p21, trans-
formed 3 T3 cell double minute 2 (MDM2) and tumor protein p53 inducible protein 
3 (TP53I3) [30]. The NF-κB signal pathway was impaired by EGCG and the expres-
sion of bcl2A1, a key factor in NF-κB pathway, was reduced 11.8-fold in 100 μM 
EGCG-treated uterine fibroid HuLM cells [30] compared to untreated control.
The BCL family includes proapoptotic members and antiapoptotic members, such 
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mentary depend on the balance between BCL2 and BAX rather than on the BCL2 
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analogue, tetrac can compensate for resveratrol-induced RRM2 side effects in 
colorectal cancer animal xenograft model [199]. However, to search for a safe and 
effective medication for uterine fibroid requires further human clinical trials of 
these herbal compounds before promoting widespread usage.
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Hysterectomy is the most common major gynecological operation in worldwide 
and Arabic countries. However, the psychological, physical and sexual consequences 
of hysterectomy are conflicting and the findings are mixed. While, some studies 
report that patients have experience greater improvement in their mental health, 
sexual desire and overall satisfaction. Others show that patients report various nega-
tive outcomes, with detrimental effects on sexual functioning being the main con-
cern. My previous study demonstrated that hysterectomy had significantly negative 
effects on patients’ body image, self-esteem, and identified common meanings and 
themes associated with hysterectomy stressors, which includes difficulties or limita-
tions in physical and psychological aspects perceived by patients after hysterectomy. 
In this chapter, author will expand that discuss in details the different factors that 
influence the perspective of women about body after hysterectomy. Mainly, author 
will focus on religious, cultural, and psycho-social aspects. All of these factors are 
interacting with health status of women and effect the situation and productivity 
of women in her family and culture. Different strategy need to be adopted in order 
to overcome this problem using evidence and analysis of our Arabic culture and 
structure. Recommendation of study to health care profession as physician, nurses, 
midwives and other health care provider to be aware of these potential problematic 
issues in order to provide a competent health care for women based of her needs.
Keywords: fibroid, women’s perception, hysterectomy, sexuality, self-esteem,  
body image, quality of life
1. Introduction and background 
One in three women at age of 60 years in the USA have undergone a hyster-
ectomy, it is the second most common major surgical procedure performed in 
women worldwide [1]. Also, it is the leading reason for non-obstetric surgery 
among women in many high-income settings [2–4]. Fibroids, dysfunctional uterine 
bleeding, uterine prolapse and chronic pelvic pain are the most indication for this 
surgery [5]. So, the majority of hysterectomies are performed on benign indications 
to improve quality of life with few complications post-operative.
In recent years, an increasing number of studies have shown long-term adverse 
effects of hysterectomy on the pelvic floor and some studies have demonstrated 
unwanted effects on other health aspects. Long-term effects of hysterectomy on the 
pelvic floor that should be considered in surgical decision making are: pelvic organ 
prolapse, urinary incontinence, bowel dysfunction, sexual function and pelvic 
organ fistula formation. These outcomes are particularly relevant as life expectancy 
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has increased and sequel may occur a long time after the surgical procedure and 
severely [1]. The surgery can take an emotional toll on woman as well. These effects 
might be very personal; she may feel differently than others, this leads her to depres-
sion. Losing the ability to become pregnant is hard for many women in worldwide 
and especially in Arabic countries, where the reproductively in considered the main 
reason for marriage. Some women feel “changed.” They may also mourn the loss 
of their fertility [6]. Fears of looking less “womanly” Younger women who have a 
hysterectomy sometimes are anxious about whether the surgery will change their 
appearance. They worry that it will make them more masculine [6]. A lot of Women 
who are the power of the community depressed, as a result of this operation, 
because of losing a something that a part of her femininity, make their body image 
and self-esteem disrupted, feelings that their different from others women who can 
childbearing, and she is not, all of that make them isolated from the community, 
when this community need for their power and productivity. In next section authors 
will highlighted on women perspective on her body, and focus on factors that might 
directly and indirectly influence these perspectives that includes religious, cultural, 
economic, political and psycho-social aspects based on review.
2. Narrative review
In this part, author will offer a narrative review that present a group of studies, 
to see the experiences and results of previous studies that discuss the experience 
of women who had done hysterectomy. As well as discuss the role of health care 
profession and recommended strategies to overcome these problem. This sec-
tion will include four themes which are quality of life; physical and psychological 
changes; sexuality; Cultural and religious aspects; finally the review conclusion and 
recommendations.
Sexuality is written as separate theme not under physical and psychological 
theme due to its important and effects based on Maslow hierarchy. Another point 
is the sensitivity of talking in this subject in conservative Arabic culture even from 
health care profession themselves. If I ask myself if any of health care profession 
provided women with health education about her sexuality after hysterectomy, the 
answer is obviously clear. Might be there is no time to provide that after operation 
but the important point the negligence of this type of education. This indicates that 
health care professions are playing a big role to solve or complicate this issue. They 
have to deliver a competent health care for women based of her needs. This is the 
woman’s right not luxury, especially for ethnic minorities group.
2.1 Quality of life
Improvements of quality of life and decrease gynecologic symptoms are the 
main reason of any decision that taken by women for undergoes hysterectomy. In 
a systematic review study, authors investigated and analyzed six studies which 
evaluated QOL after hysterectomy. The authors concluded that a significant 
improvement above baseline in QOL scores [7]. However, many evidence as illus-
trated in this review showed the suffer of women physically and psychologically 
post-operative.
Hysterectomy is the one of surgery that needs more physical & psychological 
support by nurses in hospitals or/and outpatient clinics. Also provide a full background 
or knowledge for women who will do a hysterectomy that help to avoid the impact of 
hysterectomy [8]. There are four major subjects relating to the participant’s experience 
were identified by Valerie Fleming [9], doubts and justifications, pain, embodiment 
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and sense of bitterness. In addition there are three domains must to integrate biophysi-
cal care of women, psychological, sociological, and spiritual domains [10]. Both of 
these study spotlight on the importance of provider training and education, also efforts 
must be directed to the community to enlighten men and families about hysterectomy 
by dispelling myths and providing current health information related to women’s 
gynecological health and alternatives to, indications for, and types of hysterectomy.
2.2 Physical and psychological changes
As a result of study that examined by Gul Pinar et al., there is a relationships 
between hysterectomy and body image, self-esteem, and dyadic adjustment, which 
appears significantly in the scores, lower than the healthy women [11]. This indicates 
for the reduction of psychological support from community in general and family 
in specific. The most impact of hysterectomy as discussed on previous study [12], is 
the emotional side, seven themes that divided from this side, fear; pain; death and 
dying; numbness or delay in emotional reaction; bonding with baby; communica-
tion; and the need for information. Something that must to focus on managing it 
by enhances the quality of life or to avoid it before happened by providing correct 
health information by care providers. Like study which discussed in relation to the 
importance of information provision by gynecologists and its effects on women’s 
decision-making about hysterectomy [13]. So gynecologists must initiate a compre-
hensive discussion about other treatments and their advantages and disadvantages. 
To explain the differences in complications between women after surgery, there are 
factors can determine this complication, Lifestyle factors (smoking and body mass 
index) and co-morbidity status, occupation and educational level [14].
The patients need for expressed their emotions and feelings after the major 
event that had happened in their life, otherwise, physical and psychological changes 
might be exaggerated. In previous qualitative study on Palestinian women, the most 
physical changes occur after hysterectomies were including pain, insomnia, eating 
disorder and immobility. One of the participants described pain as saying: “I had 
never felt like this pain in my life”. As a consequence of the pain, patients also suffer 
disturbances at night and changes in the sleep cycle. Also, Changes in the patients’ 
appetite were reported in this study and it differs from one woman to another. Some 
of the participants expressed that their appetite increased and others reported the 
opposite. Another problem that reported was the immobility which affected the 
daily performance and routine activities at home [15].
Depression, accompanied by anxiety, de-socialization, and aggression, is the most 
common complication that reported by women after hysterectomy. The depression 
was figure as the most common psychological complication of hysterectomy [15, 16].
Also psychological and emotional stress was evident in previous study and 
shown a negative emotional outcome after hysterectomy. It has been suggested 
that early detection and immediate action by healthcare providers may prevent 
these negative impacts on the psychological wellbeing of these women. This is 
especially so in younger women in whom the psychological impacts are the greatest. 
Furthermore, because the main reason for the psychological impact was related 
to the immediate postmenopausal status after surgery, younger women appear to 
be more vulnerable, thus emphasizing the need for proper counseling in younger 
women undergoing hysterectomy [17].
The most coping mechanism and adaptation technique that used by women after 
operation from literature were praying, the Holy Quran, music, and other activities 
such as walking, sports (yoga) [15]. While, other study found that the operation 
affects patients’ emotional reactions. As a result, they used these techniques to cope 
with their new condition and accept it [17].
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when this community need for their power and productivity. In next section authors 
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directly and indirectly influence these perspectives that includes religious, cultural, 
economic, political and psycho-social aspects based on review.
2. Narrative review
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to see the experiences and results of previous studies that discuss the experience 
of women who had done hysterectomy. As well as discuss the role of health care 
profession and recommended strategies to overcome these problem. This sec-
tion will include four themes which are quality of life; physical and psychological 
changes; sexuality; Cultural and religious aspects; finally the review conclusion and 
recommendations.
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health care profession themselves. If I ask myself if any of health care profession 
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woman’s right not luxury, especially for ethnic minorities group.
2.1 Quality of life
Improvements of quality of life and decrease gynecologic symptoms are the 
main reason of any decision that taken by women for undergoes hysterectomy. In 
a systematic review study, authors investigated and analyzed six studies which 
evaluated QOL after hysterectomy. The authors concluded that a significant 
improvement above baseline in QOL scores [7]. However, many evidence as illus-
trated in this review showed the suffer of women physically and psychologically 
post-operative.
Hysterectomy is the one of surgery that needs more physical & psychological 
support by nurses in hospitals or/and outpatient clinics. Also provide a full background 
or knowledge for women who will do a hysterectomy that help to avoid the impact of 
hysterectomy [8]. There are four major subjects relating to the participant’s experience 
were identified by Valerie Fleming [9], doubts and justifications, pain, embodiment 
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and sense of bitterness. In addition there are three domains must to integrate biophysi-
cal care of women, psychological, sociological, and spiritual domains [10]. Both of 
these study spotlight on the importance of provider training and education, also efforts 
must be directed to the community to enlighten men and families about hysterectomy 
by dispelling myths and providing current health information related to women’s 
gynecological health and alternatives to, indications for, and types of hysterectomy.
2.2 Physical and psychological changes
As a result of study that examined by Gul Pinar et al., there is a relationships 
between hysterectomy and body image, self-esteem, and dyadic adjustment, which 
appears significantly in the scores, lower than the healthy women [11]. This indicates 
for the reduction of psychological support from community in general and family 
in specific. The most impact of hysterectomy as discussed on previous study [12], is 
the emotional side, seven themes that divided from this side, fear; pain; death and 
dying; numbness or delay in emotional reaction; bonding with baby; communica-
tion; and the need for information. Something that must to focus on managing it 
by enhances the quality of life or to avoid it before happened by providing correct 
health information by care providers. Like study which discussed in relation to the 
importance of information provision by gynecologists and its effects on women’s 
decision-making about hysterectomy [13]. So gynecologists must initiate a compre-
hensive discussion about other treatments and their advantages and disadvantages. 
To explain the differences in complications between women after surgery, there are 
factors can determine this complication, Lifestyle factors (smoking and body mass 
index) and co-morbidity status, occupation and educational level [14].
The patients need for expressed their emotions and feelings after the major 
event that had happened in their life, otherwise, physical and psychological changes 
might be exaggerated. In previous qualitative study on Palestinian women, the most 
physical changes occur after hysterectomies were including pain, insomnia, eating 
disorder and immobility. One of the participants described pain as saying: “I had 
never felt like this pain in my life”. As a consequence of the pain, patients also suffer 
disturbances at night and changes in the sleep cycle. Also, Changes in the patients’ 
appetite were reported in this study and it differs from one woman to another. Some 
of the participants expressed that their appetite increased and others reported the 
opposite. Another problem that reported was the immobility which affected the 
daily performance and routine activities at home [15].
Depression, accompanied by anxiety, de-socialization, and aggression, is the most 
common complication that reported by women after hysterectomy. The depression 
was figure as the most common psychological complication of hysterectomy [15, 16].
Also psychological and emotional stress was evident in previous study and 
shown a negative emotional outcome after hysterectomy. It has been suggested 
that early detection and immediate action by healthcare providers may prevent 
these negative impacts on the psychological wellbeing of these women. This is 
especially so in younger women in whom the psychological impacts are the greatest. 
Furthermore, because the main reason for the psychological impact was related 
to the immediate postmenopausal status after surgery, younger women appear to 
be more vulnerable, thus emphasizing the need for proper counseling in younger 
women undergoing hysterectomy [17].
The most coping mechanism and adaptation technique that used by women after 
operation from literature were praying, the Holy Quran, music, and other activities 
such as walking, sports (yoga) [15]. While, other study found that the operation 
affects patients’ emotional reactions. As a result, they used these techniques to cope 
with their new condition and accept it [17].
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2.3 Cultural and religious aspects
Another issue that should be highlighted in this review is the role and effect of 
environment as cultural and religious on the perception of women who undergo 
hysterectomy. The woman is not presented on isolation; she interacted with sur-
rounding that affect her status and view to her body and problem. It is important to 
figure that uterus is representing woman’s femininity and fertility.
The woman is not totally responsible for her body from legal and cultural aspect, it 
is partially. In Arabic countries as in Saudi Arabia and Palestine the health care system 
ask the husband’s consent for any medical procedure that affects the reproductive 
ability of his wife. In recent study that disuses this practice in Saudi Arabia, author rec-
ommended that “arguments advocating for discontinuing the requirement are offered 
along with measures to implement in order to overcome this social artifact” [18].
However, Islamic law closely regulates and governs the life of every Muslim. The 
basic principle is that it is impermissible for a woman to have her uterus removed 
because this entails permanent sterilization, and this conflicts with one of the most 
important higher objectives of the Sharee‘ah – fruitfulness in procreation. Anas ibn 
Maalik narrated that the Prophet, sallallaahu ‘alayhi wa sallam, said: “Marry fertile 
affectionate women, for I will be proud of your numbers in front of the Prophets on 
the Day of Judgment.” [19].
However, if there is concern of real or prevalent harm to the woman’s health if 
the uterus is not removed, or it is feared that it could cause her death or bring about 
considerable hardship beyond her ability to endure, and it is necessary, according to 
the advice of reliable and experienced doctors, for the uterus to be removed to ward 
off such harm, then it is permissible for the woman to have her uterus removed. 
This is based on the well-established principles that “elimination of harm takes 
precedence to realization of benefit” and “necessity makes something prohibited 
permissible”. Allaah The Exalted says (what means): {…while He has explained 
in detail to you what He has forbidden you, excepting that to which you are com-
pelled.} [Quran 6:119].
Moreover, the Prophet, sallallaahu ‘alayhi wa sallam, said: “There shall be no 
harm or reciprocal harm.” [Musnad Ahmad and Al-Muwatta’] [19]. According to 
catholic a hysterectomy by choice over medical necessity would be a sin because it 
would cause permanent sterilization.
It is obviously clear here the gap between the cultural practice and religions 
aspect, what presented in religion in not translate totally to reality and practice. 
The women should have the total freedom to decide what she wants on her body. 
The powering women and taking her responsibilities will help her to cope well and 
accept any change to her body and soul.
From literature, other culture as presented in Indian, the author found the term 
“normalization of hysterectomy” was mentioned in many studies. The women are 
preferred to do hysterectomy as treatment for any menstrual or uterine problem 
instead of receiving medical or pharmacological treatment. This term underscores 
“the complex negotiations between women’s agency and medically un indicated 
procedures, as well as the ethical obligations of providers—both of which require 
further consideration in the Indian context” [20]. However, this term is not 
presented in Arabic context; in contrast the family likes to have more children as 
highlighted above from religious and cultural side. Arabic families like to have more 
male children because they considered that in Arabic term “Ozwa” as a positive 
point and they will help them in future when parents become old. The more male 
children the women have delivered the more respect will receive from their culture, 
husband family and mother in law. So, we can imagine the scope of problem, how 
the effect of remove part of her women body “uterus” on her self-image.
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2.4 Impact on sexual life
It is recognized that effects of hysterectomy on women’s sexuality are debated 
and controversial from literature [17]. A Socio-cultural construction is main factor 
that influenced the sexuality that involves many factors such as gender, identity, 
sexual orientation, pleasure, intimacy, and reproduction [22]. Many previous studies 
reported that the majority of women and their partners reported zero negative 
impact on sexual satisfaction after abdominal hysterectomy, regardless of the surgery 
was subtotal or total to [23], for example the majority of Norwegian women and their 
partners reported no negative impact on sexual satisfaction after abdominal hysterec-
tomy, regardless of whether the hysterectomy was subtotal or total [23]. While From 
the literature, some of the studies are inconsistent with these findings [15, 21–26, 35].
Other study reported that only one fourth of the women reported decreased 
sexual arousal, while the majority had experienced higher sexual arousal after 
abdominal and vaginal hysterectomy [27]. Various measures are used in these 
studies so comparing the degree of improvement in sexual is difficult. Guliz et al. 
mentioned in his study that advanced age, women’s attitude towards sexuality, and 
type of hysterectomy are the main elements that determine sexual functioning 
after hysterectomy. Depression has a negative effect on sexual functioning [28]. A 
negative sexual experience before hysterectomy will be a strong predictor of having 
a negative sexual experience of partners after operation [23]. A survey conducted in 
Jordan, which is one of Arab countries found that sexual performance after hyster-
ectomy was their most significant concern, and there was a significant improve-
ment in sexual function for women undergoing this procedure [26].
When looking to change in sexual changes, Literature review reveals that dys-
pareunia, and a change in orgasm and/or less sex are happened to approximately 10 
to 20% of the women who underwent a hysterectomy [29], and in post operatively 
sexual dysfunction [30–33], then after two years of operation the sexual dysfunction 
stabilized [24]. The main reason for sexual annoyances were included the modified 
self-image perception after surgery and decrease in vaginal lubrication a [34].
One of study revealed the negative impact of hysterectomy on the sexual life, 
which lead to increased depression and anxiety, with sexual dissatisfaction [35]. 
The counseling and discussion prior hysterectomy for potential sexual changes after 
surgery is crucial and may enhance the situation [36]. Another problem that might 
occur is the urinary problems after the operation or hysterectomy for sexually active 
and healthy women, they resulted in sexual dysfunction and increase in depression. 
The age, educational status, working condition and family structure is also impor-
tant in this case [37].
In the other study, that is titled by” Women’s attitudes about sexuality”. In the 
third month after hysterectomy 49.5% of the women had begun to have sexual 
intercourse again, 34.3% of those were determined to have a decrease in sexual 
functions. It was also found that level of depression was less in the postoperative 
period compared to the preoperative period. Three months after hysterectomy, 
sexual functioning had significantly decreased. A clear resolution in symptoms of 
depression was seen after hysterectomy. It was determined that sexual functioning 
after hysterectomy was affected by advanced age, a women’s attitude about sexual-
ity, and the type of hysterectomy [28].
It is indicated in this review that sexual function is a major cause of women’s 
concern for scheduled hysterectomy; therefore, it is important to spread awareness 
among women and let them know that most probably they will neither lose their 
sexual desire after hysterectomy, nor they will lose their feminine shape or style [26]. 
It is important to figure if ethnicity, socioeconomic status and sexual function are 
taken into account; it is easily to manage the physical and psychological changes [17].
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3. Conclusion and recommendation
The health care profession should have insight regards the perception of women 
of her body after hystrectomy. In order to provide a competent health care for 
women based of her needs. Women’s sexuality fractioning is essence and concern of 
women after hysterectomy, this topic is debated and controversial from literature. It 
is important here to highlight that uterus has symbolic values related to femininity 
as mentioned previously and evidence by many studies [38]. This problem among 
Arabian women is apparent and clear, where the womb of a woman is considered 
everything for her it represent it femininity and fertility, it means a lot for her. 
The woman inside herself felt of “deficient being” in the eyes of herself and her 
extended family, taking into consideration the presented of conservative culture 
that women’s have and early marriage practice that aimed to protect women and 
produce more children from cultural lenses view. This leads us the significant to 
power women by increase her awareness pre-operative, follow up post-operative 
and having a good support system.
Educational programs for women undergoing hysterectomy will promote better 
self-care behavior, reduce postoperative anxiety and pain, and mitigate some of 
the negative influences of hysterectomy. So, interventions may not affect the actual 
incidence of the side-effects; they may help patients cope with adverse outcomes 
better, thus emphasizing the importance of the adaptation process to accept this 
condition with a positive thought.
The results of this review reveal that hysterectomy had significant argumenta-
tive effects on women’s’ quality of life, physically, psychological and sexually. For 
effective handling of this problem, healthcare profession must be aware of these 
potentially problematic issues and use effective intervention pre-post operation. 
Multidisciplinary teams have to work together, nurses have to lead the work to 
ensure of using the holistic approach that cover women’s needs that included physi-
cal, psychological, spiritually, culturally and be individually. One size not fit all.
The important point here, that we could not change the culture or the mistake 
in the interpretation of religion. So, the practical solution is to involve the family 
into the therapeutic plan, identifying and addressing the psychosocial problems of 
the particularly high-risk groups is another critical point and referred them.
Based on the findings from this review, recommendations can be made to nurses 
working at gynecological departments. Nurses could also help the patients explore 
current coping mechanisms and support systems after hysterectomy. Another 
recommendation is to conduct a future study that examine the current education 
that provides to women pre-post operatively and it suitability based on her ethnicity 
and needs where ever the women is presented in her home country or diaspora.
145




Head of Midwifery and MCH Department, Faculty of Medicine and Health Science, 
An-Najah National University, Nablus, Palestine
*Address all correspondence to: alshawish@najah.edu
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Fibroids
144
3. Conclusion and recommendation
The health care profession should have insight regards the perception of women 
of her body after hystrectomy. In order to provide a competent health care for 
women based of her needs. Women’s sexuality fractioning is essence and concern of 
women after hysterectomy, this topic is debated and controversial from literature. It 
is important here to highlight that uterus has symbolic values related to femininity 
as mentioned previously and evidence by many studies [38]. This problem among 
Arabian women is apparent and clear, where the womb of a woman is considered 
everything for her it represent it femininity and fertility, it means a lot for her. 
The woman inside herself felt of “deficient being” in the eyes of herself and her 
extended family, taking into consideration the presented of conservative culture 
that women’s have and early marriage practice that aimed to protect women and 
produce more children from cultural lenses view. This leads us the significant to 
power women by increase her awareness pre-operative, follow up post-operative 
and having a good support system.
Educational programs for women undergoing hysterectomy will promote better 
self-care behavior, reduce postoperative anxiety and pain, and mitigate some of 
the negative influences of hysterectomy. So, interventions may not affect the actual 
incidence of the side-effects; they may help patients cope with adverse outcomes 
better, thus emphasizing the importance of the adaptation process to accept this 
condition with a positive thought.
The results of this review reveal that hysterectomy had significant argumenta-
tive effects on women’s’ quality of life, physically, psychological and sexually. For 
effective handling of this problem, healthcare profession must be aware of these 
potentially problematic issues and use effective intervention pre-post operation. 
Multidisciplinary teams have to work together, nurses have to lead the work to 
ensure of using the holistic approach that cover women’s needs that included physi-
cal, psychological, spiritually, culturally and be individually. One size not fit all.
The important point here, that we could not change the culture or the mistake 
in the interpretation of religion. So, the practical solution is to involve the family 
into the therapeutic plan, identifying and addressing the psychosocial problems of 
the particularly high-risk groups is another critical point and referred them.
Based on the findings from this review, recommendations can be made to nurses 
working at gynecological departments. Nurses could also help the patients explore 
current coping mechanisms and support systems after hysterectomy. Another 
recommendation is to conduct a future study that examine the current education 
that provides to women pre-post operatively and it suitability based on her ethnicity 
and needs where ever the women is presented in her home country or diaspora.
145




Head of Midwifery and MCH Department, Faculty of Medicine and Health Science, 
An-Najah National University, Nablus, Palestine
*Address all correspondence to: alshawish@najah.edu
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
146
Fibroids
[1] Kovac SR. Hysterectomy outcomes 
in patients with similar indications. 
Obstet Gynecol 2000; 95(6 Pt 1): 787-93. 
[PMID: 10831967]
[2] Spilsbury K Semmens JB Hammond 
I Bolck A. Persistent high rates of 
hysterectomy in Western Australia: 
a population-based study of 83 000 
procedures over 23 years. BJOG: An 
International Journal of Obstetrics and 
Gynaecology 2006; 113: 804-9.
[3] Whiteman MK Hillis SD Jamieson 
DJ , et al. Inpatient hysterectomy 
surveillance in the United States, 2000-
2004. American Journal of Obstetrics 
and Gynecology 2008; 198: 34 e1-7.
[4] Stankiewicz A Pogany L Popadiuk C. 
Prevalence of self-reported hysterectomy 
among Canadian women, 2000/2001-
2008. Chronic Diseases and Injuries in 
Canada 2014; 34: 30-5.
[5] Carlson KJ Nichols DH Schiff I.  
Indications for hysterectomy. New 
England Journal of Medicine 1993; 328: 
856-60.
[6] Dorsey JH, Steinberg EP, Holtz PM. 
Clinical indications for hysterectomy 
route: patient characteristics or 
physician preference? Am J Obstet 
Gynecol 1995; 173(5): 1452-60.
[http://dx.doi.org/10.1016/0002-
9378(95)90632-0] [PMID: 7503184]
[7] Matteson KA, Raker CA, Clark MA, 
Frick KD. Abnormal uterine bleeding, 
health status, and usual source of 
medical care: Analyses using the 
medical expenditures panel survey. J 
Womens Health (Larchmt) 2013;22:959-
65. [PMC free article]
[8] Lis,Wagner.,Anne.,MetteCarls
lund,Mette.,Sorensen,Bent.,Otte
sen. Women’s experience with short 
admission in abdominal hysterectomy 
and their patterns of behavior 2005; 
(19) :330-336.
[9] Valerie,Fleming. Hyserectomy a case 
study of one woman's experience 2003; 
44(6): 575-582.
[10] Williams, R. and A. Clark. 
“A qualitative study of women's 
hysterectomy experience.” Journal 
of women's health & gender-based 
medicine 9 Suppl 2 (2000): S15-25 .
[11] Gul Pinar, SeydaOkdem., 
NevinDogan, LaleBuyukgonec., Ali 
Ayhan. The effect of hysterectomy on 
body image self-esteem and marital 
adjustment in Turkish women with 
Gynecologic cancer 2011.
[12] Cara, Z.,delacruz , Martha,L.,Coul
ter,Kathleen.,O'rourke,Aminaalio,Elle
n,M Daley.,Charles ,S Mahan. Women's 
Experiences emotional responses and 
perceptions of care after emergency 
peripartum hysterectomy a Qualitative 




hysterectomy Experience and decision 
making 2003; 38 (1): 53-67
[14] DaugbjergSignem, B., cearoniGiulia, 
Ottesen bent, Diderichesn Finn, Osler 
Merete. Effect of socioeconomic position 
on patient outcome after hysterectomy 
2014; 93(9): 926-934.
[15] Alshawish, E., Qadous, Sh., 
& Yamani, A. (2020). Experience 
of Palestinian women after 
hysterectomy using a descriptive 
phenomenological Study. The Open 
Nursing Journal, 14(1),74-79. doi: 
10.2174/1874434602014010074.
[16] GulizOnat,Bayram.,NevinSahin. 
Hystrectomy's psychosexual effects in 
Turkish Women, 2008; 26:149-158.
[17] Li ping wong., Kulenthran 
Arumugam. physical psychological 
and sexual effects in multi-ethnic 
References
147
Perspective of Women about Her Body after Hysterectomy
DOI: http://dx.doi.org/10.5772/intechopen.94260
Malaysian women how have undergone 
hysterectomy 2012; 38:1095-1105.
[18] Muaygil, R. U. A. I. M. “Her Uterus, 
Her Medical Decision? Dismantling 
Spousal Consent for Medically Indicated 
Hysterectomies in Saudi Arabia,” 
Cambridge Quarterly of Healthcare 
Ethics. Cambridge University Press 
2018; 27(3):397-407. doi: 10.1017/
S0963180117000780.
[19] islamweb.net . Ruling on the 
surgical removal of the uterus. 2020; 
Fatwa No: 296863. https://www.
islamweb.org/en/fatwa/296863/ruling-
on-the-surgical-removal-of-the-uterus
[20] Desai, S., Campbell, O. M., Sinha, T., 
Mahal, A., & Cousens, S. Incidence and 
determinants of hysterectomy in a low-
income setting in Gujarat, India. Health 
Policy and Planning 2016; 32(1), 68-78.
[21] Kürek Eken M, İlhan G, Temizkan O, 
Çelik EE, Herkiloğlu D, Karateke A. The 
impact of abdominal and laparoscopic 
hysterectomies on women’s sexuality 
and psychological condition. Turk J 
Obstet Gynecol 2016; 13(4): 196-202. 
[http://dx.doi.org/10.4274/tjod.71245] 
[PMID: 28913121]
[22] Farquhar CM, Steiner CA. 
Hysterectomy rates in the United States 
1990-1997. Obstet Gynecol 2002; 99(2): 
229-34. [PMID: 11814502]
[23] Lonnée-Hoffmann RA, Schei B, 
Eriksson NH. Sexual experience of 
partners after hysterectomy, 
comparing subtotal with total 
abdominal hysterectomy. Acta 




[24] Mylonas I, Friese K. Indications for 
and Risks of Elective Cesarean Section. 
Dtsch Arztebl Int 2015; 112(29-30): 
489-95. [http://dx.doi.org/10.3238/
arztebl.2015.0489] [PMID: 26249251]
[25] Danesh M, Hamzehgardeshi Z, 
Moosazadeh M, Shabani-Asrami F. The 
Effect of Hysterectomy on Women’s 
Sexual Function: a Narrative Review. Med 
Arh 2015; 69(6): 387-92.[http://dx.doi.
org/10.5455/medarh.2015.69.387-392] 
[PMID: 26843731]
[26] Fram KM, Saleh SS, Sumrein IA.  
Sexuality after hysterectomy at 
University of Jordan Hospital: a teaching 
hospital experience. Arch Gynecol 
Obstet 2013; 287(4): 703-8. [http://
dx.doi.org/10.1007/s00404-012-2601-2] 
[PMID: 23132049]
[27] Goetsch MF. The effect of total 
hysterectomy on specific sexual 
sensations. Am J Obstet Gynecol 
2005; 192(6): 1922-7. [http://dx.doi.
org/10.1016/j.ajog.2005.02.065] [PMID: 
15970852]
[28] Bayram., NevinSahin. Hystrectomy’s 
Psychosexual Effects in Turkish Women 
2008; 26: 149-58.
[29] Lonnée-Hoffmann R, Pinas I.  
Effects of Hysterectomy on Sexual 
Function. Curr Sex Health Rep 2014; 
6(4): 244-51. [http://dx.doi.org/10.1007/
s11930-014-0029-3] [PMID: 25999801]
[30] Farquhar CM, Steiner CA. 
Hysterectomy rates in the United States 
1990-1997. Obstet Gynecol 2002; 99(2): 
229-34. [PMID: 11814502]
[31] Altman D, Granath F, Cnattingius S, 
Falconer C. Hysterectomy and risk of 
stress-urinary-incontinence surgery: 




[32] Pauls RN. Impact of gynecological 
surgery on female sexual function. Int 
J Impot Res 2010; 22(2): 105-14.[http://
dx.doi.org/10.1038/ijir.2009.63] [PMID: 
20072131]
[33] Adorna E, Morari-Cassol E, 
Ferraz N. A Mastectomia e suas 
146
Fibroids
[1] Kovac SR. Hysterectomy outcomes 
in patients with similar indications. 
Obstet Gynecol 2000; 95(6 Pt 1): 787-93. 
[PMID: 10831967]
[2] Spilsbury K Semmens JB Hammond 
I Bolck A. Persistent high rates of 
hysterectomy in Western Australia: 
a population-based study of 83 000 
procedures over 23 years. BJOG: An 
International Journal of Obstetrics and 
Gynaecology 2006; 113: 804-9.
[3] Whiteman MK Hillis SD Jamieson 
DJ , et al. Inpatient hysterectomy 
surveillance in the United States, 2000-
2004. American Journal of Obstetrics 
and Gynecology 2008; 198: 34 e1-7.
[4] Stankiewicz A Pogany L Popadiuk C. 
Prevalence of self-reported hysterectomy 
among Canadian women, 2000/2001-
2008. Chronic Diseases and Injuries in 
Canada 2014; 34: 30-5.
[5] Carlson KJ Nichols DH Schiff I.  
Indications for hysterectomy. New 
England Journal of Medicine 1993; 328: 
856-60.
[6] Dorsey JH, Steinberg EP, Holtz PM. 
Clinical indications for hysterectomy 
route: patient characteristics or 
physician preference? Am J Obstet 
Gynecol 1995; 173(5): 1452-60.
[http://dx.doi.org/10.1016/0002-
9378(95)90632-0] [PMID: 7503184]
[7] Matteson KA, Raker CA, Clark MA, 
Frick KD. Abnormal uterine bleeding, 
health status, and usual source of 
medical care: Analyses using the 
medical expenditures panel survey. J 
Womens Health (Larchmt) 2013;22:959-
65. [PMC free article]
[8] Lis,Wagner.,Anne.,MetteCarls
lund,Mette.,Sorensen,Bent.,Otte
sen. Women’s experience with short 
admission in abdominal hysterectomy 
and their patterns of behavior 2005; 
(19) :330-336.
[9] Valerie,Fleming. Hyserectomy a case 
study of one woman's experience 2003; 
44(6): 575-582.
[10] Williams, R. and A. Clark. 
“A qualitative study of women's 
hysterectomy experience.” Journal 
of women's health & gender-based 
medicine 9 Suppl 2 (2000): S15-25 .
[11] Gul Pinar, SeydaOkdem., 
NevinDogan, LaleBuyukgonec., Ali 
Ayhan. The effect of hysterectomy on 
body image self-esteem and marital 
adjustment in Turkish women with 
Gynecologic cancer 2011.
[12] Cara, Z.,delacruz , Martha,L.,Coul
ter,Kathleen.,O'rourke,Aminaalio,Elle
n,M Daley.,Charles ,S Mahan. Women's 
Experiences emotional responses and 
perceptions of care after emergency 
peripartum hysterectomy a Qualitative 




hysterectomy Experience and decision 
making 2003; 38 (1): 53-67
[14] DaugbjergSignem, B., cearoniGiulia, 
Ottesen bent, Diderichesn Finn, Osler 
Merete. Effect of socioeconomic position 
on patient outcome after hysterectomy 
2014; 93(9): 926-934.
[15] Alshawish, E., Qadous, Sh., 
& Yamani, A. (2020). Experience 
of Palestinian women after 
hysterectomy using a descriptive 
phenomenological Study. The Open 
Nursing Journal, 14(1),74-79. doi: 
10.2174/1874434602014010074.
[16] GulizOnat,Bayram.,NevinSahin. 
Hystrectomy's psychosexual effects in 
Turkish Women, 2008; 26:149-158.
[17] Li ping wong., Kulenthran 
Arumugam. physical psychological 
and sexual effects in multi-ethnic 
References
147
Perspective of Women about Her Body after Hysterectomy
DOI: http://dx.doi.org/10.5772/intechopen.94260
Malaysian women how have undergone 
hysterectomy 2012; 38:1095-1105.
[18] Muaygil, R. U. A. I. M. “Her Uterus, 
Her Medical Decision? Dismantling 
Spousal Consent for Medically Indicated 
Hysterectomies in Saudi Arabia,” 
Cambridge Quarterly of Healthcare 
Ethics. Cambridge University Press 
2018; 27(3):397-407. doi: 10.1017/
S0963180117000780.
[19] islamweb.net . Ruling on the 
surgical removal of the uterus. 2020; 
Fatwa No: 296863. https://www.
islamweb.org/en/fatwa/296863/ruling-
on-the-surgical-removal-of-the-uterus
[20] Desai, S., Campbell, O. M., Sinha, T., 
Mahal, A., & Cousens, S. Incidence and 
determinants of hysterectomy in a low-
income setting in Gujarat, India. Health 
Policy and Planning 2016; 32(1), 68-78.
[21] Kürek Eken M, İlhan G, Temizkan O, 
Çelik EE, Herkiloğlu D, Karateke A. The 
impact of abdominal and laparoscopic 
hysterectomies on women’s sexuality 
and psychological condition. Turk J 
Obstet Gynecol 2016; 13(4): 196-202. 
[http://dx.doi.org/10.4274/tjod.71245] 
[PMID: 28913121]
[22] Farquhar CM, Steiner CA. 
Hysterectomy rates in the United States 
1990-1997. Obstet Gynecol 2002; 99(2): 
229-34. [PMID: 11814502]
[23] Lonnée-Hoffmann RA, Schei B, 
Eriksson NH. Sexual experience of 
partners after hysterectomy, 
comparing subtotal with total 
abdominal hysterectomy. Acta 




[24] Mylonas I, Friese K. Indications for 
and Risks of Elective Cesarean Section. 
Dtsch Arztebl Int 2015; 112(29-30): 
489-95. [http://dx.doi.org/10.3238/
arztebl.2015.0489] [PMID: 26249251]
[25] Danesh M, Hamzehgardeshi Z, 
Moosazadeh M, Shabani-Asrami F. The 
Effect of Hysterectomy on Women’s 
Sexual Function: a Narrative Review. Med 
Arh 2015; 69(6): 387-92.[http://dx.doi.
org/10.5455/medarh.2015.69.387-392] 
[PMID: 26843731]
[26] Fram KM, Saleh SS, Sumrein IA.  
Sexuality after hysterectomy at 
University of Jordan Hospital: a teaching 
hospital experience. Arch Gynecol 
Obstet 2013; 287(4): 703-8. [http://
dx.doi.org/10.1007/s00404-012-2601-2] 
[PMID: 23132049]
[27] Goetsch MF. The effect of total 
hysterectomy on specific sexual 
sensations. Am J Obstet Gynecol 
2005; 192(6): 1922-7. [http://dx.doi.
org/10.1016/j.ajog.2005.02.065] [PMID: 
15970852]
[28] Bayram., NevinSahin. Hystrectomy’s 
Psychosexual Effects in Turkish Women 
2008; 26: 149-58.
[29] Lonnée-Hoffmann R, Pinas I.  
Effects of Hysterectomy on Sexual 
Function. Curr Sex Health Rep 2014; 
6(4): 244-51. [http://dx.doi.org/10.1007/
s11930-014-0029-3] [PMID: 25999801]
[30] Farquhar CM, Steiner CA. 
Hysterectomy rates in the United States 
1990-1997. Obstet Gynecol 2002; 99(2): 
229-34. [PMID: 11814502]
[31] Altman D, Granath F, Cnattingius S, 
Falconer C. Hysterectomy and risk of 
stress-urinary-incontinence surgery: 




[32] Pauls RN. Impact of gynecological 
surgery on female sexual function. Int 
J Impot Res 2010; 22(2): 105-14.[http://
dx.doi.org/10.1038/ijir.2009.63] [PMID: 
20072131]
[33] Adorna E, Morari-Cassol E, 
Ferraz N. A Mastectomia e suas 
Fibroids
148
Repercussões na Vida Afetiva, Familiar 
e Social da Mulher. Rev Saúde (Santa 
Maria) 2017; 43(1): 163-8.
[34] Schmidt, Alessandra, Sehnem, 
Graciela Dutra, Cardoso, Leticia 
Silveira, Quadros, Jacqueline Silveira de, 
Ribeiro, Aline Cammarano, & Neves, 
Eliane Tatsch. Sexuality experiences of 
hysterectomized women. Ginekol Pol 
Esc Anna Nery 2019; 23(4)
[35] G So, sozeri-varma., N kalkan –
Oguzbanolgu ,F., Karadag , gand 
O.Ozdel. The effect of hysterectomy and 
oophorectomy on sexual satisfaction 
2011;14: 275-281.
[36] Meston CM, Bradford A. Sexual 
dysfunctions in women. Annu Rev Clin 
Psychol. 2007;3:233-56. doi: 10.1146/
annurev.clinpsy.3.022806.091507. PMID: 
17716055.
[37] Goktas SB, Gun I, Yildiz T, 
Sakar MN, Caglayan S. The effect of 
total hysterectomy on sexual function 
and depression. Pak J Med Sci. 
2015;31(3):700-5. doi: 10.12669/
pjms.313.7368. PMID: 26150871; 
PMCID: PMC4485298.
[38] Silva CMC, Vargens OMC. A mulher 
que vivencia as cirurgias ginecológicas: 
enfrentando as mudanças impostas 




Repercussões na Vida Afetiva, Familiar 
e Social da Mulher. Rev Saúde (Santa 
Maria) 2017; 43(1): 163-8.
[34] Schmidt, Alessandra, Sehnem, 
Graciela Dutra, Cardoso, Leticia 
Silveira, Quadros, Jacqueline Silveira de, 
Ribeiro, Aline Cammarano, & Neves, 
Eliane Tatsch. Sexuality experiences of 
hysterectomized women. Ginekol Pol 
Esc Anna Nery 2019; 23(4)
[35] G So, sozeri-varma., N kalkan –
Oguzbanolgu ,F., Karadag , gand 
O.Ozdel. The effect of hysterectomy and 
oophorectomy on sexual satisfaction 
2011;14: 275-281.
[36] Meston CM, Bradford A. Sexual 
dysfunctions in women. Annu Rev Clin 
Psychol. 2007;3:233-56. doi: 10.1146/
annurev.clinpsy.3.022806.091507. PMID: 
17716055.
[37] Goktas SB, Gun I, Yildiz T, 
Sakar MN, Caglayan S. The effect of 
total hysterectomy on sexual function 
and depression. Pak J Med Sci. 
2015;31(3):700-5. doi: 10.12669/
pjms.313.7368. PMID: 26150871; 
PMCID: PMC4485298.
[38] Silva CMC, Vargens OMC. A mulher 
que vivencia as cirurgias ginecológicas: 
enfrentando as mudanças impostas 
pelas cirurgias. Rev Latino-Am Enferm 
2016; 24(e2780): 1-8.
Fibroids
Edited by Hassan Abduljabbar
Edited by Hassan Abduljabbar
Uterine fibroids are benign tumors of the smooth muscle of the uterus. They are 
the most common pathologic abnormalities of the female genital tract, occurring 
in 20%–50% of women older than 30 years. Some fibroids present with symptoms, 
whereas others are asymptomatic. The etiology of uterine fibroids is unclear. As such, 
this book presents comprehensive information on clinical presentation, diagnosis, and 
management of myoma. Chapters discuss symptoms such as bleeding, pain, and sexual 
dysfunction, as well as imaging modalities for diagnosis and options for treatment, 
including medications and surgery.
Published in London, UK 
©  2021 IntechOpen 
©  magicmine / iStock
ISBN 978-1-83962-995-2
Fibroids
8 011 3
